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Primary immunodeficiency diseases (PID) are a heterogeneous group of inborn errors of 
immunity, resulting in significant morbidity and mortality in affected infants and young children. 
To date, over 320 distinct genetic abnormalities resulting in PID have been described. Of 
interest to this thesis is severe combined immunodeficiency (SCID), where survival and long-
term outcomes are significantly improved if haematopoietic stem cell transplantation (HSCT) 
is performed prior to 3.5 months of age. Hence, early detection of affected individuals with PID 
is of critical importance. The ideal infant screening strategy for PID remains controversial. 
Most established screening programs utilise a T cell receptor excision circle (TREC) assay to 
screen newborns for SCID. TREC are surrogate markers for thymic T cell output, with low 
levels indicative of T cell lymphopaenia. B cell lymphopaenia can also be detected through 
quantification of kappa-deleting recombination excision circles (KREC). This thesis presents 
the results of a two-year, prospective screening study for severe forms of PID manifested by 
T and/or B cell lymphopaenia. This was the first large-scale screening study using a 
multiplexed TREC/KREC assay to simultaneously detect T and B cell lymphopaenia. This 
assay was used to screen 58,834 newborns, resulting in the identification of three infants with 
PID. The findings of this study confirm the efficacy of DNA-based screening strategies to 
identify infants with PID and highlight the additional benefits of simultaneous screening for T 
and B cell lymphopaenia. 
TREC and KREC assays have predominantly been used in the context of newborn screening 
for PID, with limited application of these assays beyond the newborn period. This thesis 
investigated the utility of these assays in the clinical evaluation of older patients with suspected 
PID. The results showed that KREC levels remain low or undetectable throughout life in 
patients with X-linked agammaglobulinaemia (XLA). These findings, therefore, demonstrate a 
wider application and diagnostic utility of these assays in older children and adults. 
Hypogammaglobulinaemia is a feature of several forms of PID, including primary antibody 
deficiency disorders and combined immunodeficiencies such as SCID. Currently, there is no 
strategy by which to screen infants for hypogammaglobulinaemia, and measuring antibody 
levels in infants is confounded by the presence of maternal antibodies. This thesis presents 
the results of a small pilot study evaluating a transcriptomic approach to the identification of 
children with hypogammaglobulinaemia. Our findings show that RNA can be successfully 
extracted from dried bloods spots, and that immunoglobulin heavy chain gene expression 
assays are useful to analyse the immunoglobulin transcriptome of healthy individuals and 
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patients with PID. In addition, this assay is able to identify children with complete deficiencies 
of immunoglobulin production (XLA and X-linked hyper-IgM syndrome). 
In approaching the era of personalised medicine, it would be advantageous not only to screen 
individuals for disease states, but also to identify augmentable disease susceptibility factors, 
thereby enabling prevention of disease. Knowledge of susceptibility factors enables the 
provision of patient-specific advice regarding the need for screening, therapy or prophylaxis. 
This thesis describes a newborn screening strategy which identifies specific SNPs in 
fucosyltransferase (FUT2 and FUT3) genes which determine the expression of histo-blood 
group antigens (HBGA) (H type 1 and Lewis). These HBGA are important for microbial 
attachment and metabolism and, therefore, influence an individual’s predisposition to selected 
infectious diseases (including rotavirus and norovirus). They also play a role in shaping the 
microbiome and have been associated with the development of autoimmune and inflammatory 
diseases. In this thesis, a genotyping method was developed to determine the frequency of 
SNPs in FUT2 and FUT3, and the ensuing Lewis b and secretor status. Our results 
demonstrated that a higher than expected proportion of newborns in the cohort were non-
secretors and Lewis b negative, predisposing them to specific infections and other diseases, 
with potential implications for vaccination.   
This thesis contributes to the literature regarding newborn screening strategies for PID, 
providing evidence for the efficacy of combined TREC/KREC screening to identify infants with 
severe forms of PID manifested by T and/or B cell lymphopaenia. It outlines the utility of 
screening tests beyond the newborn period as tools for the diagnostic work-up of patients with 
PID. Evidence is provided for the utility of a newborn screening approach for SNPs conferring 
disease susceptibility, which has implications for the provision of personalised, precision 
medicine. These findings are discussed and reviewed with respect to the current international 
status of newborn screening for PID, highlighting differences in screening approaches. This 
thesis reviews application of other methods, including protein-based assays and targeted 
sequencing to expand the range of currently screened diseases. The potential utility of 
screening newborns using up-front next generation sequencing (whole exome and whole 
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CHAPTER 1: INTRODUCTION 
1.1 Contextual Statement and Targeted Literature Review 
The case for newborn screening for primary immunodeficiency diseases 
Primary immunodeficiency diseases (PID) are a heterogeneous group of inborn errors of 
immunity which typically present in infancy and childhood. To date, over 320 different 
molecular causes of PID have been identified1. Affected children suffer from recurrent, severe 
or unusual infections, resulting in increased morbidity, health system utilisation and in some 
cases, death. Diagnosing children with PID is frequently delayed, due to a lack of awareness 
of these conditions by health professionals, and lengthy clinical and laboratory diagnostic 
processes. Delayed diagnosis portends a poorer prognosis, given that by the time a diagnosis 
is eventually made, children are significantly unwell due to severe complications of untreated 
disease. Hence, there is a clear case for newborn screening for severe forms of PID, where 
early diagnosis and treatment can be life-saving and significantly reduce long-term morbidity2-
6. 
Severe combined immunodeficiency (SCID) is a particularly catastrophic form of PID which is 
manifested by absent or reduced T cells, with variable presence of B and NK cells depending 
on the underlying molecular genetic defect1. Without definitive treatment with haematopoietic 
stem cell transplantation (HSCT), SCID is uniformly fatal. Evidence suggests that survival and 
long-term outcomes are significantly improved if HSCT is performed prior to 3.5 months of 
age6. Hence, early detection of infants with PID is critically important. The only realistic way to 
achieve the goal of early HSCT for SCID is by identifying affected infants soon after birth, in 
population-based newborn screening programs. 
PID were previously thought to be rare entities; however results of international newborn 
screening studies provide evidence that disease frequency is much higher than initially 
thought. The incidence of SCID has been determined to be 1/58,000, and 1/7,300 infants will 
have T cell lymphopaenia due to other causes7. It is, therefore, highly likely that many cases 
of SCID have been missed in the past, with affected infants dying without their disease being 
recognised. This further strengthens the case for systematic newborn screening for these 
conditions. 
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Current scope of identifiable diseases and methods for newborn screening for 
severe forms of primary immunodeficiency 
Newborn screening programs aim to identify infants with a range of severe conditions which 
are asymptomatic at birth, for which curative treatment is available8. The ideal strategy by 
which to screen infants for PID remains controversial, with various approaches having been 
adopted in different centres around the world. Current screening practices utilise a DNA-based 
method which measures surrogate markers of T cell production (T cell receptor excision 
circles, TREC)9 in order to identify infants with T cell lymphopaenia. At the present time, most 
screening centres worldwide have adopted TREC-only assays to identify SCID as the target 
screened condition. More recently, a method has been established to enable simultaneous 
detection of T and B cell lymphopaenia, using an assay to measure surrogate markers of B 
cell production (kappa-deleting recombination excision circles, KREC) in addition to TREC10. 
This strategy enables identification of other forms of PID, including congenital B cell deficiency 
diseases (such as X-linked agammaglobulinaemia (XLA) and XLA-like autosomal recessive 
disorders, Nijmegen Breakage syndrome and late onset ADA deficiency)10. These conditions 
could otherwise be missed by a TREC-only assay. The combined TREC/KREC screening 
approach has not previously been assessed in a large, prospective population-based cohort.  
Application of newborn screening tests beyond the newborn period 
Until screening for PID becomes an integral component of newborn screening programs, 
patients will continue to present for clinical evaluation with suspected immunodeficiency 
diseases. There has been limited evaluation of the role of TREC and KREC assays beyond 
the newborn period in patients with suspected PID. KREC levels have been used to evaluate 
immune reconstitution after haematopoetic stem cell transplantation11,12. The role of 
TREC/KREC levels in the sub-classification of patients with CVID have also been evaluated13-
15. However, the utility of TREC/KREC assays as an adjunctive diagnostic tool in the work-up
of patients with suspected PID has not been evaluated in other contexts.
The need to expand current newborn screening technologies to enable detection 
of a higher number of primary immunodeficiency diseases 
Currently available screening strategies enable the identification of infants with severe forms 
of PID manifested by T and/or B cell lymphopaenia which are detectable by TREC or 
TREC/KREC assays. However, these will capture only a fraction of the 320+ different forms of 
PID. Whilst it can be argued that SCID is an appropriate primary screening target (given its 
severity and the need for urgent treatment), it has been well established that late diagnosis of 
any form of PID is associated with poorer health outcomes for affected patients16-18. Various 
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strategies have been considered to enable the identification of other forms of PID that cannot 
be detected by TREC/KREC assays. These include protein-based assays to identify 
complement deficiencies and granulocyte disorders19,20 and targeted sequencing, for example 
to determine UNC13D copy number variation to screen infants for familial haemophagocytic 
lymphohistiocytosis (FHL)21. 
Primary antibody deficiencies constitute the largest group of immunodeficiency disorders, and 
hypogammaglobulinaemia is also a presenting feature of several forms of PID, including SCID 
and other combined immunodeficiencies1. Due to the presence of maternal immunoglobulins 
in the neonatal circulation, it is not possible to accurately measure these proteins in 
infancy using standard methods such as nephelometry20,22. Hence, it is not yet possible to 
 an infant’s endogenous immunoglobulin production. It follows, then, that aside from 
those primary antibody deficiency disorders associated with low or absent KREC levels 
(XLA and XLA-like disease), there is no strategy by which infants can be screened for 
immunoglobulin deficiency disorders.  
Given the advances in genomic medicine, the role of up-front next-generation sequencing 
(NGS) has been suggested as a potential newborn screening strategy. Rapid NGS has already 
been evaluated in neonatal and paediatric intensive care unit settings to facilitate early 
diagnosis and inform treatment decisions23-26, and has already been described in the context 
of screening for PID27,28. This approach shows promise as a means by which to screen for a 
large number of diseases simultaneously. 
The role of newborn screening in identifying disease susceptibility factors 
In approaching the era of personalised medicine, it would be advantageous not only to screen 
individuals for disease states, but also to identify augmentable disease susceptibility factors, 
to enable the prevention of disease development or, at least, its progression. Knowledge of 
susceptibility factors enables the provision of patient-specific advice regarding the need for 
screening, therapy or prophylaxis. One such example is screening infants for polymorphisms 
in fucosyltransferase genes (FUT2 and FUT3) which determine human blood group antigen 
expression and susceptibility to specific disease states, such as increased risk of rotavirus or 
norovirus infection29-31. 
1.2 Aims 
This thesis aims to address several gaps in the literature regarding optimal strategies for 
newborn screening for PID. It also explores additional approaches which may enable detection 
of a wider range of conditions in the future. Specifically, this thesis aims to: 
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1. Determine the efficacy of a combined TREC/KREC screening approach for the
identification of newborns with severe forms of PID manifested by T and/or B cell
lymphopaenia
2. Determine the utility of screening assays beyond the newborn period, as part of the
diagnostic evaluation of patients with suspected immunodeficiency
3. Establish a method for screening newborns for hypogammaglobulinaemia
4. Explore the role of novel genetic screening strategies to identify newborns with key
disease susceptibility factors and facilitate the application of personalised medicine
1.3 Thesis Outline 
This thesis is presented in publication format, and includes four published papers, one paper 
accepted for publication and one chapter presenting unpublished data from a small pilot study. 
Where relevant, supplementary figures and tables follow each publication. 
The following chapter provides an extensive review of the literature, which explores the history 
and recent developments in the field of newborn screening for PID (Paper I). Gaps in the 
literature are also highlighted, several of which are addressed in the subsequent chapters of 
this thesis.  
Materials and methods, including ethical considerations and laboratory techniques developed 
for this work are presented in Chapter 3. In Chapter 4, the findings of a prospective screening 
study are presented. In this study, almost 60,000 newborns were screened for PID manifested 
by T and/or B cell lymphopaenia (Paper II), providing evidence to support a combined 
TREC/KREC screening approach. Chapter 5 demonstrates the utility of newborn screening 
assays beyond infancy in the evaluation of patients with suspected PID by showing that KREC 
levels remain low or absent throughout life in patients with XLA (Paper III). In Chapter 6, early 
pilot data is presented from a small study evaluating a transcriptomic approach to screen 
children for hypogammaglobulinaemia using RNA extracted from dried blood spots. Chapter 7 
provides an evaluation of the application of a genotyping-based method to screen newborns 
for polymorphisms in key genes which confer specific infectious disease susceptibility. This 
chapter also examines the implications of this screening strategy for provision of personalised 
medicine (Paper IV). In Chapter 8, the current status of newborn screening worldwide is 
presented, coupled with a forward-looking discussion of future testing strategies to expand 
current screening capabilities, including NGS (Paper V). The final chapter of this thesis 
provides a summary of the key findings arising from this research, together with a discussion 
of the clinical implications of these findings and directions for future research. Supplementary 
information and other details are provided as Appendices. 
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CHAPTER 2: LITERATURE REVIEW: NEWBORN 
SCREENING FOR PRIMARY IMMUNODEFICIENCY 
DISEASES 
2.1 Introduction and Contextual Statement 
This chapter presents a comprehensive review of the literature, which includes a discussion of 
the history of newborn screening, from its origins in the early 1960s. The review draws attention 
to currently available, and future strategies for newborn screening for immunodeficiency 
diseases. 
2.2 Publication: Newborn Screening for Primary Immunodeficiency 
Diseases: History, Current and Future Practice 
This chapter presents the first publication included in this thesis. 
The paper entitled ‘Newborn Screening for Primary Immunodeficiency Diseases: History, 
current and future practice’ by Jovanka King and Lennart Hammarström was published in the 
peer reviewed journal, Journal of Clinical Immunology, in November 2017 (38:56, 
doi:10.1007/s10875-017-0455-x). 
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ORIGINAL ARTICLE
Newborn Screening for Primary Immunodeficiency Diseases:
History, Current and Future Practice
Jovanka R. King1,2 & Lennart Hammarström1,3
Received: 11 August 2017 /Accepted: 16 October 2017
# The Author(s) 2017. This article is an open access publication
Abstract The primary objective of population-based newborn
screening is the early identification of asymptomatic infants with
a range of severe diseases, for which effective treatment is avail-
able and where early diagnosis and intervention prevent serious
sequelae. Primary immunodeficiency diseases (PID) are a het-
erogeneous group of inborn errors of immunity. Severe com-
bined immunodeficiency (SCID) is one form of PID which is
uniformly fatal without early, definitive therapy, and outcomes
are significantly improved if infants are diagnosed and treated
within the first few months of life. Screening for SCID using T
cell receptor excision circle (TREC) analysis has been introduced
in many countries worldwide. The utility of additional screening
with kappa recombining excision circles (KREC) has also been
described, enabling identification of infants with severe forms of
PID manifested by T and B cell lymphopenia. Here, we review
the early origins of newborn screening and the evolution of
screening methodologies. We discuss current strategies
employed in newborn screening programs for PID, including
TREC and TREC/KREC-based screening, and consider the po-
tential future role of protein-based assays, targeted sequencing,
and next generation sequencing (NGS) technologies, including
whole genome sequencing (WGS).
Keywords Newborn screening . Primary immunodeficiency
diseases . TREC . KREC . Next-generation sequencing
Introduction
Population-based newborn screening enables the early identifi-
cation of asymptomatic infants with a range of severe diseases,
for which effective treatment is available and where early diag-
nosis and intervention prevent serious sequelae. Primary immu-
nodeficiency diseases (PID) are a heterogeneous group of inborn
errors of immunity, the majority of which present in infancy and
result in significant morbidity andmortality. Until recently, it was
not possible to identify infants with PID prior to the onset of
clinical symptoms, at which point they typically have complica-
tions of severe and protracted infection. Advances in technology
have enabled identification of infants with severe forms of PID
manifested by Tand/or B cell lymphopenia. Here, we review the
early origins of newborn screening and the evolution of screening
methodologies. We review current strategies employed in new-
born screening programs for PID, including T cell receptor exci-
sion circle (TREC) and kappa recombining excision circles
(KREC)-based screening approaches, and discuss the potential
future role of protein-based assays, targeted sequencing, and next
generation sequencing (NGS) technologies.
The Early Origins of Newborn Screening
Phenylketonuria: Discovery, Treatment, and Screening
Phenylketonuria (PKU), also known as Følling’s disease, was
first identified in 1934 by the Norwegian biochemist and
This review is based on a keynote lecture given by Lennart Hammarström




1 Department of Clinical Immunology, Karolinska University Hospital
Huddinge, SE-141 86 Stockholm, Sweden
2 Department of Immunopathology, SA Pathology, Women’s and
Children’s Hospital Campus; Robinson Research Institute and
Discipline of Paediatrics, School of Medicine, University of
Adelaide, North Adelaide, South Australia 5006, Australia




CHAP ER : I ERA RE RE IE
physician Ivar Asbjörn Følling (1888–1973), who evaluated
two siblings aged 4 and 7 years with developmental delay and
an unusual urinary odor [1]. He postulated that these features
might be linked and set about identifying a potential causative
compound in their urine. As a result of a series of experiments,
he hypothesized that defective phenylalanine metabolism was
responsible for their symptoms. A survey of 430 patients in a
nursing home and school for children with intellectual disabil-
ity led to identification of eight further cases, including two
sibling pairs, with further pedigree analyses suggesting an
autosomal recessive inheritance pattern [1, 2]. Følling named
the disease Bimbecillitas phenylpyruvica,^which in later years
became known as Bphenylketonuria,^ a term coined by
English geneticist Lionel Penrose [2]. The biochemical defect
was described by George Jervis in 1945 [3]. In 1953, Bickel
et al. highlighted the beneficial effects of a phenylalanine-free
diet in a child with PKUwhose developmental progress mark-
edly improved, but regressed upon cessation of the dietary
restriction [4]. In 1956, Horner and Streamer reported marked
improvement (but not complete reversal) of behavior and de-
velopment in two children with PKU aged 4 and 4.5 years
treated with a low-phenylalanine diet [5]. In comparison,
when the diet was commenced at 8 weeks of age in the youn-
ger sibling of one of these children, the child developed nor-
mally [5], providing evidence for the necessity of early insti-
tution of the low-phenylalanine diet in infants with PKU.
Although infants with affected siblings could be identified
and treated early, it became clear that all infants should be
tested for PKU in the newborn period to prevent long-term
sequelae [2]. In the late 1950s, Willard Centerwall developed
a Bdiaper test^ to screen newborns for PKU using a ferric
chloride reaction on freshly wet diapers, which enabled early
identification and treatment of many infants with PKU in
California [6]. However, one limitation was the absence of
the compound in the urine until the child was a few weeks
old [2], prompting development of a blood testing strategy
which could be carried out in the first few days of life.
Robert Guthrie (1916–1995), an American microbiologist,
described a method of specimen collection from newborns,
where blood from a heel puncture was applied to filter paper,
dried, and then subjected to testing [7]. This later became
known as the BGuthrie card,^ and this method continues to
be used in newborn screening programs worldwide. In 1963,
Guthrie and Ada Susi described a method for detection of
PKU in newborns based on the inhibition of growth of
Bacillus subtilis by phenylalanine and associated compounds
[7]. Small, circular punches taken from the dried blood spots
(DBS) were placed on agar medium, and high levels of phe-
nylalanine in PKU patients resulted in bacterial growth inhi-
bition [7]. This marked the beginning of large-scale popula-
tion screening in the USA, with the PKU screening program
starting inMassachusetts in 1963, followed by rapid uptake in
other states and in other countries around the world [8].
Recognition of the Important Role of Screening in Population
Health
In 1968, JamesMaxwell GloverWilson (1913–2006), Principal
Medical Officer at the Ministry of Health, in London, England,
and Gunnar Jungner (1914–1982), Chief of Clinical Chemistry
at Sahlgren’s Hospital in Gothenburg, Sweden, published their
World Health Organization (WHO) report entitled BPrinciples
and practice of screening for disease^ [9]. This was, and remains
to this day, a highly significant contribution to the public health
and population screening literature. Their description of the prin-
ciples underpinning screening practices and the BWilson and
Jungner Criteria^ for disease inclusion in screening programs
(Table 1) [9] are still highly relevant in guiding decision-
making.
Beyond PKU: Expansion of Newborn Screening Programs
Following the successful implementation of newborn screen-
ing for PKU in several locations worldwide, attention was
then given to expanding programs to screen for other types
of metabolic disease and other conditions. In Sweden, screen-
ing for PKU commenced in 1965, followed by the addition of
galactosemia (1967), congenital hypothyroidism (1980), con-
genital adrenal hyperplasia (1986), and biotinidase deficiency
(2002). In 2010, an additional 19 disorders were added using
tandem mass spectrometry and currently, 24 diseases are in-
cluded in the national screening program.
Newborn Screening Methodologies
Through the work of these pioneers throughout history, newborn
screening practices have evolved and expanded to include a
wider number of screened diseases. Technological advances have
enabled development of new assays, with improved sensitivity,
specificity and capacity for automation [10]. From the first gen-
eration of PKU screening using ferric chloride reactions in neo-
natal diapers to Guthrie and Susi’s bacterial inhibition assay, the
next significant milestone in newborn screening methodology
was the advent of tandem mass spectrometry (MS/MS). This
technology enables identification of a compound in a biological
sample based on the mass/charge ratio and provides an opportu-
nity to screen for several compounds simultaneously, hence in-
creasing the number of screened disorders [8]. This modality
continues to be used in newborn screening programs around
the world. Other techniques include spectrophotometry, fluorom-
etry, and immunoassay [10].
Screening methodologies have subsequently expanded to in-
clude DNA-based testing strategies. A DNA-based screening
program for glutaric academia type 1 was established in the
Canadian provinces of Manitoba and north-western Ontario in
1998. Here, a high incidence of this disorder has been noted in a
local indigenous population, attributable to a single homozygous
J Clin Immunol
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mutation in glutaryl-CoA-dehydrogenase [11]. Targeted se-
quencing of this mutation enabled identification of several affect-
ed infants, facilitating early institution of treatment [11]. Targeted
genetic testing has also been included in newborn screening al-
gorithms for cystic fibrosis, where an elevated immunoreactive
trypsinogen measurement is followed by screening for a panel of
CFTR (cystic fibrosis transmembrane conductance regulator)
mutations [12]. A targeted genetic testing strategy has also been
described for screening newborns for familial hemophagocytic
lymphohistiocytosis (FHLH) due to UNC13D inversion muta-
tions [13].
Newborn Screening Programs Worldwide
Therrell et al. recently published a comprehensive report on the
status of newborn screening worldwide, which reflects the great
variability in screening practices in different regions [14]. Most
programs are structured to screen for a number of core disor-
ders, along with secondary target disorders (typically organic
and amino acidemias and fatty acid oxidation disorders) that are
differential diagnoses of the core disorders [8]. As well as
laboratory-based testing performed on dried blood spot sam-
ples, in many countries, newborns are also screened for hearing
loss and cardiac disease using bedside assessment techniques
[14]. There is currently a capacity to screen for over 50 different
conditions, and diseases which are included in newborn screen-
ing programs or potential future inclusions are listed in Table 2.
Decisions regarding disease inclusion at the local level should
be guided by knowledge of the natural history of the disease,
availability of treatment modalities, ability to decrease morbid-
ity and mortality through screening and results of cost-
effectiveness analyses [14].
Primary Immunodeficiency Diseases
Primary immunodeficiency diseases (PID) are a heterogeneous
group of inborn errors of immunity, which were first recognized
in the 1950s with the description byOgden Bruton (1908–2003)
of a young boy with recurrent infections and agammaglobulin-
emia [15]. Since this time, the broad clinical spectrum of PID
has been recognized, and well over 300 different genetic muta-
tions resulting in PID have been described to date [16]. Patients
with PID typically present with a predisposition to infection, and
delayed diagnosis results in significant complications and asso-
ciated increased morbidity and mortality. PID present with a
spectrum of clinical phenotypes and are caused by different
pathophysiological mechanisms. They may be broadly classi-
fied as follows: immunodeficiencies affecting cellular and hu-
moral immunity, combined immunodeficiencies with associated
or syndromic features, predominant antibody deficiencies, im-
mune dysregulatory diseases, congenital defects of phagocyte
number or function, innate or intrinsic immune defects, auto-
inflammatory disorders, complement deficiencies, or PID
phenocopies [16].
Severe combined immunodeficiency (SCID) is one of the
most severe forms of PID and is manifested by a lack of T
cells. B and NK cells may be variably absent depending on the
molecular defect. This condition is an immunological emer-
gency and requires prompt diagnosis and management. SCID
is uniformly fatal without treatment. This condition came to
public attention in the 1970s, when David Vetter (1971–
1984), known as the Bbubble boy,^ was diagnosed with
SCID and immediately after birth, was placed in a protective
sterile environment at the Houston Children’s Hospital in
Texas. Unfortunately, a matched donor for hematopoietic stem
cell transplantation (HSCT) was not available, and David
lived in the Bbubble^ until his death at age 13 years from
EBV-associated lymphoma (https://primaryimmune.org/).
David’s case was an example of how early diagnosis and
management of SCID augment clinical progress. Recent
evidence suggests that patient outcomes are markedly
improved if definitive therapy with HSCT is performed
before the age of 3.5 months, prior to the onset of severe
infections and other complications [17]. Realistically, this is
Table 1 Wilson and Jungner
principles of early disease
detection
1 The condition sought should be an important health problem.
2 There should be an accepted treatment for patients with recognized disease.
3 Facilities for diagnosis and treatment should be available.
4 There should be a recognizable latent or early symptomatic stage.
5 There should be a suitable test or examination.
6 The test should be acceptable to the population.
7 The natural history of the condition, including development from latent to declared disease, should be
adequately understood.
8 There should be an agreed policy on whom to treat as patients.
9 The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically
balanced in relation to possible expenditure on medical care as a whole.
10 Case-finding should be a continuing process and not a Bonce and for all^ project.
Wilson and Jungner 1968 [9]
J Clin Immunol
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only achievable by early identification of infants with SCID
through newborn screening programs.
History of Newborn Screening for Primary
Immunodeficiency Diseases
Screening for Severe Combined Immunodeficiency (SCID)
Severe combined immunodeficiency (SCID) is an important
health problem, for which the natural history is known and
treatment is available, and as such, it meets the Wilson and
Jungner criteria [9] and is a suitable candidate for population
screening. SCID manifests with low or absent T lymphocytes,
and thus screening newborns for T cell lymphopenia is an
ideal strategy for identifying the disease. The first strategy
proposed involved screening each newborn with a full blood
count to determine the lymphocyte count [18], which was
deemed to lack sensitivity. Subsequently, screening cord
blood for T cell populations by flow cytometry was also con-
sidered [19]; however, given that this was likely to be time-
consuming and expensive, other screening methods for the
detection of T cell lymphopenia were considered.
T cell receptor excision circles (TREC) are small, circular
pieces of episomal DNA which are formed during T cell re-
ceptor (TCR) rearrangement in naïve T cells and are thus
surrogate markers for recent thymic emigrants. TREC were
first visualized by electron microscopy as circular, extra-
chromosomal DNA in mouse thymocytes in 1982 [20] and
were later demonstrated to be the product of TCR rearrange-
ment [21]. The TREC assay was developed by Douek et al.
who demonstrated that TREC were specific to naïve T cells
and described an age-related decline in healthy individuals
and reduced levels in HIV infection [22]. TREC were noted
to be stable, not prone to degradation, and did not replicate
with subsequent cell division, making them an ideal marker
Table 2 Included conditions in newborn screening programs
Amino acid disorders
Phenylketonuria





Other secondary conditions (argininemia, citrullinemia type II,
hypermethioninemia, benign hyperphenylalaninemia, biopterin
defects, tyrosinemia type II and III)
Organic acid disorders
Methylmalonic acidemia (with or without homocystinuria)







Other secondary conditions (malonic acidemia, isobutyrylglycinuria,
2-methylbutyrylglycinuria, 3-methylglutaconic acidurias,
2-methyl-3-hydroxybutyric acidurias)
Fatty acid β-oxidation disorders
Medium-chain acyl-CoA deficiency
Very long-chain acyl-CoA dehydrogenase deficiency
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
Trifunctional protein deficiency
Carnitine transport defect
Carnitine palmitoyltransferase I deficiency
Carnitine palmitoyltransferase II deficiency
Carnitine acylcarnitine translocase deficiency
Glutaric acidemia type II
Other secondary conditions (short-chain acyl-CoA dehydrogenase
deficiency, medium-short-chain K-3-hydroxyacyl-CoA dehydroge-













Human immunodeficiency virus (HIV)
Toxoplasmosis





















Villoria et al. [8], Clague and Thomas [10], Therrell et al. [14]
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for naïve T cell production. In 2005, Kee Chan and Jennifer
Puck first described application of the TREC assay for large-
scale population screening for SCID and other forms of T cell
lymphopenia [23]. The TREC assay was subsequently opti-
mized, and the first state-wide SCID screening pilot study was
commenced in Wisconsin in 2008, led by Jack Routes and
James Verbsky [24]. Later that year, the first child with
SCID who was identified by newborn screening was success-
fully transplanted (Jeffrey Model Foundation, http://www.
info4pi.org). Subsequently, screening was implemented in
Massachusetts, Louisiana, and New York in 2009, and
California, Texas, and Pennsylvania in 2010. Screening for
SCID is now routinely conducted or due to commence in the
near future in the majority of states, including the District of
Columbia, Navajo Nation and Puerto Rico, with 92% of
American infants undergoing screening at the present time
[25, https://primaryimmune.org/idf-advocacy-center/idf-scid-
newborn-screening-campaign/].
Although identification of infants with SCID was the
intended aim of TREC-based newborn screening programs,
it became evident that in addition to this disorder, the assay
would also identify infants with T cell lymphopenia due to
other primary and secondary causes (Table 3). For example,
low TREC levels have been detected in individuals with 22q
deletion syndrome, CHARGE association, and Trisomy 21
[26]. In addition, infants with forms of PID other than SCID
may have low TREC, for example in ataxia telangiectasia and
combined immunodeficiency diseases (CID). Thus far in pro-
spective pilot studies, many cases of CID without an identifi-
able molecular cause have been detected using the TREC
assay [27, 28, 30] and these patients require clinical charac-
terization and long-term follow-up.
In addition to TREC analysis, other SCID screening ap-
proaches have been proposed. In Italy, newborns are screened
for SCID with the TREC assay, along with tandem mass spec-
trometry to identify ADA deficiency, which also enables iden-
tification of infants with delayed-onset ADA deficiency
[31–33]. A similar approach has been described to identify
patients with PNP deficiency [34]. A two-tiered testing ap-
proach using TREC analysis combined with IL-7 measurement
has also been proposed as a means to increase the specificity of
SCID screening [35]; however, this has not yet been optimized
for application in large-scale screening programs [36].
Primary immunodeficiency diseases were previously
thought to be rare entities, and the incidence of SCID was
unknown. Prospective screening programs have since enabled
the true incidence of SCID to be determined. Furthermore,
screening has facilitated the identification and treatment of
infants who would have otherwise died from complications
of undiagnosed SCID. Based on studies in the USA where
over 3 million infants were screened, the incidence of SCID
was found to bemuch higher than expected at 1/58000 and the
incidence of clinically relevant T cell lymphopenia was
1/7300 [27]. The annual live birth rate in the USA is approx-
imately 4 million. Given that it was previously estimated that
the incidence of SCID was 1/100000, screening has thereby
increased the number of expected cases from approximately
Table 3 Disorders detectable by TREC and KREC screening























- Including 6p deletion, ring
chromosome 14, ring chromosome 17,































DOCK8 , dedicator of cytokinesis 8; CHARGE, coloboma, heart defects,
atresia choanae, growth retardation, genital abnormalities, ear abnormal-
ities; CLOVES, congenital, lipomatous, overgrowth, vascular
malformations, epidermal nevi, spinal/skeletal anomalies, and/or scolio-
sis; ECC, ectodermal dysplasia, ectrodactyly, and clefting; TAR, throm-
bocytopenia and absent radius; HIV, human immunodeficiency virus;
EDA-ID, ectodermal dysplasia-associated immunodeficiency
*Excluding Zap70 deficiency, MHCII deficiency, and late-onset ADA
deficiency
**Low TREC and KREC levels
Jyonuchi et al. [26], Kwan et al. [27], Chien et al. [28], Barbaro et al. [29]
J Clin Immunol
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40 to 69 annually, equating to an additional 29 cases each year
identified and managed with potentially curative treatment.
Given that PID constitute a large and heterogeneous group
of genetic disorders which are individually rare entities, new-
born screening offers additional benefits beyond individual
patient care. Screening provides important opportunities to
increase our knowledge of the clinical and pathophysiological
spectrum of PID and gain additional experience in manage-
ment of these conditions, particularly as affected infants are
identified early in their disease course. Newborn screening
thereby facilitates continued, collaborative research and pro-
gression of our knowledge in this field by enabling collation
of rare and diverse cases and building national and interna-
tional expertise.
Screening for Congenital B Cell Deficiency Disorders
Mutations in key genes which are essential for B cell ontogeny
give rise to congenital B cell deficiency disorders including X-
linked agammaglobulinemia (XLA) (resulting from a muta-
tion in the BTK gene) and autosomal recessive XLA-like dis-
orders. Patients have absent B cells, extremely low or unde-
tectable immunoglobulin levels, and an increased susceptibil-
ity to severe infection with bacteria and other pathogens [16].
Like T cells, B cells also undergo rearrangement of the vari-
able, diversity, and joining domains (V(D)J recombination)
during development in order to produce unique B cell antigen
receptors, and this process also yields episomal, circular DNA
referred to as a kappa recombining excision circles (KREC).
V(D)J recombination within the IGK locus results in a Vk-Jk
coding joint, followed by rearrangement of the intron RSS and
Kde elements with deletion of the Ck exon and enhancers. The
coding joint remains present in the genome, whereas the
KREC with the corresponding signal joint is excluded as a
stable, circularized DNA fragment [37]. In 2007, van Zelm
et al. described this process and developed a KREC assay
using a PCR-based method [37]. They demonstrated that
KREC levels reflected the replication history of B cells and
had potential utility in assessing B cell recovery following
HSCT and in the assessment of patients with antibody defi-
ciency disorders such as common variable immunodeficiency
(CVID) [37]. In 2011, Nakagawa et al. were the first to dem-
onstrate the utility of the KREC assay in identifying newborns
with B cell deficiency disorders, showing that signal joint
KREC were absent in blood and Guthrie card specimens in
patients with XLA [38].
Concurrent Screening for Severe Forms of Primary
Immunodeficiency Manifested by T and B Cell Lymphopenia
Given the potential utility of the KREC assay in newborn
screening for PID, a multiplexed TREC/KREC assay has been
described, which enables simultaneous identification of
infants with severe forms of PID manifested by T and/or B
cell lymphopenia (Table 3 and 4) [40]. This approach has
since been adopted in newborn screening pilot studies in
Sweden and Spain [29, 41]. Multiplexed TREC/KREC assays
offer many advantages over TREC screening alone, as well as
identification of congenital B cell defects; it enables identifi-
cation of individuals with different forms of PID which might
be missed by a TREC-alone assay, including late-onset ADA
deficiency, some cases of Nijmegen breakage syndrome and
other selected disorders [40].
Limitations of Current Screening Strategies for Primary
Immunodeficiency
It has been established that although TREC screening will
identify the majority of infants with SCID, cases where the
molecular defect lies downstream of T cell receptor rearrange-
ment will not be detected. This includes Zap70 deficiency,
MHC Class II deficiency, and some cases of delayed ADA
deficiency [42–47]. Defects of T cell function despite a quan-
titatively normal Tcell number will also not be detected by the
TREC assay.
The Current Status of Newborn Screening for Primary
Immunodeficiency Diseases Worldwide
Screening programs for PID have been instituted in many
regions. TREC-based PID screening programs have been
established in the majority of American states (including the
Navajo region, District of Columbia, and Puerto Rico),
Taiwan, Israel, Qatar, and several Canadian regions, and are
due to commence in New Zealand in the near future [48].
Screening programs utilizing TREC-only, TREC/KREC, or
TREC/ADA strategies have also been evaluated in pilot stud-
ies in Italy, Sweden, Germany, The Netherlands, Japan,
France, Spain, Norway, France, the UK, Turkey, Slovenia,
Saudi Arabia, Iran, Iceland, Denmark, and Brazil, and many
more regions have applications in progress to commence
screening programs [48].
The Future of Newborn Screening for Primary
Immunodeficiency Diseases
Screening for Complement and Granulocyte Disorders Using
Protein-Based Methods
Complement proteins are an important component of the in-
nate immune system, and deficiencies in complement give rise
to a variable clinical phenotype, including autoimmune dis-
ease, renal disease, and a susceptibility to specific bacterial
infections which frequently result in life-threatening infection
[16]. Disorders of granulocyte number and function are an
important group of disorders, with affected individuals
J Clin Immunol
Page 1
CHAP ER : I ERA RE RE IE
typically presenting with severe bacterial or fungal infections
and other features such as colitis [16]. Atypical presentations
frequently result in delayed diagnosis and treatment. Patients
with complement or granulocyte disorders will not be
Table 4 Results of prospective newborn screening programs for primary immunodeficiency











TREC 3,030,083 SCID (n = 52)
- Typical SCID (n = 42)
- IL2RG (n = 9)
- IL7RA (n = 6)
- ADA (n = 5)
- RAG1 (n = 4)
- JAK3 (n = 3)
- DCLRE1C (n = 1)
- RAG2 (n = 1)
- CD3D (n = 1)
- TC7A (n = 1)
- Pallister-Killian syndrome;
tetrasomy 12p (n = 1)
- Molecular defect unknown
(n = 6)
- Genetic testing incomplete
(n = 4)
- Leaky SCID (n = 10)
- RAG1 (n = 4)
- RMRP (n = 2)
- IL2RG (n = 1)
- DCLRE1C (n = 1)
- Molecular defect unknown
(n = 2)
Kwan et al. 2014 [27]
Taiwan 2010–2017 (78 months) TREC 920,398 SCID (n = 7)
- IL2RG (n = 3)
- RAG1 (n = 1)
- Molecular defect unknown
(n = 3)
SCID variant, molecular defect
unknown (n = 8)
EDA-HT (n = 1)





TREC/KREC 89,462 SCID (n = 2)
- Artemis deficiency) (n = 1)
- ADA deficiency (n = 1)
Ataxia telangiectasia (n = 1)
CID,molecular defect unknown
(n = 2)
Barbaro et al. 2016 [29]
Zetterström et al. 2017
[30]
Israel 1 October 2015–30 April
2017 (18 months)
TREC 290,864 SCID (n = 13)
- Typical SCID (n = 10)
- DCLRE1C (n = 3)
- IL7RA (n = 2)
- RMRP (n = 1)
- Ligase 4 deficiency (n = 1)
- Complete DiGeorge
Syndrome (n = 1)
- Molecular defect unknown
(n = 2)
- Leaky SCID (n = 3)
- DCLRE1C (n = 2)
- MHC2 deficiency/RFX5
(n = 1)
Undefined PID (n = 6)
Rechavi et al. 2017 [39]
Rechavi et al. (personal
communation)
TREC T cell receptor excision circles, KREC kappa recombining excision circles, SCID severe combined immunodeficiency, CID combined immuno-
deficiency, EDA-HT X-linked recessive anhidrotic ectodermal dysplasia-associated immunodeficiency
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identified using current TREC or TREC/KREC-based meth-
odologies, which identify PID manifesting with T and/or B
cell lymphopenia, respectively. As such, protein-based screen-
ing methodologies have been proposed as a means by which
to identify infants with complement and granulocyte disor-
ders. Specific complement proteins, including C2 and C3,
can be eluted from DBS and quantified, enabling identifica-
tion of infants with low or undetectable protein levels at birth
[49, 50], facilitating early intervention with prophylactic mea-
sures to prevent potentially catastrophic outcomes. It has also
recently been demonstrated that complement deficiency can
be identified using a whole genome sequencing (WGS)-based
newborn screening strategy [51].
Screening for Familial Hemophagocytic Lymphohistiocytosis
Targeted DNA sequencing has previously been employed as a
screening strategy for selected diseases, such as glutaric
acidemia type I and cystic fibrosis. This approach has also
been described as a potential method by which infants with
familial hemophagocytic lymphohistiocytosis (FHLH) due to
mutations inUNC13Dmay be identified [13]. Fifty percent of
FHLH cases in Scandinavia are due to homozygousUNC13D
inversion mutations, and it has been demonstrated that a re-
duction in the wild type gene copy numbers is an effective
way to screen for affected individuals [13].
The Role of Next Generation Sequencing in Newborn
Screening for PID
Primary immunodeficiency diseases are a heterogeneous
group of disorders, which differ in terms of clinical phenotype,
laboratory findings, and underlying molecular abnormalities.
There are currently over 300 different genetic mutations asso-
ciated with PID [16], and this number continues to increase.
As such, there is no single test which can reliably identify all
infants with PID at birth. Rapid advances in genomic medi-
cine have resulted in increased availability and reduced costs
of next-generation sequencing (NGS), and whole exome se-
quencing (WES) and whole genome sequencing (WGS) have
an established role in diagnostic medicine. Previously, the
time taken from sample collection to receipt of results of
NGS-based studies has been prolonged, often taking weeks
or months. However, Brapid^ NGS has been described in the
setting of critically ill infants in the pediatric intensive care
unit (PICU) and neonatal intensive care unit (NICU) setting,
where a 26 hour turnaround time has been achieved, and re-
sults have impacted upon patient care [52–54]. In one cohort
of 35 acutely unwell infants, 20 were diagnosed with a genetic
disease using rapid WGS, 13 of whom had de novo mutations
identified, and the diagnosis directly influenced management
decisions (including specific management or palliation) in
10 cases [52]. It follows then, that in addition to diagnostic
medicine, NGS is likely to have a future role in newborn
screening for PID and other conditions.
The National Institutes of Health is currently evaluating the
role of up-front NGS in newborn screening as part of the
NSIGHT (Newborn Sequencing in Genomic Medicine and
Public Health) project [55]. Whole-exome-based newborn
screening for currently screened and additional disorders will
be evaluated, along with the experience of parents and clini-
cians in the exchange and utility of genomic information. The
ethical, legal, and social implications will also be explored
[55]. In addition, rapid NGS in the NICU setting will be fur-
ther evaluated [55].
Recently, Pavey et al. used WGS to screen 1349 newborn
and parent trios for variants in 329 known PID-associated
genes [51]. Applying a genotype-first pipeline, pathogenic
or likely pathogenic mutations were identified in 396 infants;
however, only one was found to have a genomically predicted
PID (complement component C9 deficiency). A phenotype-
first approach resulted in identification of 29 infants in the
cohort who were potentially immunodeficient based on clini-
cal features; however, no mutations were identified in the
interrogated PID genes. Pathogenic mutations were identified
in other (non-PID associated) genes in three of the children
[51]. Lucarelli et al. also recently described a WGS-based
screening strategy for cystic fibrosis, involving interrogation
of a panel of 188 CFTR mutations [56]. Bodian et al. also
evaluated up-front WGS as a screening strategy to evaluate
1696 newborns for variants in 163 genes which are implicated
in diseases which are currently screened for in the USA, dem-
onstrating that WGS was complementary to conventional
newborn screening and gave fewer false positive results, re-
solved inconclusive findings and provided more precise diag-
nostic information compared to conventional techniques [57].
Applying a WGS-based approach to newborn screening
represents a change in paradigm, and there are many factors
which must be taken into consideration before adopting this
approach in population-based screening programs [48, 58].
Firstly, candidate diseases and target genes for evaluation
should be identified. In the case of PID, an ideal starting point
would be establishing a panel of the currently identified 300+
PID-associated genes, which would need to be updated as new
genes are described. Care must be taken to screen only for
diseases with an established genotype-phenotype correlation.
Robust and cost-effective testing systems must be established.
The tests must be appropriately sensitive and specific, with an
agreeable turnaround time and data should be analyzed and
managed appropriately. An appropriate pipeline should be
established to manage abnormal results, including confirma-
tory and second-tier testing and seamless integration with clin-
ical services. The cost-effectiveness of this screening ap-
proach must also be formally assessed. Ethical, legal, and
social implications are major considerations, including issues
pertaining to consent, biobanking of genetic material, and data
J Clin Immunol
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and implications of genetic findings for other familymembers.
A plan must also be in place for management of variants of
unknown significance, including mutations in genes known to
cause debilitating or lifespan-reducing disease for which there
is no known treatment [48]. A screening approach using up-
front WGS must be evaluated in large, prospective trials prior
to adopting this strategy in population-based newborn screen-
ing programs. We support the consideration ofWGS as an up-
front screening method.
Management of PID is variable and is dependent on the
disease, clinical phenotype, and molecular defect. In the
case of SCID, HSCT or gene therapy is currently available
curative therapies. Advances in CRISPR-Cas based ge-
nome editing have led to interest in potential therapeutic
applications of this modality. Scott and Zhang recently
highlighted that prior to institution of CRISPR-based ther-
apy, patients should be screened using WGS to ensure
safety and reduction of off-target effects [59]. The early
identification of a specific PID-associated mutation as a
result of newborn screening by NGS will enable timely
initiation of the aforementioned therapies, along with oth-
er targeted, personalized treatment options [60].
Prenatal Screening
Newborn screening enables identification of infants with
key disorders requiring early intervention soon after birth.
Prenatal screening for disorders such as Trisomy 21 and
neural tube defects is well established in obstetric prac-
tice, along with prenatal diagnostics in the case of a high
risk of a specific genetic disorder based upon positive
family history or other factors. However, this has typically
required invasive procedures which carry associated risks,
such as amniocentesis and chorionic villus sampling.
Technological advances have resulted in the ability to de-
tect fetal DNA in maternal plasma, and Lo et al. demon-
strated that massively parallel sequencing (MPS) enables
detection of fetal aneuploidies such as trisomies 21, 13,
and 18 [61]. In addition to chromosomal aneuploidy, this
technique also enables detection of sub-chromosomal de-
letions and duplications including 22q11 (DiGeorge
Syndrome) and 5p (Cri-du-chat Syndrome) deletions and
deletions associated with Prader-Willi and Angelman
Syndromes. Monogenic traits and disorders such as RhD
status and FGFR3 mutations which give rise to achondro-
plasia can also be identified. Targeted or whole genome
sequencing of the fetus is also possible, along with se-
quencing of the fetal transcriptome and methylome, en-
abling identification of a wide range of disorders [62].
Prenatal screening technologies may well also become
part of the changing landscape of screening practices for
PID and other disorders in the future.
Conclusion
Newborn screening practices worldwide have evolved signif-
icantly since the discovery of PKU in 1934, with rapid devel-
opment of new and improved assays to enable identification
of a wider range of conditions in infants and facilitating early
diagnosis and treatment, and improving clinical outcomes.
Primary immunodeficiency diseases are a heterogeneous
group of disorders, and no single assay at the present time will
identify all forms of PID, necessitating a challenge of current
newborn screening paradigms. In the genomic era, it is likely
that this will involve up-front next generation sequencing,
including whole exome sequencing and ultimately, whole ge-
nome sequencing. This approach must be evaluated in large,
prospective trials prior to adopting this strategy in population-
based newborn screening programs.
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Introduction and Contextual Statement 
This chapter presents an overview of the materials and methods used to conduct the work 
included in this thesis. In this chapter, ethical considerations, patient and sample recruitment 
procedures and a summary of the laboratory techniques utilised, are described. 
3.2 Ethical Considerations 
All research included in this thesis was performed in accordance with the ethical standards of 
the Regional Ethical Board in Stockholm (Regional Ethical Committee, Karolinska Institutet), 
and the Women’s and Children’s Health Network Human Research Ethics Committee and 
Research Governance Committee. All research was performed in accordance with the 1964 
Helsinki Declaration and its later amendments or comparable ethical standards.  
Ethics approval was sought and obtained from the local ethical committees in each jurisdiction 
where the research was conducted: 
 Regional Ethical Committee, Karolinska Institutet
o 2013/414-31/4
o 2016/189-31/2




3.3 Participant and Sample Recruitment 
Research participants were patients recruited from clinical immunology departments at three 
clinical centres in Sweden and one centre in South Australia. Healthy control participants were 
also recruited from each site. Written, informed consent was obtained from all participants 
recruited into the studies. Anonymised biological samples (i.e., dried blood spot specimens) 
were used in accordance with the standing Regional Ethical Committee and Karolinska 
Institutet / Women’s and Children’s Health Network policies permitting the use of such samples 
for research purposes.  
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3.3.1 Paper II (Chapter 4): TREC/KREC newborn screening study 
Dried blood spot (DBS) samples from 58,834 infants recruited to the TREC/KREC screening 
study were obtained and processed at the Center for Inherited Metabolic Diseases (CMMS), 
Karolinska University Hospital, Stockholm.  
3.3.2 Paper III (Chapter 5): KREC in agammaglobulinaemia study 
Thirteen patients with agammaglobulinaemia were recruited from the clinical immunology 
departments in three clinical centres in Sweden. Whole blood and DBS specimens were 
collected from each patient. Where possible, each patient’s original DBS, collected at birth, 
was accessed from archives at CMMS. Stored DNA samples, extracted at the time of diagnosis 
for each patient, were collected from the Clinical Research Centre at the Karolinska University 
Hospital. Anonymised, time-controlled specimens were also obtained from CMMS. 
3.3.3 Unpublished paper (Chapter 6): Transcriptomic approach to screening for 
hypogammaglobulinaemia study 
Nineteen patients and 13 healthy control subjects were recruited from a single South Australian 
clinical immunology department. Anonymised newborn DBS samples were provided by the 
South Australian Neonatal Screening Laboratory. 
3.3.4 Paper IV (Chapter 7): Fucosyltransferase polymorphism screening study 
Anonymised DBS specimens were obtained from 520 newborns. These were sourced from 
CMMS. Five hundred and twenty anonymised DBS specimens were obtained from CMMS, as 
described for Chapter 5 above. 
3.4 DNA Extraction from Dried Blood Spots 
DNA was extracted from DBS samples using the following method, optimised for a 96-well 
plate format. One 3.2mm punch was taken from each DBS sample, and placed in a 96-well 
plate. Ninety µL of Qiagen Generation DNA Purification Solution 1 was added to each well. 
The plate was centrifuged briefly, then incubated for 15 minutes at room temperature. The 
plate was then centrifuged at 2204 g for 5 minutes. The supernatant was removed from the 
wells. This procedure was repeated once, before addition of 90µL of sterile water to each well. 
The plate was briefly centrifuged before removal of the supernatant. Twenty µL of DNA Elution 
Solution 2 including 1µL/mL of yeast tRNA was added to each well before brief vortex mixing 
and centrifugation. The plate was then incubated in a thermal cycler (SimpliAmp Thermal 
Cycler, Thermo Fisher Scientific, MA, USA) at 990C for 30 minutes. The plate was briefly 
centrifuged before transfer of the eluate into another 96-well plate. 
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3.5 DNA Extraction from Whole Blood 
DNA was extracted from whole blood samples using the salting-out method. Briefly, 10mL of 
blood and 40mL of lysis buffer were placed in a Falcon tube and gently inverted, followed by 
incubation at 370C for 10 minutes. The tube was centrifuged at 1500 rpm for 10 minutes at 
room temperature. The supernatant was discarded, 25mL of lysis buffer was added and gently 
shaken to dissolve the pellet. The tube was centrifuged at 1500 rpm for 10 minutes at room 
temperature and the supernatant was discarded. Ten mL of DNA buffer and 100µL of DNA 
Proteinase K was added to the pellet and incubated for 12 hours at 500C. Five mL of 6M sodium 
chloride was added and mixed for 30 minutes on a mixing table, before centrifugation at 4000 
rpm (with no brake) for 10 minutes at room temperature. The supernatant was transferred to 
a new tube and the centrifugation step repeated. Twenty mL of 99% ethanol was added and 
mixed by hand, before centrifugation at 4000 rpm for 5 minutes at room temperature. The 
ethanol was discarded. Five mL of 70% ethanol was added, before centrifugation at 4000 rpm 
for 5 minutes at room temperature. The pellet loosened and transferred to an Eppendorf tube, 
which was then centrifuged at 13,000 rpm for 3 minutes. The ethanol was removed, and the 
tube dried for 10 minutes. One hundred - 800µL of TE buffer was added to the pellet 
(depending on pellet size) and incubated at room temperature for 48 hours. 
3.6 TREC/KREC/ACTB Quantitation by qPCR 
Eight µL of DNA extracted from the DBS specimens, or 40ng of DNA extracted from whole 
blood, was added to 10µL of TaqMan Gene Expression Master Mix and 2µL of 
TREC/KREC/ACTB primer mix (Applied Biosystems, California, USA) in a 96-well plate. The 
plate was run on an Applied Biosystems Quantstudio 7500 qPCR instrument, under the 
following conditions: hold at 500C for 2 minutes, heating cycle at 950C for 20 seconds, followed 
by 45 cycles of 30 seconds at 950C and 30 seconds at 600C. 
3.7 RNA Extraction from Dried Blood Spots & cDNA Synthesis 
Two 3.2mm punches were removed from each DBS sample for each specimen. RNA was 
extracted from the DBS punches using a method we developed. Briefly, the DBS punches 
were eluted in 200µL of rapid RNA extraction solution (Ambion, Applied Biosystems, MA, 
USA), and incubated at room temperature on a plate shaker for 15 minutes. The eluate was 
removed, and RNA and DNA was extracted using the QiaAMP MinElute Virus Spin Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. cDNA was synthesised using 
the Bio-Rad cDNA iScript synthesis kit (Bio-Rad, California, USA). Twenty nanograms of RNA 
was added to 4µL of 5X iScript Reaction Mix, 1µL of iScript Reverse Transcriptase and 
nuclease-free water to give a final volume of 20µL. Thermal cycler conditions were as follows: 
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Priming 250C for 5 minutes, reverse transcription 460C for 20 minutes, RT inactivation 950C for 
1 minute, hold 40C for 20 minutes. 
3.8 Gene Expression Analysis 
Five microlitres of the cDNA product, diluted 1:5, was added to 10µL of 2X TaqMan Gene 
Expression Mastermix (Applied Biosystems, MA, USA), 7µL of RNAse-free water and 1µL of 
10X TaqMan gene expression assay for one of the following per reaction: IGHG1 
(Hs00378340_m1, Cat. No. 4331182, FAM-MGB), IGHA1 (Hs00733892_m1, Cat. No. 
4331182, FAM-MGB), IGHM (Hs00378435_m1, Cat. No. 4331182, FAM-MGB) and ACTB 
(Hs01060665_g1, Cat. No. 4331182, FAM-MGB) (Applied Biosystems, MA, USA). ACTB (β-
actin) was used as a housekeeper gene. Samples were run in triplicate for the genes of interest 
and housekeeper gene, with appropriate positive and negative (non-template) controls on a 
Bio-Rad iQ5 qPCR instrument (Bio-Rad, California, USA). Thermal cycler conditions were as 
follows: hold 500C for 2 minutes, hold 950C for 10 minutes followed by 70 X cycles (950C for 
15 second, 600C for 1 minute), standard ramp rate. Quality control was maintained by 
assessment of a minimum CT threshold for ACTB for each sample, samples achieving 
threshold at a CT of >45 with poor traces were considered non-specific. Given that the RNA 
used was derived from DBS and was therefore of a lower concentration and quality compared 
with RNA extracted from other sources (such as fresh whole blood or purified PBMCs), later 
than usual amplification was noted for ACTB and other genes assessed. 
3.9 FUT Polymorphism in silico Analysis 
Specificity of the primers used in different publications for genotyping the SNPs rs601338 and 
rs602662 in FUT2 and rs778986, rs28362459, rs3894326 and rs3745635 in FUT3 was 
assessed by checking the annealing region for each pair of primers using the Ensembl BLAST 
tool (http://www.ensembl.org/index.html). 
3.10 Nested PCR of FUT2 and FUT3 Genes 
Genomic DNA (extracted from DBS as detailed above) was pre-amplified by PCR using 
primers specific for FUT2 and FUT3 regions containing the SNPs of interest. Thirty nanograms 
of genomic DNA, 10µL of 1x goTaq colourless buffer (Promega, Madison, WI, USA), 3uL of 10 
mM deoxy-ribonucleotide triphosphate (dNTP) (Invitrogen, Carlsbad, CA), 3µg of 1.5mM/µL 
MgCl2 (Promega, Madison, WI, USA), 2µL of each forward and reverse amplification primer 
at 10nM (Eurofins), 0.25µL of goTaq DNA polymerase (Promega, Madison, WI, USA) and 
26.75µL of distilled water were combined to give a total reaction volume of 50µL. Thermal 
cycler conditions were as follows: initial denaturation at 95°C for 2 minutes, followed by 30 
cycles of: denaturalization 95°C for 30 seconds, annealing 68°C (FUT2) or 60°C (FUT3) for 30 
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seconds, and extension 72°C for 1 minute, then final extension at 72°C for 10 minutes. PCR 
products were visualised in 1% agarose gel. 
3.11 FUT2 and FUT3 Genotyping using TaqMan Chemistry 
TaqMan chemistry (Life Technologies, Carlsbad, CA, USA) was used to genotype two SNPs 
in FUT2 (rs601338 (C_2405292_10), rs602662 (C_2405293_10) and two in FUT3, rs3894326 
(C_801690_10), rs778986 (C_11458475_20). Non-template negative controls, and samples 
confirmed to have mutant alleles (by Sanger sequencing) were used as positive controls in the 
assays. Four microliters of amplified PCR product diluted 1:200 were used in the TaqMan 
reaction according to manufacturer conditions in a final volume of 20µl, (Life Technologies, 
Carlsbad, CA, USA) and analysed using a Real-Time PCR system under conditions 
recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA). 
3.12 FUT2 and FUT3 Genotyping using Sanger Sequencing 
The FUT3 SNPs rs3745635 and rs28362459 were genotyped using 4µl of amplified PCR 
product diluted 1:80 as a template for Sanger sequencing, which was performed by Eurofins, 
Munich, Germany. Results were analysed using Mutation Taster software. 
3.13 Meta-Analysis and Systematic Review 
A systematic review and meta-analysis was conducted using PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), Medline Ovid (http://www.ovid.com) and Cochrane 
Library (http://www.cochranelibrary.com) databases applying the MeSH Terms ‘FUT2’, ‘FUT3’, 
‘single nucleotide polymorphism’, ‘secretor’, ‘non-secretor’, ‘Lewis b’, ‘Lewis b negative’. Minor 
genotype frequencies for each SNP in published studies and the 1000 Genomes Project 
(http://www.internationalgenome.org) for selected populations were reviewed. Review 
Manager 5.0 (2008 Cochrane Collaboration, Oxford, United Kingdom) was used to carry out 
the statistical analysis.  
3.14 Statistical Analyses 
Statistical analyses in included studies were performed using SPSS Statistics Version 23 (IBM, 
USA), GraphPad Prism Version 6.0 (GraphPad Software, San Diego, CA) and Review 
Manager 5.0 (2008 Cochrane Collaboration, Oxford, United Kingdom). 
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CHAPTER 4: NEWBORN SCREENING FOR SEVERE 
FORMS OF PRIMARY IMMUNODEFICIENCY DISEASE 
MANIFESTED BY T AND/OR B CELL LYMPHOPAENIA 
4.1 Introduction and Contextual Statement 
The ideal strategy for screening newborns for severe forms of PID has not yet been 
determined. Most centres are currently screening infants for SCID using a TREC-only assay. 
However, there are several merits to adopting a screening approach with enables 
simultaneous detection of both TREC and KREC levels.  
This chapter examines the efficacy of a qPCR-based, multiplexed TREC/KREC screening 
approach in a prospective screening study of almost 60,000 newborns. It is the largest study 
of its kind to date. 
4.2 Publication: Newborn Screening for Severe Primary 
Immunodeficiency Diseases in Sweden – a Two-Year Pilot TREC & 
KREC Screening Study 
This chapter presents the second publication included in this thesis. The following paper, 
entitled ‘Newborn screening for severe primary immunodeficiency diseases in Sweden– a two-
year pilot TREC & KREC screening study’, by Michela Barbaro, Annika Ohlsson, Stephan 
Borte, Susanne Jonsson, Rolf Zetterström, Jovanka King, Jacek Winiarski, Ulrika von Döbeln 
and Lennart Hammarström was published in the peer reviewed journal, Journal of 
Clinical Immunology, in November 2016 (37(1), 51–60, doi.org/10.1007/
s10875-016-0347-5). Supplementary material follows the paper. 
ARTICLE METRICS (AS AT 11 JANUARY 2019): 
Journal Impact Factor: 3.382 
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Altmetrics score: 3 
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ORIGINAL ARTICLE
Newborn Screening for Severe Primary Immunodeficiency
Diseases in Sweden—a 2-Year Pilot TREC and KREC Screening
Study
Michela Barbaro1,2 & Annika Ohlsson1,3 & Stephan Borte4,5 & Susanne Jonsson1 &
Rolf H. Zetterström1,2 & Jovanka King4,6,7 & Jacek Winiarski8,9 & Ulrika von Döbeln1,3 &
Lennart Hammarström4
Received: 11 July 2016 /Accepted: 18 October 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Newborn screening for severe primary immunode-
ficiencies (PID), characterized by T and/or B cell lymphope-
nia, was carried out in a pilot program in the Stockholm
County, Sweden, over a 2-year period, encompassing 58,834
children. T cell receptor excision circles (TREC) and kappa-
deleting recombination excision circles (KREC) were mea-
sured simultaneously using a quantitative PCR-based method
on DNA extracted from dried blood spots (DBS), with beta-
actin serving as a quality control for DNA quantity.
Diagnostic cutoff levels enabling identification of newborns
with milder and reversible T and/or B cell lymphopenia were
also evaluated. Sixty-four children were recalled for follow-up
due to low TREC and/or KREC levels, and three patients with
immunodeficiency (Artemis-SCID, ATM, and an as yet un-
classified Tcell lymphopenia/hypogammaglobulinemia) were
identified. Of the positive samples, 24 were associated with
prematurity. Thirteen children born to mothers treated with
immunosuppressive agents during pregnancy (azathioprine
(n = 9), mercaptopurine (n = 1), azathioprine and tacrolimus
(n = 3)) showed low KREC levels at birth, which spontane-
ously normalized. Twenty-nine newborns had no apparent
cause identified for their abnormal results, but normalized
with time. Children with trisomy 21 (n = 43) showed a lower
median number of both TREC (104 vs. 174 copies/μL blood)
and KREC (45 vs. 100 copies/3.2 mm blood spot), but only
one, born prematurely, fell below the cutoff level. Two chil-
dren diagnosed with DiGeorge syndrome were found to have
low TREC levels, but these were still above the cutoff level.
Michela Barbaro, Annika Ohlsson and Stephan Borte contributed equally
to this work.
Electronic supplementary material The online version of this article
(doi:10.1007/s10875-016-0347-5) contains supplementary material,
which is available to authorized users.
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This is the first large-scale screening study with a simulta-
neous detection of both TREC and KREC, allowing identifi-
cation of newborns with both T and B cell defects.
Keywords Newborn screening . primary immunodeficiency
diseases . severe combined immunodeficiency . TREC .
KREC
Introduction
The purpose of neonatal screening is the early recognition of
treatable, mostly genetically determined diseases that manifest
with a high rate of morbidity and mortality. Mass screening of
newborn infants with dried blood spots (DBS) started in the
early 1960s based on a method developed by Guthrie and Susi
for diagnosing phenylketonuria [1]. Peripheral blood from a
heel stick was blotted onto filter paper (referred to as BGuthrie
card^) at 3 to 5 days after birth, dried, and sent by mail to
centralized laboratories for analysis.
The US congress decided in 2006 to include 29 core and 25
secondary disorders in its newborn screening program based
on a priority list of disorders. In recent years, a number of
additional disorders, among them severe combined immuno-
deficiency (SCID), have been included in this list, based on
the well-recognized Wilson and Jungner criteria [2]. In
Sweden, neonatal screening with DBS was initiated in 1965
and today, a total of 24 disorders are included in the program.
Genetically determined disorders of immunity are com-
monly referred to as primary immunodeficiencies (PID) and
were first recognized clinically over 60 years ago with the
identification of X-linked agammaglobulinemia (XLA) [3].
Today, the group of PID includes more than 250 distinct enti-
ties, which are divided into Tcell deficiencies, B cell deficien-
cies (the predominant group), combined T and B cell deficien-
cies, complement defects, and granulocyte defects [4].
Primary immunodeficiencies as a group are not rare dis-
eases, but should be considered in all patients presenting with
severe, atypical, or recurrent infections. The overall preva-
lence is unknown, but varies greatly (from 1:600 for IgA de-
ficiency, 1:20,000 for common variable immunodeficiency,
1:50,000 for SCID, and 1:100,000 for XLA) [4] and refer-
ences therein [5]. The estimated incidence of severe forms of
PID, which require immediate attention, is variable in differ-
ent populations, but would be expected to be in the order of 5–
10 per 100,000 live births.
In 2005, Chan and Puck published a seminal paper, describing
the T-cell receptor excision circle (TREC) assay as a tool for
large-scale screening for SCID and other T cell lymphopenias
[6]. T cell receptor genes are normally edited during T cell dif-
ferentiation, and the deleted fragments are circularized and do not
undergo further replication in dividing cells. Thus, TRECs are a
marker of recently formed T cells. The TREC copy number can
be determined using a quantitative PCR-based method using
DNA extracted from routinely collected DBS. The TREC assay
was implemented in the state of Wisconsin in 2008 [7] and its
inclusion in the newborn screening programs in the USA was
recommended in 2010. Currently, 38 states are screening for
SCID using the TREC assay, with the remaining 12 states due
to commence in 2017 (Jeffrey Modell Foundation, http://www.
info4pi.org/).More than threemillion newborns have been tested
to date [8]. The results show a frequency of SCID of 1/58,000
children (overall 1/7300 with clinically relevant forms of T cell
lymphopenia) and a high survival rate (92 %) after treatment.
Congenital B cell lymphopenia can be identified by screen-
ing for kappa-deleting recombination excision circles
(KREC), the circular by-product of B cell immunoglobulin
kappa gene rearrangement [9]. Patients with severe forms of
B cell deficiency such as XLA are easily identified by the
KREC assay [10] and are treated with regular gammaglobulin
infusions, thereby allowing a near to normal life. Furthermore,
it has been shown that delayed-onset forms of SCID and other
severe forms of PID that present with normal T cell numbers
and TREC levels above cutoff in newborn screening programs
may be identified using a combined TREC and KREC screen-
ing approach [11].
We thus initiated a screening program for all newborns in
the county of Stockholm in Sweden using a combined TREC
and KREC assay [12]. We previously analyzed 10,058 sam-
ples as part of a feasibility study, and one XLA patient was
identified (Bruton tyrosine kinase gene mutation, c.1480C>T,
p.Gln494Ter), thus demonstrating proof of principle of the
combined screening approach [12]. Although a small cohort
of Spanish newborns have been screened using the combined
TREC/KREC assay [13], this represents the first large-scale
prospective study where both T and B cell defects
(lymphopenia) can be identified and the results of the first
2 years of the screening program are reported here.
Materials and Methods
Sampling
We carried out a study encompassing samples from all children
born in the Stockholm County from November 15, 2013 to
November 15, 2015, searching for children with T and B cell
lymphopenia, in order to identify those with severe forms of
PID. A total of 58,834 samples were analyzed. For 24 addition-
al infants, the parents chose not to participate in the study. The
blood sample was collected onto Whatman 903 filter paper as
soon as possible after 48 h of age, presently at a mean age of
2.8 days, and was then mailed to the laboratory. The average
age at recall for a positive screening result was 6 days.
The regional ethical board in Stockholm approved the
study (Ethical permit 2013/414-31/4).
J Clin Immunol
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TREC/KREC Screening Assay
The TREC/KREC newborn screening assay described previ-
ously [12] was utilized, with minor technical modifications.
Briefly, DNA was extracted from single 3.2-mm punches of
the original DBS in a 96-well format, and quantitative triplex
real-time qPCR for TREC, KREC, and beta-actin (ACTB)
was performed using a ViiA7 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) on DNA eluates
as previously described [12]. The qPCR procedure was opti-
mized using custom reagents provided by Affymetrix (Santa
Clara, CA, USA). TREC and KREC levels were determined
per 3.2-mmpunch. Amplification of ACTBwas used to assess
that a sufficient quantity of DNA was extracted from each
DBS, but this was disregarded if TREC and KREC copy
numbers were above the cutoff level. The samples were ini-
tially analyzed once, and if the value was below the cutoff,
they were reanalyzed in duplicate. Samples in which TREC
and/or KREC levels were below cutoff in association with a
reduction in ACTB copy number were considered inconclu-
sive. Cutoff levels for TREC/KREC were adjusted during the
study based on the yield of positive samples.
Genetic Characterization of Patients with Low
TREC/KREC Levels
For the three children with suspected PID, whole exome se-
quencing (WES) was performed, followed by confirmatory
Sanger sequencing. DNA purification, library preparation,
read mapping, variant determination, and analysis of WES
data were performed as described previously [14, 15].
Sequences were generated as 90-bp pair-end reads and aligned
to the human genome reference (UCSC hg 19 version, build
37.1) by using the SOAP aligner (soap 2.21) software.
Duplicated reads were filtered out and only uniquely mapped
reads were kept for subsequent analysis. The SOAPsnp (ver-
sion 1.03) software was subsequently used with default pa-
rameters to assemble the consensus sequence and call geno-
types in target regions. For single nucleotide polymorphism
(SNP) quality control, low-quality SNPs that met one of the
four following criteria were filtered out: (1) a genotype quality
of less than 20, (2) a sequencing depth of less than 4, (3) an
estimated copy number ofmore than 2, and (4) a distance from
the adjacent SNPs of less than 5 bp. Small insertions/deletions
were detected by using the Unified Genotype tool fromGATK
(version v1.0.4705) after alignment of quality reads to the
human reference genome using BWA (version 0.5.9-r16).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
Version 6.0 (GraphPad Software, San Diego, CA). Given the
nonparametric distribution of the data, the Mann-Whitney U
test was used for group comparison analyses, and the
Spearman correlation coefficient was calculated for correla-
tion analyses. Differences were considered statistically signif-
icant when the p value was less than 0.05.
Results
Screening Overview
In total, 58,834 newborns were screened. Samples with TREC
and/or KREC copies below the cutoff values were considered
Babnormal^ (positive), whereas those that also had reduced
ACTB copy numbers were considered to be Binconclusive.^
Initially, 572 samples were found to be either abnormal
(positive) or inconclusive (n = 399 and n = 173, respectively)
(Fig. 1). After repeat testing on the original DBS, 64 abnormal
(positive) samples remained, i.e., 99.9 % were considered
normal and were not evaluated further. A total of 13 patients
were recalled for repeat sampling due to poor quality of their
initial DBS sample.
The definition of Blow^ levels of TREC and KREC copies
will determine how many samples are considered positive.
The dilemma is to avoid unnecessary recalls while still cap-
turing all patients with a severe form of PID (i.e., SCID and
XLA), as well as additional patients with profound distur-
bance of T and B cell homeostasis at birth. Three different
cutoff levels for recall were used during the study as the limits
were adjusted based on the number and outcome of the recalls.
During the first period, a cutoff level of 15 copies/3.2 mm
blood spot or below for TREC and 10 copies/3.2 mm blood
spot blood or below for KREC was applied. In total, 16,582
children were screened and 35 were considered to have a
positive result. However, the vast majority recovered sponta-
neously (Supplementary Table 1) and the cutoff was subse-
quently lowered to a TREC level of 8 copies/3.2 mm blood
spot or below and a KREC level of 4 copies/3.2 mm blood
spot blood or below. Another 28,298 children were screened
during this period and 11 were found to be positive, among
them PID patients 1 and 2. As these cutoffs were ultimately
considered too stringent, they were finally changed to a TREC
level of 10 copies/3.2 mm blood spot or below and a KREC
level of 6 copies/3.2 mm blood spot or below. Altogether,
13,954 children were subsequently screened and 18 were
found to be positive, among them PID patient 3.
The patients with TREC/KREC levels below the cutoff
(Supplementary Table 1) were referred to a pediatrician spe-
cialized in the diagnosis and management of PID. The patient
with absent TREC and KREC was immediately hospitalized
whereas in the vast majority of patients, a follow-up sample
for TREC and KREC analysis was collected within 2–
10 weeks (Table 1) depending on the clinical urgency and
gestational age. The recall was almost exclusively due to
J Clin Immunol
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low KREC levels, and these patients were usually seen and
resampled at around 3 weeks of age. In the majority of cases,
the TREC/KREC values had normalized at the time of resam-
pling (Supplementary Table 1) and only three patients (ap-
proximately 1/20,000) were referred for flow cytometric
(fluorescence-activated cell sorting, FACS) analysis and ge-
netic work-up (WES). In the majority of recalled patients,
follow-up investigation with FACS analysis was not per-
formed, as it was not deemed clinically relevant. To date, none
of the infants in whom KREC/TREC levels normalized have
subsequently developed features of PID.
Abnormal (Positive) TREC/KREC Results
Altogether, 64 children were recalled for follow-up due to low
TREC and/or KREC levels and three patients with severe
primary immunodeficiency were identified (Supplementary
Table 1). Among the positive samples (Fig. 2), several infants
had more than one potential etiological factor contributing to
their low TREC and/or KREC levels. A total of 24 infants
were premature, including one with trisomy 21 and 11 were
a twin or triplet. Furthermore, 13 infants were born to mothers
receiving immunosuppressive therapy. Twenty-nine had no
apparent cause identified and the TREC/KREC levels in the
children tested (n = 27) normalized with time. Resampling
was declined for four of the 64 children recalled.
The 13 children born to mothers who were treated with
immunosuppressive agents during pregnancy (azathioprine
(n = 9), mercaptopurine (n = 1), azathioprine and tacrolimus
(n = 3)) showed low KREC levels at birth, which however
spontaneously normalized after 2–10 weeks. Two children
from a mother treated with azathioprine, born almost 2 years
apart, both showed low KREC at birth.
Other Conditions Influencing the Screening Result
Children with trisomy 21 (n = 43) showed a lower median
number of both TREC (104 vs. 174 in the total material) and
KREC (45 vs. 100), but only one child, born prematurely, fell
below the cutoff levels applied at the time of testing. Two
children were diagnosed with DiGeorge syndrome in the
Department of Clinical Genetics, and both had a low TREC
level but these were still above the cutoff level at the time of
testing.
Among the 3457 infants born prematurely (prior to
37 weeks gestation), 24 screened positive with low TREC
(n = 12) , KREC (n =11) l eve l s , o r bo th (n = 1)
(Supplementary Table 1). Although T cells appear to mature
late in fetal life, TREC and KREC levels were surprisingly
Bnormal^ in the majority of children, even at very low gesta-
tional ages (Table 2), albeit as a group they were still signifi-
cantly below the levels in children born at term (p < 0.0001,
Mann-Whitney U test) (Fig. 3).
A total of 896 twin pairs and 16 triplet sets (n =1840) were
identified in the cohort, and the TREC and/or KREC values
differed markedly between the newborns in both those sib-
lings with low levels (Table 3) and in those with values within
the normal range (Fig. 4).
To the best of our knowledge, no patients with severe PID
characterized by absent T or B cells at birth have been missed
to date among those infants included in the screening
program.
PID Patients
Three patients were found to have repeatedly low levels of both
TREC and KREC (n= 1) or TREC alone (n = 2) (Table 1) and
Fig. 1 Summary of all newborn screening results between 15 November 2013 and 15November 2015. *Two infants had low TREC levels, and one had
low TREC and KREC levels. **See Fig. 2
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were considered to have a severe immunodeficiency disorder.
The first patient had a homozygous splice-site mutation in
Artemis (DLCLRE1C c.333+2T>G) with absent protein expres-
sion and underwent a successful stem cell transplantation at the
age of 2 months. The second child shows clinical features of
ataxia-telangiectasia and carries compound heterozygous muta-
tions in ATM, where the mother contributed a c.3673C>T muta-
tion resulting in a stop codon (p.Gln1225Ter) and the father
contributed a c.8653_8654insT mutation resulting in a
Val2886CysfsTer10 mutation. The third child was found to have
T cell lymphopenia and hypogammaglobulinemia, but genetic
analysis (including whole genome sequencing) has not as yet
revealed any causativemutation in known PID genes. The results
of immunological investigations for the three PID patients iden-
tified are given in Supplementary Table 2.
Discussion
Since 2008, TREC analysis has been the method of choice for
screening of newborns for severe forms of primary T cell
lymphopenia [6, 7, 16], a method that will capture most, but
not all, children with SCID (exceptions being patients with
mutations in ZAP70 [17, 18], MHC class II [19–21], and
ADA (delayed-onset disease [11]). We subsequently devel-
oped a triplex method that also includes KREC analysis to
assess for potential B cell lymphopenia in DBS samples.
This method can successfully identify patients with XLA
[12], selected patients with delayed-onset adenosine deami-
nase deficiency (ADA) [11], Nijmegen-breakage syndrome
(NBS) [12], and purine nucleoside phosphorylase (PNP) de-
ficiency [22]. The combined assay has recently also been used
to screen patients with SCID [23, 24], ATM [12, 25], Wiskott-
Aldrich syndrome (WAS) [26], DiGeorge syndrome [27–29],
and trisomy 21 [30], and it has been suggested to be included
in routine screening of newborns for primary immunodefi-
ciency [31–34]. KREC levels have also been used to monitor
immune reconstitution after bone marrow/stem cell transplan-
tation [35–37].
Ours is the largest study to date using a combined
TREC/KREC assay for newborn screening. One SCID patient
was identified (and successfully transplanted) in our cohort of
58,000 infants, comparable with the data published by Kwan
et al. on a very large US cohort [8]. One patient with ATM was
also identified. This disorder is very rare, with an estimated
incidence of 1 in 200,000 according to recent figures from the
Fig. 2 Characteristics of the 64
infants with abnormal screening
results recalled for repeat testing.
*Azathioprine (n = 9),
mercaptopurine (n = 1),
azathioprine + tacrolimus (n = 3).
**One infant who was premature
also had trisomy 21
Table 1 Serial TREC and KREC levels in PID patients with abnormal screening test results
TREC copies/3.2 mm blood spot KREC copies/3.2 mm blood spot
Case Sex Gestational
age (weeks)
Diagnosis Result 1 Result 2 Result 3 Result 4 Result 1 Result 2 Result 3 Result 4
















































a Tcell lymphopenia and hypogammaglobulinemia. At follow-up at 15months of age, the child’s hypogammaglobulinemia had resolved but a persistent
idiopathic CD3+ T cell lymphopenia (absolute CD3+ count = 0.9 × 109 /L) was evident
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USA [38]. It will be interesting to determine if this finding is due
to serendipity or if the disease is more frequent in Scandinavia.
Our third patient showed a T cell lymphopenia of unknown
cause. Such cases have been previously described in studies in
the USAwith incidences varying between 3 and 4 per 100,000
children in different states and with a predicted incidence of 1 in
160,000 in a British study (Professor Bobby Gaspar, Great
Ormond Street Hospital, personal communication). Recently,
during the third year of screening, yet another SCID patient
(ADA deficiency) and a patient with severe T cell lymphopenia
have been identified.
The number of referrals for flow cytometric analysis in our
cohort was low (approximately 1:20,000), markedly lower than
that reported in the US study of Kwan et al. [8] (ranging from
1/735 to 1/7500 in the different states). This is a reflection of the
strict resampling strategy that was applied to children with low,
Table 2 Mean TREC and KREC
levels at different gestational ages Gestational
age (weeks)
Infants (n) Mean TREC level
(copies/3.2 mm blood spot)
Mean KREC level
(copies/3.2 mm blood spot)
20 1 262 139
21 2 97 180
22 3 84 97
23 23 53 52
24 31 68 58
25 38 64 70
26 50 71 62
27 58 89 65
28 53 93 76
29 97 114 91
30 97 139 110
31 122 134 99
32 199 146 90
33 283 139 87
34 390 142 93
35 663 153 97
36 1347 156 103
Total 3457

























KREC levels according to gestational age
**** p < 0.0001
****
**** ****
n = 148 n = 3309 n = 55377

























TREC levels according to gestational age
****
**** p < 0.0001**** ****
n = 60 n = 3397 n = 55377
A B
Fig. 3 Comparison of TREC levels (a) in infants born prior to 25 weeks,
between 25 and 36 weeks, and at term (≥37 weeks) gestation.
Comparison of KREC levels (b) in infants born prior to 27 weeks,
between 27 and 36 weeks, and at term (≥37 weeks) gestation. Each
point represents one infant and the number of infants in each group is
indicated. The horizontal blue line indicates the mean value of all
samples. The dashed horizontal red line represents the cutoff value for
TREC (<10 copies/3.2 mm blood spot) and KREC (<6 copies/3.2 mm
blood spot) levels, respectively. ****p < 0.0001, Mann-Whitney U test
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but not absent TREC or KREC levels. These results also indicate
that the addition of KREC testing to the TREC assay in a new-
born screening program does not critically drive the demand for
second tier testing nor does it increase the fiscal impact of the test
itself due to the minimal additional cost of multiplexing.
Prematurity has been considered a predisposing factor for
low TREC numbers in studies in American infants [8]. The
TREC and KREC levels in our study did show a downward
trend with decreasing gestational age, although in the vast
majority, the levels were above the cutoff, even in markedly
Table 3 Discrepant TREC and
KREC levels in twin and triplet
















1aa 38 Female TW I 3 1 18 Deceased
1b 38 Female TW II 3 138 161
2a 34 Male TW I 2 51 259
2ba 34 Male TW II 2 13 92
3aa 25 Female TW I 0 5 25 Deceased
3b 25 Female TW II 0 19 178
4a 29 Male TR I 3 20 42
4ba 29 Female TR II 3 15 29
4c 29 Female TR III 3 70 56
5a 29 Male TW I 2 76 130
5ba 29 Male TW II 2 5 16
6a 27 n.a TR I Deceased
6b 27 n.a TR II Deceased
6ca 27 Male TR III 3 5 28
7aa 38 Female TW I 3 149 6
7ba 38 Female TW II 3 132 5
8a 32 Female TW I 2 77 40
8ba 32 Female TW II 2 13 5
9a 24 Male TW I 2 16 68
9ba 24 Female TW II 2 9 13
10a 23 n.a TW I Deceased
10ba 23 Female TW II 2 7 11
TW twin 1, TR triplet, n.a. not available
a Recalled twin/triplet





Correlation between TREC levels within each twin pair




































Correlation between KREC levels within each twin pair































Fig. 4 Correlation between TREC (a) and KREC (b) levels within all
896 twin pairs. Each point represents one twin pair, where the TREC
value for twin 1 (x axis) is plotted against the TREC value for twin 2 (y
axis) (a). KREC levels for each pair are similarly depicted (b). Overall,
there was poor correlation between specimen pairs, with a calculated
Spearman correlation coefficient (Rs) of 0.6 for TREC and 0.57 for
KREC (p < 0.0001)
J Clin Immunol
Page 38
CHAP ER 4: NE RN SCREENIN  R PID
premature infants. This notion was also recently supported
[13] in a small Spanish cohort of newborns.
Twins and triplets were markedly overrepresented among the
positive samples (n = 11/64), potentially reflecting prematurity in
themajority of cases (n= 8/11). There was a notable difference in
TREC and KREC levels within twin pairs returning normal
screening results. Although information regarding zygosity was
not available, it is expected that one in four pairs is monozygotic
and therefore genetically identical, and this observation will thus
be further investigated in the future studies.
Thirteen children with low KREC levels were born to 12
mothers who had been treated with azathioprine during pregnan-
cy, three of whomwere concomitantly receiving tacrolimus. Two
children born to the same azathioprine-treated mother, 2 years
apart, both had low KREC levels. Low KREC levels were also
recently noted by de Felipe et al. [13] in a small cohort of Spanish
children born to mothers treated with azathioprine. As azathio-
prine may cross the placenta (and is mutagenic), it is generally
contraindicated during pregnancy unless used for treatment of
severe disease. As B lymphocytes are markedly more sensitive
to drug-induced apoptosis than T lymphocytes [39], the selectiv-
ity for a reduction in KREC copies alone is not surprising.
We anticipated that some infants with trisomy 21 would
screen positive since they may have low B cell and/or T cell
production [30]. However, only one of the 43 infants screened
during the 2-year period had a KREC level below cutoff,
although infants with trisomy 21 had generally lower levels
than those in the general newborn population. In Sweden, the
estimated frequency of chromosome 22q deletions is around
1/4000, suggesting that some 14–15 children in the screened
cohort would suffer from this form of PID. However, less than
10 % of chromosome 22q deletion patients had pronounced T
cell lymphopenia (measured as low TREC levels) and an ad-
ditional 5–10% had levels close to the cutoff. Thus, we would
have expected only one to two children to be identified in our
tested cohort, which is not statistically different from the pres-
ent result (no child identified).
Most of the children in our study were recalled due to low
KREC levels. This was expected, as we did not knowwhat the
Btrue^ cutoff level for children with XLAwould be and thus
applied a fairly large safety margin. Ongoing studies in our
laboratory, analyzing KREC levels in a large cohort of chil-
dren with mutation proven XLA, may allow further adjust-
ment of the recall level of KREC, thus reducing the efforts
and costs associated with Bfalse^ positive results.
Newborn screening formetabolic diseases has undergonema-
jor changes during the past decades with inclusion of numerous
very rare diseases in the program. We anticipate a similar devel-
opment in the PID screening field where the KREC may ulti-
mately be added to the TREC assay currently used in several
national screening programs. The decision regarding implemen-
tation of TREC vs. combined TREC/KREC screening can be
guided by considering the advantages and disadvantages of each
screening approach. The advantages for adding KREC screening
include the identification of children with XLA, late onset ADA,
some patients with NBS, and other selected forms of PID whose
disease may be undetected by TREC screening alone [8, 23, 40].
In addition, it may assist in distinguishing patients with SCID
caused by deficiency in the production of T as well as B cells or
only T cells, thus aiding in the diagnostic process. On the nega-
tive side, increased costs associated with the additional KREC
assaymay be considered a disadvantage of the combined screen-
ing strategy. With the possibility to multiplex PCR reactions, the
individual cost for additional screeningmarkers such asKREC in
an existing TREC screening system is negligible (<€0.10 per
newborn), but associated costs incurred in follow-up and further
testing for infants with abnormal screening results should also be
considered. However, it should be noted that the recall rate using
the combined TREC/KREC assay is similar to that of TREC
screening alone [8], with a lower rate of follow-up FACS studies
than in other published studies to date.
As markers for other genetic diseases have been proposed
which can be multiplexed with the TREC/KREC system, fu-
ture efforts may be focused on the extension of existing new-
born screening tests for PID [26]. This may potentially include
complement deficiencies (using DBS eluates as described by
Janzi et al. [41] for C3 deficiencies and Hamsten et al. [42] for
C2 deficiencies) and granulocyte defects, thus allowing cov-
erage of a majority of the primary immunodeficiency diseases.
Targeted exome sequencing or even whole genome sequenc-
ing of newborns may ultimately be considered, which could
lead to identification of additional defects of immunity and a
large number of other inherited, potentially fatal diseases.
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CHAPTER 5: APPLICATION OF DNA-BASED SCREENING 
METHODOLOGIES BEYOND THE NEWBORN PERIOD 
5.1 Introduction and Contextual Statement 
In newborn screening programs, the quantitation of TREC and KREC has been demonstrated 
to be an effective method by which to identify infants with severe forms of PID manifested by 
T and/or B cell lymphopaenia. However, there is limited data regarding the utility of these 
assays in the diagnostic evaluation of patients with suspected PID beyond the newborn period. 
Chapter 5 examines the role of TREC/KREC assays beyond the newborn period, particularly 
in the context of XLA and XLA-like disease. 
5.2 Publication: Kappa Recombining Excision Circle Levels Remain 
Low or Absent Throughout Life in Patients with X-Linked 
Agammaglobulinemia 
This chapter presents the third publication included in this thesis. The following paper, entitled 
‘Kappa recombining excision circle levels remain low or absent throughout life in patients with 
X-linked agammaglobulinemia’, by Jovanka King, Stephan Borte, Nicholas Brodszki, Ulrika
von Döbeln and Lennart Hammarström was published in the peer reviewed journal, Paediatric
Allergy and Immunology, in March 2018 (2018:1-4, doi.org/10.1111/pai.12893).
ARTICLE METRICS (AS AT 11 JANUARY 2019): 
Journal Impact Factor: 4.137 
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L E T T E R  T O  T H E  E D I T O R
Kappa- deleting recombination excision circle levels remain 
low or undetectable throughout life in patients with X- linked 
agammaglobulinemia
To the Editor,
X- linked agammaglobulinemia (XLA) is an inborn antibody defi-
ciency syndrome, resulting from mutations in the BTK gene which
give rise to a maturational arrest in B  cell development at the pre-
 B cell stage and subsequent absence of peripheral B lymphocytes,
hypogammaglobulinemia and ensuing severe and recurrent infec-
tions.1,2 Early diagnosis and treatment with immunoglobulin re-
placement therapy are essential to prevent sequelae of chronic,
untreated infections.3
It has previously been demonstrated that XLA can be diagnosed 
soon after birth through kappa- deleting recombination excision cir-
cle (KREC) level quantification.4,5 KREC are circular, episomal pieces 
of DNA which are produced during V(D)J recombination within the 
IGK locus of B lymphocytes.6 As such, KREC are a surrogate marker 
of bone marrow output of B lymphocytes and can be quantified 
using real- time quantitative polymerase chain reaction (qPCR) tech-
niques.4,6 KREC levels have previously been shown to be absent or 
markedly reduced in the newborn dried blood spots (DBS) of pa-
tients with XLA, whereas T  cell receptor excision circle (TREC) levels 
are similar to those of healthy controls.4,5 However, the utility of the 
KREC assay as a diagnostic tool for XLA in a clinical setting outside of 
neonatal screening programs has not previously been evaluated. We 
aimed to quantify serial KREC levels in patients with XLA at three 
time points: at birth; the time of diagnosis; and the current day to 
evaluate the trend over time and to determine the clinical utility of 
the KREC assay in the diagnosis of XLA beyond the newborn period.
Twelve male patients with XLA and one female patient with an 
autosomal recessive, XLA- like disease were recruited from three 
clinical centers in Sweden. Thirteen healthy adult and storage time- 
matched newborn control specimens were also included in the 
study. The regional ethical board in Stockholm approved the study 
(ethical permit 2016/189- 31/2). Written, informed consent was ob-
tained from all participants in accordance with the ethical standards 
of the Helsinki declaration and amendments.
Where available, DNA samples were obtained for each patient at 
birth (extracted from DBS from archived Guthrie cards), time of di-
agnosis, and the current day. DNA was extracted from whole blood 
and DBS specimens using our previously described method.4 KREC, 
TREC, and ACTB (β- actin) levels were quantified using a multiplexed 
qPCR method, as previously described.4
All 13 patients had hypogammaglobulinemia and absent or 
markedly reduced B lymphocyte counts quantitated by flow 
cytometry, and a causative mutation was identified in all cases 
(Table 1). KREC levels were markedly reduced in all patients at birth, 
the time of diagnosis, and the current day compared with healthy 
control subjects (Figure 1A). In most cases, TREC levels in the XLA 
patients were comparable to those in healthy control subjects, al-
though levels were noted to be higher in a few cases (Figure 1B). 
Although TREC levels typically decline with increasing age, there 
are significant interindividual differences in TREC levels both in 
newborns and across the age spectrum, and therefore, this likely 
reflects biologic variation.
Patients with XLA and XLA- like disease are expected to present 
in the first year of life, corresponding to waning protective maternal 
immunoglobulin levels at 6- 9 months of age. However, diagnosis is 
frequently delayed. In a study of 73 patients with XLA, the mean age 
of diagnosis was 3.5 years.3 In our cohort, only 2 of 13 patients were 
diagnosed in the first year of life, whereas the diagnosis was signifi-
cantly delayed (up to 6 years of age) in the remainder of cases. The 
association between delayed diagnosis and an increased rate of dis-
ease complications is well described, with evidence suggesting that 
outcomes are improved with early institution of immunoglobulin re-
placement therapy.3 Our results suggest that a newborn screening 
program incorporating a KREC assay would have successfully iden-
tified these patients at birth, thereby facilitating early institution of 
therapy and prevention of complications. These results reinforce 
our previous findings demonstrating that a KREC assay will success-
fully identify patients with XLA in the newborn period.4 In addition, 
we have demonstrated that this assay also enables identification 
of newborns with autosomal recessive XLA- like disease. Some pa-
tients with XLA or XLA- like disease are described to have a “leaky” 
phenotype, resulting in production of very small numbers of poorly 
functional B lymphocytes. In our cohort, despite minor KREC level 
fluctuations observed in some individual patients, these remained 
well below observed levels in healthy control subjects, suggesting 
that even those patients with a leaky phenotype will still be accu-
rately identified using a KREC assay.
In addition to the identification of patients with congenital 
B cell defects, newborn screening protocols incorporating mul-
tiplexed TREC/KREC assays offer many advantages over TREC 
screening alone. This includes improved characterization of patients 
with SCID and identification of a variety of other conditions asso-
ciated with immunodeficiency including Nijmegen breakage syn-
drome, late onset ADA deficiency, and ataxia telangiectasia.4 KREC 
P        P
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level estimation has also been useful in other contexts in addition 
to newborn screening, including the assessment of immune recon-
stitution following hematopoietic stem cell transplantation.6 Our 
data suggest that KREC level estimation is a useful diagnostic test 
for investigation of patients with suspected congenital B  cell defi-
ciency disorders beyond the newborn period. It may be an adjunct or 
alternative to FACS- based B lymphocyte enumeration. KREC anal-
ysis may be used to verify FACS findings, or used in lieu of FACS 
should this not be readily available. KREC analysis may be more cost- 
effective and also confers some technical advantages including the 
ability to run the assay on stored DNA or DBS samples, which can 
easily be transported between laboratories and negates the need for 
a fresh blood sample for testing.
We quantified serial KREC levels in a cohort of patients with 
XLA and demonstrated that these are markedly reduced or absent at 
birth and remain consistent over time. The same pattern was noted 
in one patient with XLA- like disease. Thus, we have reinforced the 
diagnostic utility of the KREC assay in identifying patients with XLA 
and other forms of congenital B- cell deficiency at birth and beyond 
the newborn period.
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this study and also Susanne Hansen (Immunodeficiency Unit at 
the Karolinska University Hospital Huddinge) and Jacek Winiarski 
(at the Department of Pediatrics at Karolinska University Hospital 
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CHAPTER 6: A TRANSCRIPTOMIC APPROACH TO 
NEWBORN SCREENING FOR 
HYPOGAMMAGLOBULINAEMIA 
6.1 Contextual Statement 
Currently available newborn screening strategies for primary immunodeficiency diseases 
enable detection of conditions manifested by T and/or B cell lymphopaenia. Several forms of 
PID are associated with hypogammaglobulinaemia, and thus screening for immunoglobulin 
deficiency provides an opportunity to increase our capacity to identify a broader range of 
diseases. In this chapter, preliminary results from a small pilot investigation are presented, 
evaluating a transcriptomic approach to the identification of children with 
hypogammaglobulinaemia with potential application as a newborn screening test. This chapter 
is presented in the form of an unpublished manuscript. 
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6.2 Introduction 
Immunoglobulin deficiency disorders constitute the largest group of primary immunodeficiency 
disorders1. In addition, hypogammaglobulinaemia is a feature of other forms of PID, including 
severe combined immunodeficiency (SCID) and other combined immunodeficiencies (CID)1. 
Maternal immunoglobulin transfer, particularly in the last trimester of pregnancy, is an 
important factor contributing to the immunity of the infant, whose own endogenous 
immunoglobulin production increases over time with advancing maturity22. Due to the presence 
of maternal Immunoglobulin G (IgG) and Immunoglobulin A (IgA) in the cord blood and 
neonatal circulation, it is not possible to reliably quantify endogenous production of either 
protein in infants using standard techniques such as nephelometry on serum samples, nor on 
eluates from dried blood spots20.  
There are well over 300 genetic causes of PID, and currently available newborn screening 
strategies only enable a small number of these conditions to be detected32. Newborn screening 
for severe forms of PID manifested by T and/or B cell lymphopaenia using TREC and KREC 
assays have been well described, and are used in prospective screening programs and studies 
in many countries33. Expansion of screening technologies to increase the number of screened 
diseases has included development of protein-based assays for the detection of granulocyte 
and complement deficiencies, targeted genetic sequencing and gene copy number assays33. 
However, there is no currently available strategy exists by which to screen infants for 
immunoglobulin deficiency. It is well documented that early detection of all forms of PID 
enables timely commencement of therapy and improved patient outcomes in terms of 
morbidity, mortality and quality of life16. 
Newborn screening cards are suitable for extraction and quantification of protein, DNA and 
RNA using various techniques34,35. RNA can be extracted from DBS specimens for analysis, 
and remains relatively stable for many years35,36. Karlsson et al. demonstrated that RNA can 
be successfully extracted from DBS at 1 month, 21 years and 27 years following collection, 
regardless of storage conditions (either at -40C or room temperature)36. Microarray technology 
on RNA extracted from DBS specimens to acquire genome-wide expression profiles has been 
described, supporting the notion that RNA can be successfully extracted and amplified from 
DBS specimens34.  
Immunoglobulin molecules are comprised of heavy and light chains, which are derived from 
genetic loci on chromosome 14 (heavy chain) and chromosome 2 (kappa light chain) and 
chromosome 22 (lambda light chain). Functional antibodies are formed as a result of 
recombination events in the variable, diversity and junctional regions (V(D)J), with increased 
affinity owing to later class switch recombination events and somatic hypermutation. 
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Expression of the immunoglobulin heavy chain genes has been evaluated in patients 
with CVID, with reduced transcript production noted, correlating with low  
immunoglobulin levels37. This suggests that assessment of gene expression may be one 
approach to identifying children with PID manifested by hypogammaglobulinaemia or 
agammaglobulinaemia, in the setting where protein cannot be reliably measured due to 
confounding factors such as maternal immunoglobulin contamination or gammaglobulin 
replacement therapy. 
6.3 Aims and Hypotheses 
The aim of this study was to: 
1. Establish an effective method by which to extract RNA from DBS.
2. Develop an assay to evaluate expression of the Immunoglobulin G (IGHG1), A (IGHA1)
and M (IGHM) heavy chain genes in healthy individuals and in patients with
hypogammaglobulinaemia.
3. Determine the efficacy of this approach in identifying patients with
hypogammaglobulinaemia and evaluate its applicability as a potential newborn
screening test for PID manifested by hypogammaglobulinaemia.
It was hypothesised that: 
1. RNA can be effectively extracted from DBS for downstream use.
2. Expression of the IGHG1, IGHA1 and IGHM genes will be reduced in patients with
hypogammaglobulinaemia compared with healthy control subjects.
3. This testing strategy can be applied as a newborn screening testing strategy to enable
identification of infants with PID manifested by hypogammaglobulinaemia.
6.4 Materials and Methods 
Ethical considerations 
This study was approved by the Women’s and Children’s Hospital Network Human Ethics 
Research Committee (HREC/16/WCHN/164) and Research Governance Committee 
(SSA/16/WCHN/192). Written, informed consent was obtained from all participants. This 
research was conducted in accordance with the Helsinki Declaration of 1964 and its later 
amendments. 
Patient and sample recruitment 
Nineteen paediatric patients with PID, including five patients with X-linked 
agammaglobulinaemia (XLA) and one with X-linked hyper IgM syndrome (X-HIGM) were 
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recruited from the immunology department in a single South Australian centre. Characteristics 
of included patients are provided in Table 6.5.1. The majority of these patients were currently 
hypogammaglobulinaemic based on nephelometry results, and/or were receiving either 
intravenous or subcutaneous gammaglobulin replacement therapy. In addition, 13 healthy 
adult control subjects were recruited. Blood was collected from each participant onto filter 
paper, mimicking dried blood spots collected on Guthrie cards in the neonatal period. The 
original Guthrie card specimen for one XLA patient (Patient 5) was also accessed. Fifteen 
anonymised dried blood spot samples, up to 17 years of age, were accessed from the SA 
Neonatal Screening Laboratory, Adelaide.  
RNA extraction and cDNA synthesis 
Two 3.2mm punches were removed from each DBS sample for each specimen. RNA was 
extracted from the DBS punches using a method we developed. Briefly, the DBS punches 
were eluted in 200µL of rapid RNA extraction solution (Ambion, Applied Biosystems, MA, 
USA), and incubated at room temperature on a plate shaker for 15 minutes. The eluate was 
removed, and RNA and DNA was extracted using the QiaAMP MinElute Virus Spin Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. cDNA was synthesised using 
the Bio-Rad cDNA iScript synthesis kit (Bio-Rad, California, USA). Twenty nanograms of RNA 
was added to 4µL of 5X iScript Reaction Mix, 1µL of iScript Reverse Transcriptase and 
nuclease-free water to give a final volume of 20µL. Thermal cycler conditions were as follows: 
Priming 250C for 5 minutes, reverse transcription 460C for 20 minutes, RT inactivation 950C for 
1 minute, hold 40C for 20 minutes. 
Gene expression analysis 
Five microlitres of the cDNA product, diluted 1:5, was added to 10µL of 2X Taqman Gene 
Expression Mastermix (Applied Biosystems, MA, USA), 7µL of RNAse-free water and 1µL of 
10X TaqMan gene expression assay for one of the following per reaction: IGHG1 
(Hs00378340_m1, Cat. No. 4331182, FAM-MGB), IGHA1 (Hs00733892_m1, Cat. No. 
4331182, FAM-MGB), IGHM (Hs00378435_m1, Cat. No. 4331182, FAM-MGB) and ACTB 
(Hs01060665_g1, Cat. No. 4331182, FAM-MGB) (Applied Biosystems, MA, USA). ACTB (β-
actin) was used as a housekeeper gene. Samples were run in triplicate for the genes of interest 
and housekeeper gene, with appropriate positive and negative (non-template) controls on a 
Bio-Rad iQ5 qPCR instrument (Bio-Rad, California, USA). Thermal cycler conditions were as 
follows: hold 500C for 2 minutes, hold 950C for 10 minutes followed by 70 X cycles (950C for 
15 second, 600C for 1 minute), standard ramp rate. Quality control was maintained by 
assessment of a minimum CT threshold for ACTB for each sample, and samples achieving 
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threshold at a CT of >45 with poor traces were considered non-specific. Given that the RNA 
used was derived from DBS and was therefore of a lower concentration and quality compared 
with RNA extracted from other sources (such as fresh whole blood or purified PBMCs), later 
than usual amplification was noted for ACTB and other genes assessed. 
Data analysis 
Data was analysed using the ∆CT method, comparing the gene of interest with the 
housekeeper gene for each patient, and comparing these with pooled healthy control values 
to determine relative gene expression. Statistical analysis was not performed due to the low 
number of samples and heterogeneity of patient groups. Figures were generated using 
GraphPad Prism software, Version 7.0d (California, USA). 
6.5 Results 
Characteristics of included patients 
Clinical characteristics and laboratory investigation results of patients included in this study are 
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Immunoglobulin gene expression was absent in patients with XLA 
Five patients with XLA were included in this analysis, and all had absent expression of IGHG1, 
IGHA1 and IGHM, in the context of detectable ACTB expression (Figure 1 A & B). Patient 5 
was recruited as a newborn infant (sibling of patient 1) whose original Guthrie card was 
sampled for extraction of RNA. For this patient, immunoglobulin levels were measured at 3 
weeks of life and this value therefore reflects the maternal IgG level (Table 1). KREC levels 
were undetectable in all five patients. 
Figure 1: Immunoglobulin heavy chain (IGHG1, IGHA1, IGHM) and ACTB expression in 
patients with XLA. A) Representative qPCR curves from one healthy control and one 
patient with XLA. B) Relative gene expression for all XLA patients compared with healthy 
control subjects (∆Ct) and corresponding KREC and immunoglobulin protein results 
(measured by nephelometry) 
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Immunoglobulin gene expression is variable amongst healthy controls, PID 
patients with normal or partial reductions in levels of IgM, IgA and IgG
Expression of IGHM, IGHA1 and IGHG1 was variable between healthy controls and patients 
with PID who had either normal or partial reduction in their immunoglobulin levels (Figure 2). 
IGHG1 expression was reduced in most patients with low IgG levels (prior to commencing 
immunoglobulin therapy). IGHG1 was expressed in one patient with 22q deletion syndrome, 
one with APRC1B deficiency who had normal immunoglobulin levels measured by 
nephelometry, and in three patients with CVID. 
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Figure 2: IGHM, IGHA1 and IGHG1 expression (∆Ct) in healthy control subjects and patients 
with PID with normal or decreased levels of IgA and IgM as measured by nephelometry. 
A) Relative expression of IGHM in controls and PID patients with normal (left panel) and
low (right panel) IgM levels. B) Relative expression of IGHA1 in controls and PID patients
with normal (left panel) and low (right panel) IgA levels. C) Relative expression of IGHG1
in controls and PID patients. 
RNA can be extracted from DBS stored for up to 17 years and used for gene 
expression assays 
Using our method, RNA could be effectively extracted and ACTB expression was detectable 
from neonatal DBS sampled from Guthrie cards aged between 3 weeks and 18 years of age 
(Figure 3 (A)).  
Immunoglobulin gene expression is detectable in newborn DBS specimens 
Immunoglobulin heavy chain gene expression was detectable in recently collected DBS from 
newborn Guthrie card specimens. IGHA1 and IGHM were more highly expressed than IGHG1 
(Figure 3 (B)). 
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Figure 3: A) ACTB expression in neonatal DBS specimens stored at room temperature for 
up to 17 years. B) Expression of IGHG1, IGHA1 and IGHM from recently collected 
neonatal DBS specimens (n=10) (∆Ct). 
6.6 Discussion 
Despite recent technological advances in methodologies for screening for PID, at the current 
time, it is not possible to screen newborns for PID manifested by hypogammaglobulinaemia. 
Here, we describe a novel assay by which RNA extracted from DBS specimens can be used 
to evaluate immunoglobulin heavy chain gene expression as a surrogate marker for production 
of IgG, IgA and IgM.  
Our results indicate that this technique is effective in identifying children with absolute 
deficiencies of immunoglobulin production, as is the case in patients with XLA, where IGHG1, 
IGHA1 and IGHM expression are absent. We demonstrated on an original Guthrie card 
specimen that this technique could accurately identify a newborn with XLA, providing proof of 
concept of this method as a potentially useful newborn screening test.  
We also found that the degree of immunoglobulin heavy chain gene expression is highly 
variable between healthy control individuals, and amongst children with PID with either normal 
or low immunoglobulin levels measured by nephelometry. Given this, our technique in its 
current format is not sufficiently sensitive to identify partial reductions in immunoglobulin levels. 
Although it has previously been demonstrated that RNA can be extracted from DBS34-36,38, this 
has classically been challenging, due to RNA degradation over time. We demonstrated that 
our method for RNA extraction from DBS specimens yielded RNA of sufficient quality and 
quantity for downstream applications. This was effective even for DBS stored at room 
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temperature for up to 17 years. We also demonstrated, in a small number of neonatal Guthrie 
card DBS specimens, that the immunoglobulin heavy chain genes are expressed early in life. 
IGHA1 and IGHM were more highly expressed than IGHG1, which correlates with our current 
understanding that IgG production increases incrementally during early infancy22. Based on 
the results of our small pilot results, the combination of reduced or absent expression of all 
three genes simultaneously is suggestive of a severe form of antibody deficiency (i.e. XLA). 
Our one patient with X-HIGM syndrome also had absent IGHA1 and IGHG1 expression, but 
preserved IGHM gene expression.  
Current screening technologies applying a multiplexed TREC/KREC assay is able to identify 
patients with XLA10, and hence our current transcriptomic assay would not confer any 
additional benefit over this assay for detection of hypogammaglobulinaemia secondary to 
congenital B cell deficiencies. However, absent expression of IGHA1 and IGHG1 in our patient 
with X-HIGM, with preserved IGHM expression, suggesting that this severe form of antibody 
deficiency with normal KREC levels10 is detectable using our assay. Hence, this assay shows 
potential to increase the breadth of screened immunodeficiency diseases. 
A limitation of this pilot study is the small sample size.  Performing this assay on a larger 
number of patients and healthy controls, and performing correlation studies with nephelometry 
results will provide a better indication of its sensitivity and specificity. It is possible that this 
assay could be further optimised to improve testing characteristics. In order to apply this assay 
as a newborn screening test, this method requires evaluation on a large cohort of neonates to 
determine expected ‘normal ranges’ for gene expression in order to identify infants with 
abnormal results. The kinetics of immunoglobulin heavy chain gene expression over time 
during the early neonatal period and infancy could also be explored. Expression of the IGHD 
gene, encoding for IgD production, could also be assessed in follow-up studies as it may also 
be a useful marker for significant immunoglobulin deficiency states. 
Once further developed, this gene expression assay may have future applications beyond the 
newborn period. This assay may be useful as an adjunctive testing strategy in the work-up of 
patients with possible PID, and may also provide useful clinical information regarding an 
individual’s current capacity to produce their own endogenous immunoglobulins whilst 
receiving gammablobulin replacement therapy. This would be particularly useful for informing 
clinical decisions regarding optimal timing for a trial of cessation of replacement therapy, for 
example in the case of transient hypogammaglobulinaemia of infancy or in patients with 
secondary hypogammaglobulinaemia. In addition, this assay could be used as a more 
accurate estimate of endogenous immunoglobulin production in infants under 6 months, in 
whom maternal immunoglobulin G and A levels confound results obtained by 
nephelometry20,22. 
CHAPTER 6: TRANSCRIPTOMIC APPROACH TO NEWBORN SCREENING 
Page 66 
6.7 Conclusion 
This early pilot data shows that using our method, RNA can be effectively extracted from DBS 
specimens and used in gene expression assays. This assay may be used to investigate the 
immunoglobulin transcriptome in health and disease. Expression of the IGHM, IGHA1 and 
IGHG1 genes is variable in healthy controls and PID patients with normal or reduced levels of 
IgA and IgM as determined by nephelometry. Our technique does, however, effectively identify 
patients with absolute deficiencies in antibody production such as XLA, who lack expression 
of all three genes simultaneously. We have demonstrated a proof of concept that this testing 
strategy can identify a newborn with XLA. It is anticipated that further refinement of this assay 
will enable identification of individuals with moderately reduced immunoglobulin levels, thereby 
becoming a strategy by which newborns can be screened for PID manifested by 
hypogammaglobulinaemia, with other potential applications beyond the newborn period. 
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CHAPTER 7: POPULATION-BASED NEWBORN 
SCREENING MEETS PERSONALISED MEDICINE: 
IDENTIFYING SINGLE NUCLEOTIDE POLYMORPHISMS 
PREDICTING DISEASE SUSCEPTIBILITY  
7.1 Introduction and Contextual Statement 
Moving toward a modern healthcare model which aims to provide patients with personalised, 
precision medicine, it would be beneficial not only to diagnose disease states, but also to 
identify individuals at risk for developing specific diseases by screening for susceptibility 
factors. This is discussed in the context of screening neonates for genetic polymorphisms 
which confer susceptibility to specific infectious diseases. This chapter examines the role of 
genotyping-based assays as a potential tool to screen infants for single nucleotide 
polymorphisms in fucosyltransferase genes (FUT2 and FUT3), enabling identification of their 
intrinsic susceptibility to a range of infections and other disease states. It further explores this 
approach as a means by which to apply personalised medicine.  
7.2 Publication: Fucosyltransferase Gene Polymorphisms and Lewis b 
Negative Status are Frequent in Swedish Newborns, with 
Implications for Infectious Disease Susceptibility and Personalized 
Medicine 
This chapter presents the fifth paper included in this thesis. The following paper, entitled 
‘Fucosyltransferase gene polymorphisms and Lewis b negative status are frequent in Swedish 
newborns, with implications for infectious disease susceptibility and personalized medicine’, 
by Jovanka King, Jezabel Varadé and Lennart Hammarström was accepted for publication in 
the peer reviewed journal, Journal of the Pediatric Infectious Diseases Society, on 7 August 
2018. Supplementary material follows the paper. 
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FUT Polymorphisms in Swedish Newborns • JPIDS XXXX:XX (XX XXXX) • 1
O R I G I N A L  A R T I C L E
Fucosyltransferase Gene Polymorphisms and Lewisb-
Negative Status Are Frequent in Swedish Newborns, With 
Implications for Infectious Disease Susceptibility and 
Personalized Medicine.
Jovanka R. King,1,2 Jezabel Varadé,1 and Lennart Hammarström1
1Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; 2Department of Immunopathology, SA 
Pathology, Women’s and Children’s Hospital Campus, and Robinson Research Institute and Discipline of Paediatrics, School of Medicine, University of Adelaide, North Adelaide, 
South Australia
Background. Single-nucleotide polymorphisms (SNPs) in the fucosyltransferase genes FUT2 and FUT3 have been associated 
with susceptibility to various infectious and inflammatory disorders. FUT variations influence the expression of human histo-blood 
group antigens (HBGAs) (H-type 1 and Lewis), which are highly expressed in the gut and play an important role in microbial attach-
ment, metabolism, colonization, and shaping of the microbiome. In particular, FUT polymorphisms confer susceptibility to specific 
rotavirus and norovirus genotypes, which has important global health implications.
Methods. We designed a genotyping method using a nested polymerase chain reaction approach to determine the frequency of 
SNPs in FUT2 and FUT3, thereby inferring the prevalence of Lewisb-positive, Lewisb-negative, secretor, and nonsecretor phenotypes 
in 520 Swedish newborns.
Results. There was an increased frequency of homozygotes for the minor allele for 1 SNP in FUT2 and 4 SNPs in FUT3. Overall, 
37.3% of newborns were found to have Lewis b negative phenotypes (Le (a+b−) or Le (a−b−). Using our new, sensitive genotyping 
method, we were able to genetically define the Le (a−b−) individuals based on their secretor status and found that the frequency of 
Lewis b negative newborns in our cohort was 28%.
Conclusions. Given the high frequency of fucosyltransferase polymorphisms observed in our newborn cohort and the implica-
tions for disease susceptibility, FUT genotyping might play a future role in personalized health care, including recommendations for 
disease screening, therapy, and vaccination.
Keywords. fucosyltransferase; FUT2; FUT3; Lewisb; secretor; nonsecretor; rotavirus; norovirus.
The fucosyltransferase 2 (FUT2) and fucosyltransferase 3 (FUT3) 
genes give rise to H-type 1 and Lewis human histo-blood group 
antigens (HBGAs). Single-nucleotide polymorphisms (SNPs) 
located in these genes are associated with susceptibility or resis-
tance to various infectious and inflammatory diseases and play 
a role in shaping the microbiome as a result of the influence of 
HBGAs on colonization patterns of the commensal intestinal 
flora. These antigens are highly expressed in the gut mucosa 
and secretions and are implicated in susceptibility to a range of 
microorganisms and other environmental stimuli [1]. HBGAs 
are receptors for various pathogens, including rotavirus, norovi-
rus, Helicobacter pylori, and Campylobacter jejuni. The pattern of 
antigen expression by each individual, therefore, determines his 
or her susceptibility to infection [2–5]. In the case of Escherichia 
coli, HBGAs have been shown to contribute to microbial metab-
olism by providing a carbon source [6] and also to provide nutri-
tion for other bacteria, including commensal flora [1]. As a result 
of these mechanisms, FUT polymorphisms play an important 
role in infectivity by pathogenic microorganisms, intestinal col-
onization with commensal flora, and shaping of the microbi-
ome [7], and there are implications for host defense, intestinal 
homeostasis, and disease susceptibility.
The secretor (FUT2) gene is located on chromosome 19q13.3 
and encodes the enzyme α-1,2-fucosyltransferase, which con-
verts the type 1 chain precursor to H-type 1 antigen. The Lewis 
(FUT3) gene is located on chromosome 19p13.3 and encodes 
α-1,3-fucosyltransferase, which converts the H-type 1 antigen to 
Lewisb and the type 1 chain precursor to Lewisa [8, 9] (Figure 1). 
The presence of specific alleles in FUT2 and FUT3 result in 
differential gene expression, protein production, and enzyme 
activity [10, 11]. The prevalence of each haplotype and ensuing 
Lewisb and secretor phenotype markedly differs between popu-
lations (Table 1) [12, 13]. A previous study in a Swedish popula-
tion (of 207 healthy individuals) found 55% of the participants to 
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be Lewisb positive with a secretor phenotype [Se+, Le(a−b+)], 31% 
were Lewisb-negative nonsecretors [Se−, Le(a+b−)], 11% were 
secretors with a Lewis-null phenotype [Se+, Le(a−b−)], and 3% 
were nonsecretors and Lewis null [Se−, Le(a−b−)] [14].
It was noted recently that H-type 1 and Lewis HBGAs are 
putative receptors for norovirus and rotavirus VP8* and thus play 
a role in viral attachment and entry into enterocytes [2, 15, 16]. 
Interindividual genetic variations (SNPs) in HBGAs have been 
found to confer either susceptibility or resistance to infection 
with specific norovirus and rotavirus genotypes [17]. Rotavirus 
infection is an important global health issue; it is a major cause 
of infectious gastroenteritis worldwide and accounts for approxi-
mately 215 000 child deaths annually, predominantly in develop-
ing countries [18]. Rotavirus is a nonenveloped double-stranded 
RNA virus that belongs to the Reoviridae family. Rotavirus strains 
P[4] and P[8] bind to Lewisb and H-type 1 HBGAs, and strain 
P[6] binds to the H-type 1 HBGA alone. Hence, individuals who 
have a secretor phenotype (ie, express Lewisb antigen) are more 
prone to rotavirus P[8] infection [11, 17], whereas nonsecretors 
have an intrinsic resistance to infection by these strains [11]. 
This finding is supported also by the observation that secretors 
produce higher levels of anti-rotavirus antibodies than nonsecre-
tors [14]. Two safe and efficacious live attenuated rotavirus vac-
cines are available. Either monovalent Rotarix (GSK Biologicals, 
Brentford, United Kingdom) or multivalent RotaTeq (Merck & 
Co, New York, NY) is included in routine immunization sched-
ules in many countries. However, it is not yet included in the 
Swedish childhood immunization program.
Norovirus, an RNA virus in the family Caliciviridae, accounts 
for approximately 20% of all cases of acute gastroenteritis glob-
ally and represents an important public health issue because of 
its high rate of transmissibility [19]. Six genogroups of noro-
virus exist, and groups GI and GII account for the majority of 
infections [20]. A  recent meta-analysis revealed that secretors 
were 4.2 times more likely to be infected with norovirus than 
were nonsecretors and had a 9.9 times greater risk of GII.4 gen-
otype infection [20]. Secretors were found to have a 26.6 times 
greater risk of rotavirus infection than were nonsecretors [20]; 1 
included study revealed that nonsecretor status was protective 
against severe rotavirus infection [21]. The authors of this study 
further highlighted population-specific differences in the fre-
quency of FUT2 polymorphisms, showing that the prevalence of 
nonsecretors was significantly lower in Hispanic children [21].
Given the implications of fucosyltransferase gene polymor-
phisms and ensuing Lewisb and secretor phenotypes in deter-
mining disease susceptibility, we genotyped a cohort of Swedish 




Caucasian African Japanese Chinese
Se+, Le(a−b+), secretor phenotype, Lewisb positive 72 55 73 62
Se−, Le(a+b−), nonsecretor phenotype, Lewisb negative 22 20 0.2 0
Se+ or Se−, Le(a−b−), any secretor phenotype,  
Lewis-null phenotype
6 25 10 11
Sew+, Le(a+b+) (rare), Lewisb-positive “weak” secretor Rare Rare 16.8 27
aAdapted from Reid et al [12] and Daniels and Bromilow [13].
Figure 1. Histo-blood group antigen biosynthetic pathways from Type 1 and Type 2 precursors. FUT2 generally encodes for Lewis and blood group antigen 
expression on Type 1 glycans, and FUT1 generally encodes for Lewis expression on Type 2 glycans. Antigens are given in white boxes, key genes encoding 
enzymes are given in grey boxes. Effects of FUT2 and FUT3 mutations on enzyme expression and ensuing secretor, Lewis a and b phenotypes are given in 
black boxes. FUT2 = α(1,2)fucosyltransferase, FUT3 = α (1,3-4)fucosyltransferase 3, Enzyme A = Nacetylgalactosaminetransferase, Enzyme B = α-galacto-
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neonates to determine the frequencies of 4 SNPs in FUT3 and 2 
in FUT2  and the prevalence of secretors, nonsecretors, Lewisb-
negative, and Lewisb-positive neonates.
MATERIALS AND METHODS
Sample Recruitment
This study was carried out in accordance with the standing 
regional ethical committee and Karolinska Institutet policies, 
which permit the use of anonymized biological samples for 
research purposes. As part of the routine neonatal screen-
ing program, a Guthrie card specimen is collected from each 
Swedish newborn; blood from a heel punch is blotted onto 
filter paper and tested for a range of diseases in the first few 
days of life. A punch measuring 3.2 mm in diameter was taken 
from a dried blood spot from each of 520 anonymized newborn 
Guthrie cards from the Centre for Inherited Metabolic Diseases 
(Karolinska University Hospital Solna, Stockholm, Sweden).
Selection of FUT2 and FUT3 SNPs for Analysis
Two SNPs in FUT2  (rs601338 and rs602662) and 4 in FUT3 
(rs778986, rs28362459, rs3894326, and rs3745635) were 
selected for analysis on the basis of previous publications that 
suggested that polymorphisms at these sites, either alone or in 
combination with other polymorphisms, confer abnormal fuco-
syltransferase enzyme activity and therefore are associated with 
secretor or nonsecretor Lewisb-negative status (Supplementary 
Table 1).
In silico Analysis
Because FUT2  and FUT3 are partially duplicated in the genome, 
particularly in the genes FUT1, and FUT5  and/or FUT6 respec-
tively, we assessed the specificity of the primers used in different 
publications for genotyping the SNPs rs601338 and rs602662 in 
FUT2  and rs778986, rs28362459, rs3894326, and rs3745635 in 
FUT3. To establish whether the different primers described in 
the publications identified in the systematic review were specific, 
we checked the annealing region for each pair of primers using 
the Ensembl BLAST tool (see http://www.ensembl.org/index.
html, last accessed: July 19, 2017). Primer pairs that annealed in 
more than 1 chromosomal location and produced an amplicon 
of less than 100 base pairs were classified as nonspecific.
Genotyping for SNPs in the FUT2 and FUT3 Genes
Genomic DNA was extracted from the neonatal dried blood 
spots using a DNA-extraction-kit method (Qiagen, Dusseldorf, 
Germany) according to manufacturer instructions. Genomic 
DNA was preamplified by polymerase chain reaction (PCR) 
using primers specific for the FUT2  and FUT3 gene regions 
containing SNPs of interest (Supplementary Table  2). Thirty 
nanograms of genomic DNA, 10  µL of 1× GoTaq colorless 
buffer (Promega, Madison, Wisconsin), 3 µL of 10 mM deoxy-
ribonucleotide triphosphate (dNTP) (Invitrogen, Carlsbad, 
California), 3 µg of 1.5 mM/µL MgCl2 (Promega), 2 µL of each 
forward and reverse amplification primer at 10  nM (Eurofins 
Scientific, Brussels, Belgium), 0.25  µL of GoTaq DNA poly-
merase (Promega), and 26.75 µL of distilled water were com-
bined to result in a total reaction volume of 50  µL. Thermal 
cycler conditions were as follows: initial denaturation at 95°C 
for 2 minutes, followed by 30 cycles of denaturalization at 95°C 
for 30 seconds, annealing at 68°C (FUT2 ) or 60°C (FUT3) for 
30 seconds, and extension at 72°C for 1 minute and then final 
extension at 72°C for 10 minutes. PCR products were visual-
ized in 1% agarose gel. TaqMan chemistry (Life Technologies, 
Carlsbad, California) was used to genotype 2 SNPs in FUT2  
(rs601338 [C_2405292_10] and rs602662 [C_2405293_10]) 
and 2 SNPs in FUT3 (rs3894326 [C_801690_10] and rs778986 
[C_11458475_20]). Nontemplate negative controls and sam-
ples confirmed (by Sanger sequencing) to have mutant alleles 
were used as positive controls in the assays. Four microliters of 
amplified PCR product diluted 1:200 were used in the TaqMan 
reaction according to manufacturer conditions in a final vol-
ume of 20 µL (Life Technologies) and analyzed using a real-time 
PCR system under conditions recommended by the manufac-
turer (Applied Biosystems, Foster City, California). The FUT3 
SNPs rs3745635 and rs28362459 were genotyped using 4  µL 
of amplified PCR product diluted 1:80 as a template for Sanger 
sequencing.
Inferring Secretor and Lewisb Status
Neonates found to carry the ancestral (wild-type) genotype 
at all evaluated FUT2  and FUT3 SNP sites were considered to 
have normal FUT2  and FUT3 expression and were classified as 
Lewisb-positive secretors [Se+, Le(a−b+)]. Neonates who were 
homozygous for the minor allele in FUT2  at rs601338 and/or 
rs602662 with a wild-type FUT3 genotype were classified as 
Lewisb-negative nonsecretors [Se−, Le(a+b−)]. Neonates homo-
zygous for the minor allele in FUT3 at rs778986, rs28362459, 
rs3894326, and/or rs3745635 with a wild-type FUT2  genotype 
were considered to have a secretor Lewis-null phenotype [Se+, 
Le(a−b−)], and those who were homozygous for the minor allele 
at 1 or more sites in FUT2  and FUT3 were considered to have a 
nonsecretor Lewis-null phenotype [Se−, Le(a−b−)].
Statistical Analysis
The frequency of each of the 6 SNPs analyzed in our study 
population was determined and compared with data obtained 
from the 1000 Genomes Project European Caucasian (EUR) 
population (see http://www.internationalgenome.org, last 
accessed: July  3, 2017). As previously described, the frequen-
cies of the secretor, nonsecretor, Lewisb-negative, and Lewis-
null phenotypes were determined on the basis of analysis of 
the pattern of SNPs present in each neonate. Statistical anal-
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Systematic Review and Meta-analysis
To compare our genotyping results with those in other pub-
lished cohorts in different populations, we conducted a sys-
tematic review and meta-analysis using PubMed (see http://
www.ncbi.nlm.nih.gov/pubmed, last accessed:  July  3, 2017), 
Medline Ovid (see http://www.ovid.com, last accessed:  July  3, 
2017) and the Cochrane Library (see http://www.cochraneli-
brary.com, last accessed:  July  3, 2017) databases by applying 
the Medical Subject Heading terms “FUT2 ,” “FUT3,” “single 
nucleotide polymorphism,” “secretor,” “nonsecretor,” “Lewisb,” 
and “Lewisb negative.” We also evaluated minor genotype fre-
quencies for each site in the published studies and the 1000 
Genomes Project for selected populations. Review Manager 5.0 
(2008 Cochrane Collaboration, Oxford, United Kingdom) was 
used to carry out the statistical analysis. The stages of the sys-
tematic review and meta-analysis, including applied inclusion 
and exclusion criteria are shown in Figure 2.
RESULTS
Systematic Review and Meta-analysis
Of the 126 potentially eligible studies identified after initial 
exclusion of duplicates, errata, and meeting abstract communi-
cations, 96 were evaluated in more detail, and 17 were included 
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Figure 3. Forrest plots, minor genotype frequency for evaluated FUT2 SNPs (A) and FUT3 SNPs (B) in published studies, 1000 Genomes Project for selected pop-
ulations and the current study. Abbreviation: AFR, African; AMR, American; CDX, Chinese Dai in Xishuangbanna China; CHB, Han Chinese in Beijing, China; CHS, 
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in the meta-analysis (Figure 2; Supplementary Table 3). The fre-
quencies of the minor allele genotype for homozygotes for each 
evaluated SNP in our cohort were compared with those in other 
published studies and the 1000 Genomes Project for different 
populations (Figure 3). As expected, differences were noted in 
minor allele genotype frequencies in different populations.
SNP Genotyping Results
Statistically significant differences between the frequencies 
of the minor allele genotype for homozygotes for rs778986*T 
(P = .007), rs3894326*A (P ≤ 0.001), rs28362459*G (P = .003), 
and rs3745635*A (P =  .001) in FUT3 in our cohort and those 
in the 1000 Genomes Project cohort were found (Table 2). We 
found no statistically significant difference in the frequencies of 
the minor allele genotype for homozygotes for the FUT2  SNPs 
rs601338*A or rs602662*A. All except 1 SNP (rs602662) had 
a departure from Hardy–Weinberg equilibrium. We success-
fully genotyped 490 infants for rs601338, 509 for rs602662, 506 
for rs778986, 508 for rs3894326, 510 for rs28362459, and 518 
for rs3745635 (overall genotyping success rate for SNPs in this 
study, >95%).
Identification of a New SNP in FUT3
We identified 1 new SNP (G/T) at position 5844777 in the 
FUT3 gene, 4 base pairs upstream of rs28362459 in 3 sam-
ples (National Center for Biotechnology Information submit-
ted SNP number (ss) = 2137543878, rs1391064014). This SNP 
results in a synonymous change (Leu > Leu). One heterozygous 
(GT) and 2 homozygous (GG) neonates were identified (minor 
allele frequency of 0.01).
Inferred Prevalence of Secretor, Nonsecretor, Lewisb-Negative, and 
Lewis-Null Phenotypes
The most prevalent minor alleles in our cohort were rs601338*A 
in FUT2  (124 infants [25%]) and rs778986*T in FUT3 (32 
infants [6%]). To calculate the prevalence of each inferred 
phenotype correlating with the FUT2 /FUT3 haplotypes in the 
Swedish population, we included all neonates genotyped for all 
6 SNPs in this study, and 457 neonates were considered. In our 
cohort, 62.7% of the neonates were classified as Lewisb positive 
with a secretor phenotype [Se+, Le(a−b+)], 23.5% were Lewisb-
negative nonsecretors [Se−, Le(a+b−)], 9.6% were considered 
to have a secretor Lewis-null phenotype [Se+, Le(a−b−)], and 
4.2% had a nonsecretor Lewis-null phenotype [Se−, Le(a−b−)] 
(Table  3). In total, on the basis of SNP genotyping, 37.3% of 
the Swedish newborns were found to have Lewis b negative 
Table 2. Genotype and Minor Allele Frequencies of Evaluated SNPs in FUT2 and FUT3
SNP Gene Genotype Allele
Swedish Neonate Cohort 
(n [%]) 1000 Genomes CEU Cohort (n [%]) Pa,b (Homozygotes for Minor Allele) OR (95% CI)b
rs601338 FUT2 AA 124 (25) 105 (21) .097 1.28 (0.96–1.73)
AG 161 (33) 234 (47)
GG 205 (42) 164 (33)
rs602662 FUT2 AA 107 (21) 115 (23) .479 0.90 (0.67–1.21)
AG 228 (45) 241 (48)
GG 174 (34) 147 (29)
rs778986 FUT3 TT 32 (6) 14 (3) .007 2.36 (1.24–4.48)
CT 132 (26) 153 (30)
CC 342 (68) 336 (67)
rs3894326 FUT3 TT 19 (4) 2 (0.4) <.001 0.006 (0.004–0.01)
AT 99 (19) 69 (14)
AA 390 (77) 432 (86)
rs28362459 FUT3 GG 20 (4) 5 (1) .003 4.07 (1.51–10.92)
GT 72 (14) 89 (18)
TT 418 (82) 409 (81)
rs3745635 FUT3 AA 12 (2) 0 (0) .001 NA
AG 26 (5) 16 (3)
GG 480 (93) 487 (97)
Abbreviations: CEU, Northern Europeans from Utah; CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
aχ2 test.
bBold values indicates statistically significant results.
Table 3. Prevalence of Inferred Secretor/Lewisb Phenotypes in a 
Swedish Neonatal Cohort
Secretor/Lewisb Phenotype Prevalence (n [%])
Se+, Le(a−b+), secretor Lewisb-positive phenotype, normal FUT2 expres-
sion, normal FUT3 expression
286 (62.7)
Se−, Le(a+b−), nonsecretor Lewisb-negative phenotype, FUT2 mutation, 
normal FUT3 expression
107 (23.5)
Se+, Le(a−b−), secretor Lewis-null phenotype, normal FUT2 expression, 
FUT3 mutation
44 (9.6)
Se−, Le(a−b−), nonsecretor Lewis-null phenotype, FUT2 mutation, FUT3 
mutation
19 (4.2)
Sew, Le(a+b+) (rare), “weak” secretor Lewisb-positive phenotype, FUT2 
mutation (could not be assessed in this study)
NA






/jpids/advance-article-abstract/doi/10.1093/jpids/piy085/5245399 by  jovanka.king@
ki.se on 12 January 2019
Page 7 
FUT Polymorphisms in Swedish Newborns • JPIDS XXXX:XX ( XX XXXX) • 9
phenotypes (Le (a+b−) or Le (a−b−). However, using our new sen-
sitive genotyping method, we were able to genetically define the 
Le(a−b−) individuals based on their secretor status. Overall, the 
frequency of Lewis b negative newborns was 28%, in keeping 
with the expected frequency in Caucasian populations [12, 13].
DISCUSSION
We noted statistically significant higher-than-expected fre-
quencies of the minor allele genotype for homozygotes in all 4 
SNPs in FUT3 (rs778986*T, rs3894326*A, rs28362459*G, and 
rs3745635*A). The frequencies of the FUT2  SNPs rs601338*A 
and rs602662*A were not significantly different than those in 
the 1000 Genomes Project cohort. We found an ensuing higher 
prevalence of secretors and Lewisb-negative neonates in our 
cohort. Along with differences in methodology and genotyp-
ing techniques by which SNPs were identified in other studies 
and the variability of SNPs selected for analysis, other possible 
explanations for our findings include population heteroge-
neity and the presence of “weak” secretors (Sew) or compen-
satory transferases in our cohort. Weak-secretor phenotypes 
have been described for various populations and are associated 
with homozygosity for the minor allele genotype in FUT2  SNPs 
A385T (rs1047781) in East Asian populations [22] and G739A 
(rs602662) and T839C in Portuguese populations [23].
FUT2  and FUT3 gene segments are partially duplicated in 
the genome, particularly in FUT1 and FUT5   and/or  FUT6. 
Hence, we designed a nested-PCR approach to ensure binding 
specificity of our secondary primers and probes to facilitate 
acquisition of the most accurate genotyping data. Depending 
on the genotyping technique used, the replication of FUT2  
and FUT3 gene segments elsewhere in the genome indicates 
that there is a risk of nonspecific binding to irrelevant genomic 
segments and inaccurate genotyping results. However, the reli-
ability of genotyping is improved markedly if a preamplification 
step is applied to genomic DNA using highly specific primers to 
isolate the areas of interest in FUT2  and FUT3.
In addition to methodologic differences, it is likely that 
the number and combination of SNPs analyzed will affect the 
observed frequencies of various secretor and Lewisb phenotypes 
in a population. Many FUT2  and FUT3 polymorphisms have 
been identified, each with variable frequencies in different pop-
ulations, and evidence of functional effects on enzyme function 
for many, but not all, SNPs has been documented. Comparison 
between studies is difficult, given the heterogeneity in the 
assignment of Lewisb and secretor statuses based on genotyping 
alone and variable combinations of evaluated SNPs. It is possible 
that the true prevalence is even higher because of the presence 
of additional as-yet-unidentified SNPs with functional effects. 
For example, we identified a new SNP in FUT3 that might give 
rise to altered Lewis antigen expression, although the functional 
consequence of this SNP requires further exploration. The 
influences of heterozygous and compound heterozygous geno-
types on enzyme activity have also been described; however, in 
the majority of studies, only homozygosity for the minor allele 
is considered when assigning Lewisb-negative status. Hence, the 
lack of uniformity in SNPs selected for evaluation, and con-
sideration of homozygous and heterozygous genotypes might 
explain discrepancies in the reported frequencies between the 
studies. Therefore, the true frequency of Lewisb-negative indi-
viduals might be underestimated. Furthermore, the effect of 
copy-number variations, deletions, and fusions (particularly 
in FUT2 ) in some populations have been described, but they 
require further investigation [24, 25].
Population heterogeneity also might contribute to the 
higher minor allele genotype frequencies in the SNPs analyzed 
in our cohort. It is likely that a percentage of our cohort were 
of non-Caucasian ethnicity, which explains the deviation from 
Hardy–Weinberg equilibrium observed in all but 1 evaluated 
SNP. A small percentage of individuals have a FUT2  mutation 
with a Le(a+b+) phenotype and are weak secretors, but it is a rare 
phenotype in Caucasians. However, the prevalence is higher in 
other populations (Table 1) [12, 13, 26] and is indistinguishable 
from a nonsecretor phenotype on the basis of genotyping meth-
ods alone. As such, a small number of neonates in our cohort 
might have been weak secretors. Furthermore, there might be 
a role for other compensatory transferases in those with FUT2  
polymorphisms such that they were phenotypically and func-
tionally secretors, which could have inflated our nonsecretor 
frequency artificially.
In some studies, secretor and Lewis antigen status is clas-
sified phenotypically using antigen expression assays alone, 
without genotyping. It should be noted that the expression of 
HBGAs can change in people with an altered physiological 
state such as pregnancy and in those with malignancy [13, 27]. 
Although Lewis antigens are reported to be fully developed and 
detectable in saliva at birth, the presence of various red cell anti-
gens is variable in the first weeks of life and does not reach full 
maturity until approximately 2 years of age [27, 28]. As such, 
in early childhood, genotyping-based assignment of secretor 
and Lewisb status is more reliable than the detection of red cell 
antigens, but results are comparable to those in salivary antigen 
studies.
The Lewis antigen system is complex, and although our 
knowledge of the precise physiological role of these HBGAs 
remains incomplete, it has become apparent that fucosyltrans-
ferase polymorphisms and ensuing antigen expression are asso-
ciated with predisposition to certain infections and diseases. As 
such, determining an individual’s Lewisb and secretor statuses is 
likely to have important implications for the provision of person-
alized medicine, including guidance of specific advice for pre-
vention, screening, and management of disease. On a population 
level, understanding the prevalence of these polymorphisms has 
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FUT2  secretor status is associated with increased suscepti-
bility to some genotypes of norovirus and rotavirus [11, 17], 
whereas nonsecretor status protects against infection [21]. 
Therefore, from a mechanistic perspective, vaccinating nonse-
cretor individuals who lack putative rotavirus P[8] receptors 
with a monovalent vaccine for this rotavirus genotype would be 
expected to elicit a poorer immune response and be less effec-
tive in these individuals. Vaccinating nonsecretors with a mon-
ovalent vaccine might be an explanation for the high rates of 
vaccine failure in countries such as Africa, where the frequency 
of Lewisb-negative nonsecretor individuals is high. However, 
studies that compared the vaccine efficacy of monovalent and 
multivalent vaccines found that efficacies differed by only 1% in 
both moderate-to-high-income and developing-world settings 
[29, 30]. The immune response to rotavirus infection and mech-
anisms by which previous natural infection and immunization 
confer protection against subsequent infection are multifaceted, 
and the roles of neutralizing antibodies (both homotypic and 
heterotypic), interferon-mediated innate immune responses, 
and cell-mediated mechanisms have been investigated [31, 
32]. The induction of serotype-specific neutralizing antibod-
ies was thought to be critical for protection against rotavirus 
infection, resulting in the development of multivalent vaccines; 
however, the demonstrable efficacy of monovalent vaccines has 
challenged this premise [31]. A recent study found that hetero-
typic protective immunity to rotavirus is mediated by the pro-
duction of heterotypic antibodies directed primarily toward the 
stalk (VP5*) of the viral attachment protein VP4, along with 
VP8* and surface glycoprotein VP7 [33]. Heterotypic antibody 
responses have been shown to confer protection against mul-
tiple rotavirus types despite monovalent vaccination [20, 34], 
although it remains unknown if the heterotypic antibody titers 
achieved for other viral strains are sufficient to confer adequate 
long-lasting protection.
Given the safety and efficacy of rotavirus vaccination and 
its demonstrated ability to reduce rotavirus-associated morbid-
ity and death, its inclusion in routine immunization programs 
worldwide should be considered. In regions where rotavirus 
vaccination is not offered as a standard practice for all infants, 
evaluation of FUT polymorphisms and ensuing secretor and 
Lewisb statuses could identify those infants who would derive 
the greatest benefit from rotavirus vaccination. From a mech-
anistic perspective, given the high prevalence of FUT poly-
morphisms in our population, a multivalent vaccine would be 
favorable.
Secretor status has been shown to play a role in the infectivity 
of other infectious diseases, including those caused by C jejuni 
[3], H pylori [4, 35], and human immunodeficiency virus (HIV) 
[36–38]. Blood group antigens facilitate H pylori binding to the 
gastric epithelium, and individuals who are secretors [4] and 
blood group O positive [35] are at an increased risk of infection 
and subsequent gastric ulceration. Nonsecretors seem to have a 
reduced risk of HIV infection, possibly as a result of the mod-
ification of mucosal surface carbohydrates [36], and reduced 
HIV-1 disease progression was found in some series [37, 38]. 
HBGAs provide a carbon source essential for the metabolism 
of bacteria such as E coli, thereby contributing to the virulence 
of these pathogens [6]. FUT2  polymorphisms also have been 
associated with poor outcome and complications in premature 
infants, including Gram-negative sepsis and necrotizing entero-
colitis [39], although these results were not reproduced in a sub-
sequent cohort [40].
It has been found that FUT polymorphisms play a signif-
icant role in the shaping of the microbiome in terms of col-
onization with commensal microbiota. Intestinal dysbiosis is 
implicated in the pathogenesis of various autoimmune and 
inflammatory diseases [1]. Secretors likely have a better abil-
ity to stabilize their microbiome; secretion of HBGAs into 
body fluids confers an improved first line of defense against 
pathogens and other environmental elements, and beneficial 
bacteria thrive on glycosylation products [1]. FUT2  polymor-
phisms have been implicated in some populations as a risk 
factor for Crohn disease [41–43], ulcerative colitis [43, 44], 
Behçet disease [45], celiac disease [43], and diabetes mellitus. 
In addition to being a risk factor for primary sclerosing cho-
langitis (PSC) [46], FUT2  polymorphisms have been shown 
to influence biochemical parameters in patients with PSC, 
which affects interpretation of the carcinoembryonic antigen 
test that is used for malignancy screening [47]. These findings 
have important implications for surveillance and investigation 
in this patient group and might be applicable to screening for 
other gastrointestinal malignancies [47]. Serum lipase levels 
and the risk of chronic pancreatitis are elevated in nonsecre-
tors [1]. Fucosyltransferase polymorphisms have been impli-
cated also as risk factors for cardiovascular disease [10, 48] 
and various malignancies [49–51]. They have also been shown 
to influence serum metabolite pathways, including vitamin B12 
levels [52, 53].
Given the implications of fucosyltransferase polymorphisms 
for disease susceptibility, screening of individuals might pro-
vide useful information to assist clinicians in providing person-
alized healthcare. Early identification of interindividual genetic 
differences in the newborn period would enable information to 
be readily available and actionable as needed, enabling accurate 
prediction of disease predisposition and facilitating appropri-
ately informed decisions regarding screening, treatment, and 
preventative therapies such as vaccination. Furthermore, the 
role of HBGAs in disease pathogenesis should be considered in 
the development of novel treatment modalities and in vaccine 
development.
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Table 4: Characteristics of FUT2 and FUT3 SNPs selected for analysis 
Gene rs 
candidate 















G G: 0.559 (562) 
A: 0.441 (444) 
MAF 0.2 
G|G 0.326 (164) 
A|A: 0.209 (105) 







G G: 0.532 (535) 
A: 0.468 (471) 
MAF 0.33 
G|G: 0.292 (147) 








T T: 0.902 (907)  
G: 0.098 (99) 
MAF 0.01 
T|T: 0.813 (409) 
T|G: 0.177 (89) 







A A: 0.927 (933)  
T: 0.073 (73) 
MAF 0.04 
A|A: 0.859 (432) 
A|T: 0.137 (69) 







C C: 0.180 (181)  
T: 0.820 (825) 
MAF 0.03 
C|C: 0.028 (14) 
T|T: 0.304 (153) 








C C: 0.984 (990)  
T: 0.016 (16) 
MAF 0.15 
C|C: 0.968 (487) 
C|T: 0.032 (16) 
0.04### 0.866## 
EUR = European population, 1000 Genomes Project. MAF = minor allele frequency. SIFT (Sorting 
Tolerant From Intolerant) prediction results: # tolerated, ### deleterious. Polyphen prediction results: # 
benign, ## possibly damaging, ### probably damaging. 
Table 5: FUT2 and FUT3 amplification primers 
Gene / rs 
candidate 
Forward Primer 
(5’ – 3’) 
Reverse Primer 




FUT2 TCAACATCAAAGGCACTGGGACC* GGAGTGGACAGGGATTGCCG# 856 *Hu et al. [42], #Tanwar et al.
[53]
FUT3 ACACCAGCTGTGCTGATTTTT GACCTTGGCTGCTGGAGG 1499 Designed 
rs3745635 TGGAAGCCCTGGACAGATAC AACTGGAAGCCGGACTCAG 177 Designed 
rs28362459 GGAGCTTTGGTAAGCAGGAG GAAGAAACACACAGCCACCA 167 Designed 
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CHAPTER 8: FUTURE DIRECTIONS: NEWBORN 
SCREENING FOR PRIMARY IMMUNODEFICIENCY 
DISEASES IN THE NEXT GENERATION 
8.1 Introduction and Contextual Statement 
We have seen a rapid evolution in newborn screening technologies, and the future holds 
promise to expand our current capabilities. Currently, we are able to screen for a selected 
number of diseases using the TREC/KREC assay. Other methodologies, including mass 
spectrometry, sequencing-based and protein-based assays have been evaluated to determine 
their role in expanding our current repertoire of screened diseases. However, it has become 
apparent that NGS may have a future role in simultaneously screening infants for a large 
number of heterogeneous diseases. This chapter examines the future of newborn screening 
for PID, including the application of NGS-based approaches and issues for consideration prior 
to adopting this approach. 
8.2 Publication: Newborn Screening for Primary Immunodeficiency 
Diseases: The Past, the Present and the Future 
This constitutes the final published paper included in this thesis. The following paper, entitled 
‘Newborn Screening for Primary Immunodeficiency Diseases: The past, the present and the 
future’, by Jovanka King, Jonas Ludvigsson and Lennart Hammarström was published in 
the peer reviewed journal, International Journal of Neonatal Screening, in August 2017 
(3(3),19  doi:10.3390/ijns3030019). 
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Abstract: Primary immunodeficiency diseases (PID) are a heterogeneous group of disorders caused
by inborn errors of immunity, with affected children presenting with severe, recurrent or unusual
infections. Over 300 distinct genetic molecular abnormalities resulting in PID have been identified,
and this number continues to rise. Newborn screening for PID has been established in many countries,
with the majority of centers using a PCR-based T cell receptor excision circle (TREC) assay to screen
for severe combined immunodeficiency (SCID) and other forms of T cell lymphopenia. Multiplexed
screening including quantitation of kappa-recombining exclusion circles (KREC) has also been
described, offering advantages over TREC screening alone. Screening technologies are also expanding
to include protein-based assays to identify complement deficiencies and granulocyte disorders.
Given the rapid advances in genomic medicine, a potential future direction is the application of
next-generation sequencing (NGS) technologies to screen infants for a panel of genetic mutations,
which would enable identification of a wide range of diseases. However, several ethical and economic
issues must be considered before moving towards this screening strategy.
Keywords: newborn screening; primary immunodeficiency diseases; TREC; KREC; next-generation
sequencing
1. Introduction
Primary immunodeficiency diseases (PID) are a heterogeneous group of disorders which are
genetically determined inborn errors of immunity. In excess of 300 distinct genetic molecular
abnormalities resulting in PID have been identified, and this number continues to increase. Based
on estimates from the human connectome, more than 1000 genes interact with known PID genes [1].
Children with PID present with severe, recurrent or unusual infections, and these diseases are
associated with significant morbidity and mortality. Until recent years, there was no available testing
modality to identify these children prior to the onset of symptoms, frequently resulting in delayed
diagnosis and treatment, and a complicated clinical course. Currently available newborn screening
technologies have enabled the early identification of severe forms of PID, manifested by T and B
cell lymphopenia, which has been demonstrated to have a profound impact on patient outcomes [2].
PID were previously thought to represent rare disease entities, however through newborn screening
programs, true disease incidence rates can be determined and have proven to be higher than expected.
Int. J. Neonatal Screen. 2017, 3, 19; doi:10.3390/ijns3030019 www.mdpi.com/journal/neonatalscreening
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Newborn screening for PID continues to be an evolving field, with the potential for future expansion
to include screening for other forms of PID such as granulocyte disorders and complement deficiency.
The future of newborn screening for the identification of PID and other inborn errors is likely to involve
a change in screening strategy, where next-generation sequencing will have an increasingly prominent
role, potentially even as up-front testing. Here, we review the past and present aspects of newborn
screening for primary immunodeficiency diseases, and discuss potential future directions.
2. The Past: Identification of Severe Combined Immunodeficiency as a Priority for
Newborn Screening
Since the initiation of population-based newborn screening using dried blood spots (DBS) in the
1960s using a method established by Guthrie and Susi [3], there have been significant advances in
our ability to screen asymptomatic infants for severe, life-threatening diseases for which treatment
is available, and where early diagnosis and treatment is essential for preventing serious sequelae.
For inclusion in population-based screening programs, diseases must meet a series of criteria as
described by Wilson and Jungner [4]. Severe combined immunodeficiency (SCID) is a life-threatening
condition resulting from a profound lymphocyte deficiency. It manifests with significant infections
and is uniformly fatal without treatment. SCID is curable with hematopoietic stem cell transplantation
(HSCT), and it has been demonstrated that outcomes are markedly improved for infants who are
diagnosed and undergo HSCT prior to the age of 3.5 months [2]. Diagnosis and treatment is frequently
delayed, and realistically, achieving this target is only possible if affected newborns are identified by
screening prior to the onset of symptoms, acquisition of infections and other complications. As such,
SCID meets the necessary criteria and is a suitable candidate for population-based newborn screening,
and this has been borne out in prospective screening trials [5,6].
3. The Present: Screening for T and B Cell Lymphopenia
A seminal paper was published by Chan and Puck in 2005, describing the T-cell receptor excision
circles (TREC) assay for the detection of SCID in a newborn screening setting [7]. TREC are small,
circular pieces of episomal DNA which are produced during T cell receptor (TCR) rearrangement in
naïve T cells, which serve as a surrogate marker of recent thymic emigrants. TREC copy numbers,
measurable by quantitative reverse transcription polymerase chain reaction (qRT-PCR), are markedly
reduced or absent in infants with SCID and other forms of T cell lymphopenia. Screening for SCID has
become part of routine newborn screening programs in all US states, the District of Columbia and the
Navajo Nation (Jeffrey Modell Foundation, http://www.info4pi.org). Several countries in Europe,
Australasia and the Middle East have also commenced SCID screening programs, or are evaluating
these in prospective studies (Table 1).
Table 1. Worldwide status of newborn screening programs for primary immunodeficiency diseases
(PID). TREC: T-cell receptor excision circles; KREC: kappa-recombining exclusion circles; ADA:
adenosine deaminase.
Country Screening Strategy Date of Commencement Reference




TREC 2008 (Wisconsin)National implementation






TREC/ADA 2010: Pilot study2010: Pilot study
2013: Pilot study
http://ipopi.org/
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Table 1. Cont.
Country Screening Strategy Date of Commencement Reference
Taiwan TREC 2010: Pilot study2012: National implementation Chien YH et al., 2017 [9]
Israel TREC 2011: Pilot study2015: National implementation Rechavi et al., 2017 [10]
The Netherlands TREC 2012: Pilot study2015: Application approved
Blom et al., 2017 [11]
http://ipopi.org/
Qatar TREC 2012: National implementation http://ipopi.org/
Germany TREC/KREC 2013: Pilot studyApplication in progress http://ipopi.org/
Sweden TREC/KREC 2013: Pilot study Barbaro et al., 2016 [6]
Japan TREC/KREC 2014: Pilot study http://ipopi.org/
France TREC 2014: Pilot study Audrain et al., 2014 [12]http://ipopi.org/
Spain
Andalucia TREC/KREC 2014: Pilot study
de Felipe et al., 2016 [13]
http://ipopi.org/
Norway TREC 2015: Pilot study http://ipopi.org/
Puerto Rico TREC 2016: National implementation Dorsey & Puck 2017 [8]http://www.info4pi.org/
















Brazil TREC Pilot study Kanegae et al., 2016 [14]
Denmark TREC Application in progressPilot study http://ipopi.org/
Iceland TREC/KREC Application in progressPilot study http://ipopi.org/
Iran TREC/KREC Pilot study Personal communication
Saudi Arabia TREC/KREC Pilot study http://ipopi.org/
Slovenia Pilot studyApplication in progress http://ipopi.org/
Turkey TREC/KREC Pilot study Personal communication
United Kingdom TREC Application in progressPilot study http://ipopi.org/
Australia Application in progress http://ipopi.org/







Czech Republic TREC/KREC Application in progress Personal communication
Poland Application in progress http://ipopi.org/
Portugal Application in progress http://ipopi.org/
Romania Application in progress http://ipopi.org/
Switzerland TREC/KREC Application in progress http://ipopi.org/
United Arab Emirates Applications in progress http://ipopi.org/
In addition to the detection of TREC levels as surrogate markers for thymic T cell output, it is
also possible to evaluate B cell production by quantifying kappa-recombining excision circles (KREC),
which are produced by similar mechanisms during rearrangement of the variable, diversity and joining
domains (V(D)J recombination) of the B cell immunoglobulin kappa gene [15]. A multiplexed assay
measuring TREC and KREC, along with beta-actin levels as a control for DNA quantity provides a
strategy for simultaneous screening for T and B cell lymphopenia [16].
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Screening for PID by measuring both TREC and KREC offers advantages over TREC screening
alone. This includes identification of patients with X-linked agammaglobulinemia (XLA), an antibody
deficiency disorder caused by mutations in the BTK gene which is essential for B cell development.
Consequently, there is an absence of B cells, lack of antibody production, and severe infections with
bacteria and other pathogens [17–19]. Mutations in other genes involved in B cell development have
also been described, giving rise to an XLA-like disease with a similar phenotype [20]. Both groups
of patients can be identified by low or absent KREC levels. Early identification of this disease is
important, as it facilitates timely commencement of gammaglobulin replacement therapy. In addition
to XLA, multiplexed TREC/KREC screening also facilitates diagnosis of individuals with late onset
adenosine deaminase (ADA) deficiency, some cases of Nijmegen breakage syndrome (NBS) and other
forms of PID which may otherwise be missed [16]. In the case of SCID, combined screening aids in
the diagnostic process and guides targeted molecular evaluation, as different mutations will give
rise to a variable pattern of T and B cell deficiency. Potential increased costs associated with KREC
screening in addition to TREC screening have been suggested as a disadvantage of combined screening.
Intrinsic costs of laboratory testing, patient follow-up and second tier testing must all be considered.
However, the additional costs of adding KREC quantitation to a TREC-only platform are negligible,
estimated to be less than †0.10 per test. Another proposed disadvantage of combined TREC/KREC
screening was a higher recall rate for abnormal KREC levels. However, results of our recent evaluation
of the combined TREC/KREC newborn screening program in Sweden show that the recall rate is
dependent upon cut off levels set, but the recall rate in our cohort was similar to that for TREC-only
testing programs [6], suggesting that this was unlikely to be an issue. There are some limitations of
TREC-based screening. Some cases of SCID will not be identified, in the case where T cells are present
but have abnormal function, or where the molecular defect lies downstream of TCR rearrangement
(including Zap70 Deficiency, major histocompatibility complex (MHC) class II deficiency and some
cases of delayed-onset adenosine deaminase (ADA) deficiency) [21–26].
4. The Future: Screening for Other Forms of PID
In addition to screening for immunodeficiency diseases that manifest with T and B cell
lymphopenia, expanded screening for the detection of other diseases such as complement deficiencies
and granulocyte disorders using protein-based assays has also been proposed. Disorders of
granulocyte number and function give rise to severe, recurrent bacterial and fungal infections,
and one possible method to identify these diseases involves measurement of granulocyte-specific
proteins. The complement system consists of a large number of interacting components. Individuals
with complement deficiency present variably, with significant bacterial infections caused by specific
pathogens, or severe autoimmune or renal disease. In these patients, complement protein levels are
reduced as a result of the underlying genetic mutation. It has been demonstrated that complement
proteins can be eluted from DBS samples, allowing identification of C2- and C3-deficient patients
at birth who have low or absent protein levels [27,28]. This can ultimately be expanded to
develop multiplexed assays which enable detection of multiple complement cascade components
and granulocyte specific proteins to enable detection of these disorders in the neonatal period, which
would enable early diagnosis and treatment, minimizing long-term complications in these patients.
Screening for granulocyte disorders and complement deficiency will be covered elsewhere in greater
detail in this special issue on newborn screening for PID.
Targeted genetic testing is another newborn screening approach, and this is currently employed
in screening algorithms for selected diseases such as cystic fibrosis [29]. Familial hemophagocytic
lymphohistiocytosis (FHL) is a primary immunodeficiency disorder manifesting with a life-threatening
inflammatory response secondary to impaired lymphocyte cytotoxicity. Several causative genetic
mutations have been identified [20]. In Scandinavia, 50% of FHL cases are due to homozygous
UNC13D inversion mutations, and a screening strategy based on the detection of reduced UNC13D
wild type gene copy numbers was demonstrated to be an effective method by which to identify affected
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individuals [30]. This approach could be expanded to enable identification of mutations in other FHL
genes, and may have a role in screening for other disorders.
5. The Future: The Role of Next-Generation Sequencing in Newborn Screening for PID
Since completion of sequencing of the human genome project in 2003, advances in next-generation
sequencing have progressed exponentially, resulting in an increased availability of testing, improved
bioinformatic pipelines for data analysis, a faster turn-around time and a decrease in associated costs.
This makes next-generation sequencing (NGS) an attractive and affordable modality to employ not
only in a diagnostic setting, but also as a potential screening tool. Given that there is no single or
multiplexed screening assay which can reliably detect all forms of PID at birth, we propose a screening
approach for PID where all newborns undergo whole genome sequencing (WGS), with rapid analysis
of the currently known 300+ genes, which would be expanded to include additional clinically relevant
genes as they are identified.
Current strategies for newborn screening include metabolic assays, TREC/KREC quantification
and targeted genetic studies, and this list is expected to expand. Second- and third-tier testing is
required to confirm the findings of the screening test, and to make a specific diagnosis. Targeted
mutation analysis or next-generation sequencing, including whole exome sequencing (WES) and
whole genome sequencing, is often required to determine the underlying molecular diagnosis. At the
Center for Metabolic Diseases (CMMS) at the Karolinska University Hospital in Stockholm, an aberrant
result on first-tier metabolic testing that cannot be rapidly confirmed with a second-line test is further
evaluated by genetic testing by WGS. This enables specific mutations to be identified in known
disease-causing genes. If no mutation is found, parents are counselled and consented to undergo
further genomic evaluation [31]. In this model, an aberrant test is followed up with WGS. As such,
the next logical step in screening methodology would be to screen newborns for a range of genetic
mutations using up-front NGS. With targeted sequencing being of limited value and the technical
limitations of WES, WGS seems the most appropriate choice.
Pavey et al. recently reported the results of WGS-based screening for PID in a cohort of
1349 newborn and parent trios, who were analyzed for variants in 329 known immunodeficiency
genes [32]. A genotype-first pipeline resulted in identification of 396 newborns with pathogenic/likely
pathogenic mutations, however on further analysis, only one individual was found to have a
genomically predicted immunodeficiency (complement component C9 deficiency). C9 deficiency
is associated with an increased risk of life-threatening Neisserial infection [20], and early institution
of prophylactic measures including immunization are of utmost importance in this patient group.
A phenotype-first pipeline was also applied, in which 29 infants were identified to have clinical features
suggestive of possible immunodeficiency, but did not have an identifiable mutation in any of the
interrogated PID genes. Three of these children had pathogenic mutations in other (non-PID) genes
which correlated clinically. No additional causative variants were found in the other children, the
majority of whom were considered to be unlikely to have a PID [32]. These findings are consistent
with results of a survey conducted by Boyle et al., who determined a PID prevalence of 1 in 1200
in the US [33]. Taken together, it is expected that screening 1000 newborns will identify one case of
PID, however utilizing a NGS approach enables identification of other disorders. This is the first
reported study evaluating genomic testing for PID as a first-line screening strategy in newborns.
Longer-term clinical follow-up in cohorts such as these, and larger studies are required to determine
test characteristics such as sensitivity and specificity.
The National Institutes of Health are currently undertaking the ‘Newborn Sequencing in Genomic
Medicine and Public Health’ (NSIGHT) project which will evaluate the role of up-front genomic testing
in neonates (https://www.genome.gov). These projects will include evaluation of exome sequencing
in newborn screening for currently screened and additional disorders, and investigate the role of rapid
turnaround genomic sequencing in the neonatal intensive care unit setting. They will also address
key ethical, legal and social implications of implementation of such programs. This will involve
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evaluating parental experiences related to receiving clinical information arising from genomic testing
in the newborn period, and medical practitioner experiences in terms of utilizing genomic information
and its impact upon clinical care delivery [34].
The notion of performing WGS on every infant at birth is controversial, and there are several
factors that need to be considered regarding this potential approach to screening. The Global
Alliance Paediatric Task Team recently published a series of recommendations regarding this screening
approach, highlighting clinical utility, management of incidental findings, cost-effectiveness, data
management, and ethical, legal and social implications as key areas for consideration [35].
5.1. Identification of Candidate Diseases and Genes to Be Evaluated in Newborn Genomic Screening Programs
The identification of key diseases for inclusion in genomic-based screening programs, selection
of appropriate gene candidates for interrogation, and establishment of a testing panel are major
considerations. In terms of screening for PID, an approach similar to that adopted by Pavey et al. [32]
involving interrogation of a gene panel inclusive of the currently-described 300+ PID genes is an
appropriate starting point. However, such panels would need to be regularly updated to include
newly identified genes. It is probable that patients without identifiable molecular causes for their
disease will have mutations in novel genes, and hence frequent revision of gene panels will enhance
our future diagnostic capabilities. Although we advocate for the use of WGS as a screening tool
for all newborns, this must proceed with caution. More than 8000 Mendelian diseases are currently
recognized (https://omim.org/), however, initial evaluation in a WGS-based newborn screening
program should only involve interrogation of genetic mutations which have a definite disease-causing
role and where a clear genotype/phenotype correlation exists. However, it is expected that over time,
there will be an increase in the number of screened genetic mutations and diseases.
In order to gain an appreciation of which disorders were likely to be significant causes of child
mortality, and hence, possible disease candidates for newborn screening, we evaluated the causes
of death in children less than 18 years of age in Sweden between 1987 and 2015 (Figure 1). There
were 19,957 deaths during this time period. Seventy-six deaths (0.38%) were attributable to a known
primary immunodeficiency disorder. Of these 76 cases, one death was attributed to common variable
immunodeficiency, 4 to PID with predominant antibody deficiency, 5 to PID in combination with
other major defects, 13 to combined immunodeficiency (including SCID), and 53 were attributed
to unspecified immunodeficiency diseases. In addition, 849 deaths (4.3%) were due to infectious
diseases and their complications, and it is likely that there were a considerable number of additional
cases of undiagnosed PID in this group. Tambe et al. evaluated causes of child and infant mortality
in the United Kingdom between 2006 and 2008, and found a mortality rate due to diseases of the
blood, blood-forming organs and the immune system of 1.8 per 1,000,000 children in the 5–15 year
age group [36], and 3.3 per 100,000 children aged less than 5 years [37]. Infectious diseases accounted
for 9.5 deaths per 1,000,000 in the 5–15 year age group [36], and 27.9 per 100,000 neonates and 36 per
100,000 children aged 28 days to 4 years [37]. There are some limitations of the studies performed by
our group and Tambe et al., given the degree of subjectivity in International Classification of Diseases
(ICD) code assignment and potential categorization of a disease in different groups, and some cases
might not be captured correctly due to a lack of detailed coding [23]. In addition, this type of analysis
does not capture the significant morbidity associated with survivorship of severe diseases such as
PID. Evaluation of such data facilitates identification of key diseases that result in death or significant
morbidity in infancy and childhood, which should therefore be prioritized as candidates for inclusion
in population-based newborn screening programs.
P  8   
Page 92
P  8   
Page 9
Int. J. Neonatal Screen. 2017, 3, 19 8 of 10
programs. Genetic data storage and management, biobanking of genetic material and its implications
for other uses must also be considered. Variants of unknown significance are commonly found in
NGS analyses. A clear plan must be established for the identification and reporting of such results.
In addition, the finding of ‘unexpected’ or unrelated genetic mutations may have far-reaching effects
on the individual and their family. The potential for identification of mutations in genes known to
lead to debilitating or lifespan-reducing disease later in life for which no treatment exists must be
considered, and how this will be managed should also be considered.
5.4. A New Model for Newborn Screening
Population-based NGS screening strategies represent a reversed approach to current screening
practices, where typically a marker of disease is identified by a screening test, and then confirmed by
genetic analysis. It stands to be determined if an upfront NGS testing approach will ultimately save
time or money, given that functional tests may then be needed to confirm the genotype–phenotype
correlation. This also raises the question as to if NGS screening will ultimately replace current
screening tests, or if they would continue to be run in tandem. It is anticipated that the results of
prospective genomic-based newborn screening programs will answer many of these questions, and
inform future practice.
6. Conclusions
In the past, there was no method by which to identify infants with severe forms of PID, resulting
in delayed diagnosis and significant complications. At the present time, newborn screening for the
detection of severe forms of PID manifest by T and/or B cell lymphopenia using TREC or TREC/KREC
screening has been established in many countries. There is the potential for future expansion to
employ other screening modalities, such as protein-based assays and targeted genetic sequencing to
enable identification of other forms of PID. However, it is not currently possible to screen for a wide
range of diseases simultaneously using a single modality. It seems logical that the most effective and
efficient way to screen newborns for an extensive list of diseases, which differ in terms of classification,
pathophysiology and manifestation is using an up-front NGS testing strategy. Prior to adopting
a genomic screening approach, selection of appropriate gene candidates for inclusion in screening
panels, program structure, laboratory-clinical pipeline establishment, ethical, legal, social and financial
implications must be both considered and evaluated in large, prospective studies to inform decisions
regarding future implementation.
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CHAPTER 9: SUMMARY AND CONCLUSION 
9.1 Introduction and Contextual Statement 
This thesis sought to address gaps in the literature regarding optimal strategies for newborn 
screening for PID, and the application of novel approaches to enable identification of a wider 
range of diseases. Specifically, this thesis aimed to: 
1. Determine the efficacy of a combined TREC/KREC screening approach for the
identification of newborns with severe forms of PID manifested by T and/or B cell
lymphopaenia
2. Determine the utility of screening assays beyond the newborn period, as part of the
diagnostic evaluation of patients with suspected immunodeficiency
3. Establish a method for screening newborns for hypogammaglobulinaemia
4. Explore the role of novel genetic screening strategies to identify newborns with key
disease susceptibility factors and facilitate the application of personalised medicine
Key findings arising from this thesis are summarised below, along with a discussion of the 
implications of these results. Final conclusions are drawn, and further questions arising from 
this work are presented with a view to informing future research efforts. 
9.2 Summary of Key Findings 
Seven key findings can be drawn from the research presented in this thesis. 
1. Prospective newborn screening programs for PID have been established
in several countries
 Based on published, prospective studies, 4,330,807 infants have been screened
for PID in 4 countries
 Ninety-five infants with severe forms of PID have been successfully identified and
treated in these studies
 Newborn screening for PID is seen as health priority worldwide, with many
countries currently evaluating or piloting screening programs, or planning to
commence screening in the near future
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2. There remains a lack of consensus regarding the optimal testing strategy
to screen newborns for PID
 Most centres with established programs are screening infants for SCID as the target
condition using a TREC-only assay
 Other approaches include combined TREC/KREC assays, or TREC/ADA deficiency
screening using mass spectrometry
3. A multiplexed TREC/KREC/ACTB assay is an effective modality by which
to screen newborns for PID manifested by T and/or B cell lymphopaenia,
thereby confirming the efficacy of DNA-based screening strategies for PID
 Three patients with severe forms of PID were identified in a cohort of 58,834 newborns
screened over a two-year period, facilitating early diagnosis and treatment
 Most premature infants will return a normal TREC/KREC screening result, irrespective
of gestational age
 There are several benefits of simultaneous screening for both T and B cell
lymphopaenia using a multiplexed TREC/KREC assay, including identification of a
broader range of immunodeficiency diseases
4. In addition to their utility as newborn screening tests, TREC/KREC assays
have an important role beyond the neonatal period
 KREC levels remain low or absent in patients with XLA throughout life, whereas TREC
levels are comparable with those in healthy control subjects
 TREC/KREC assays therefore provide a useful adjunctive testing strategy in the
evaluation of older children and adults with suspected PID
 The diagnosis of XLA is frequently significantly delayed beyond the ‘classic’ 6-12 month
age of presentation, providing further evidence supporting the case for screening for
congenital B cell deficiency disorders
5. An immunoglobulin heavy chain gene expression assay performed on
RNA extracted from dried blood spots can identify children with complete
antibody deficiency disorders such as XLA and X-HIGM syndrome,
providing a novel approach to screening newborns for
hypogammaglobulinaemia
 Expression of the immunoglobulin heavy chain genes is undetectable in patients with
XLA and X-HIGM syndrome
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 Immunoglobulin heavy chain gene expression is variable in healthy controls and
patients with PID who have normal or reduced immunoglobulin levels
 RNA can be successfully extracted from DBS up to 17 years of age using our method
6. Newborns can be screened for single nucleotide polymorphisms which
predispose to certain disease states, providing opportunities for
personalised and precision medicine
 Newborns can effectively be screened for SNPs in the fucosyltransferase (FUT2 and
FUT3) genes, which determine the expression of histo-blood group antigens (HBGA)
(H type 1 and Lewis) with implications for predisposition to specific infectious and
inflammatory diseases
 A higher than expected proportion of newborns in the cohort were found to have
polymorphisms in the FUT2 and FUT3 genes resulting in an increased proportion of
non-secretors and Lewis b negative individuals with ensuing predisposition to specific
infections and other diseases
 If available in the early neonatal period, information regarding genetic polymorphisms
may be used to inform tailored health care decisions regarding vaccination, screening
and therapy for specific diseases
7. There is potential to further expand newborn screening to enable
detection of a broader range of primary immunodeficiency diseases
 Future approaches include protein-based assays and targeted sequencing strategies
 Up-front NGS (whole exome or whole genome sequencing) is a testing strategy which
would enable screening of the largest number of additional forms of PID through
identification of mutations in all currently known PID-associated genes
 Genotype-phenotype correlation, clinical and laboratory pipelines, costs, management
of variants of unknown significance along with ethical, legal and social implications of
an NGS-based screening program must be evaluated prior to adopting this approach
9.3 Discussion 
The aim of newborn screening programs is to identify infants with severe diseases, which are 
asymptomatic at birth, and for which effective treatment exists39. Primary immunodeficiency 
diseases meet these and other criteria for inclusion as screened diseases39, given the 
potentially devastating effects of untreated disease. It is well documented that early 
identification of severe forms of PID such as SCID and rapid commencement of therapy results 
in reduced morbidity and mortality6. 
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Screening for PID has been embraced as a health care priority around the world, with reports 
outlining prospective screening programs, pilot studies and applications to commence 
programs in several regions (Paper V). At the time of publication of Paper I, four centres had 
published the results of their prospective programs, where cumulatively 4,330,807 infants had 
been screened and 95 infants were diagnosed with severe forms of PID. The number of 
screened infants worldwide continues to increase exponentially as more centres establish PID 
screening programs. 
Despite the uptake of newborn screening programs for PID in several countries worldwide, the 
ideal screening strategy for PID remains controversial. In fact, there is great variability in 
newborn screening practices in general between different countries, and even between 
different centres within the same country (Paper V). There are several factors determining the 
choice of screened diseases in any given centre, impacted upon by issues such as disease 
prevalence, available methodologies and instruments, and economic considerations40-42. 
TREC-only screening programs enable identification of PID manifested by T cell 
lymphopaenia, however the inclusion of KREC quantitation has the additional benefit of 
detecting disorders associated with B cell lymphopaenia10. Paper II presents the findings of 
the largest prospective newborn screening study utilising a multiplexed TREC/KREC/ACTB 
assay, confirming the efficacy of DNA-based screening strategies for PID. Three infants with 
PID were identified during this two-year program, and, to our knowledge, no infants with severe 
forms of PID were missed.  
It is important to note that there are some limitations to currently available screening assays. 
TREC assays will detect most, but not all forms of SCID. Infants with T cell functional defects 
(with preserved number), SCID due to functional anomalies downstream of the T cell receptor 
(e.g. Zap 70 deficiency) or MHC Class II deficiency, and some cases of late-onset ADA 
deficiency, will not be identified by this assay43-45. The benefits of multiplexed TREC/KREC 
assays include the ability to screen for additional disorders that would otherwise be missed, 
including congenital B cell deficiency disorders, such as XLA and autosomal recessive, XLA-
like disorders. Although XLA is not generally considered to be as ‘urgent’ to treat (as compared 
with SCID), it is worth noting that the diagnosis of this condition is frequently significantly 
delayed, as demonstrated in Paper III. This delay results in the evolution of complications of 
severe, untreated infection, such that by the time of diagnosis, patients have already 
developed bronchiectasis and other irreversible comorbidities17. Identifying infants with these 
conditions in the newborn period would therefore enable commencement of gammaglobulin 
replacement therapy prior to onset of symptoms. 
KREC assays were initially established to mark the replication history of B cells and assess B 
cell recovery following HSCT11,46, prior to their application as a newborn screening assay47. 
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The potential clinical utility of TREC/KREC assays in the diagnostic work-up of patients with 
suspected PID who were not screened at birth was demonstrated (Paper III). We showed that 
KREC levels remain low or absent throughout life in patients with XLA and XLA-like disease, 
and hence, this test may be a useful adjunct to current laboratory tests in the clinical evaluation 
of patients beyond the newborn period. The utility of TREC/KREC assays in the sub-
classification of patients with CVID has been evaluated. One group classified 40 patients 
according to their TREC and KREC levels, and found an association between these levels and 
disease severity13. Two subsequent studies found reduced levels in patients compared with 
controls, however levels did not correlate with specific disease phenotypes14,15. The assay may 
assist in differentiating between patients with CVID and CID13,14. Given that TREC/KREC 
testing can be performed on stored DNA or DBS specimens, this overcomes the need to collect 
fresh blood specimens and simplifies sample transport between laboratories in situations 
where this is challenging. 
Newborn immunoglobulin levels measured by nephelometry or other protein-based 
quantitation techniques reflect maternal levels, and therefore these methods are not suitable 
to determine an infant’s endogenous capacity to produce antibodies20. 
Hypogammaglobulinaemia may be due to a primary antibody deficiency disorder, or may be a 
feature of other forms of PID1, and hence an ability to screen for this has the potential to identify 
infants with a variety of immunodeficiency diseases. We developed a method by which to 
extract RNA from DBS specimens, and evaluate expression of the immunoglobulin heavy 
chain genes (IGHG1, IGHA1, IGHM) (Chapter 6). We demonstrated a proof of concept that 
this method could effectively identify children with complete failure of antibody production (i.e., 
XLA and X-HIGM syndrome) who had absent expression of these genes. We performed this 
assay on the original DBS of one newborn with a known family history of XLA, providing 
additional evidence that this approach could be used as a screening test for 
hypogammaglobulinaemia. The currently available KREC assay would have enabled 
identification of the infants with XLA, and hence the gene expression assay would not offer 
any additional diagnostic benefit. However, as expected, children with X-HIGM syndrome have 
been demonstrated to have normal TREC and KREC levels10 and hence would be missed on 
a standard TREC/KREC screening assay. This provides an example of how this 
transcriptomic-based assay could potentially increase our capacity to detect a broader range 
of disorders. This assay, also performed on healthy controls and patients with various forms 
of PID, provided a proof of concept that this strategy can be used to evaluate expression of 
the immunoglobulin gene transcriptome in health and disease. Although our assay in its 
present form is not sufficiently sensitive to detect more minor degrees of 
hypogammaglobulinaemia, we believe that with further refinement, this will be achievable in 
the near future. This assay may also have further applicability in the future to determine 
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endogenous antibody production in those patients in whom protein measurement is 
confounded, for example by maternal transfer (in infants) and gammaglobulin replacement 
therapy. 
In addition to screening for specific disease states, we explored the utility of screening 
newborns for a series of SNPs which confer susceptibility to specific infectious and 
inflammatory diseases (Paper IV). This would therefore determine an individual’s risk factors 
for disease, and facilitate provision of individualised recommendations regarding treatment, 
screening and preventative measures, such as vaccination. Polymorphisms in the FUT2 and 
FUT3 genes determine the expression of histo-blood group antigens (HBGA) (H type 1 and 
Lewis), which influence an individual’s susceptibility to various diseases29. 
Of specific interest was the susceptibility to norovirus and rotavirus30,48,49, and the implications 
this has for vaccine recommendations. We found that a higher than expected proportion of 
infants were non-secretors and Lewis b negative, with an increased predisposition to infections 
such as rotavirus. This data supports the importance of rotavirus vaccination and in settings 
where this is not readily available, information from this newborn screening genotyping assay 
could assist clinicians to make recommendations as to which children would benefit most from 
vaccination. This screening approach may be expanded in the future to identify susceptibility 
factors for other specific diseases. In addition, this approach could be used to screen for 
polymorphisms predisposing individuals to adverse drug reactions, thereby enabling specific 
recommendations regarding pharmacotherapy and avoidance of severe reactions. Performing 
these studies soon after birth would be advantageous in that a ‘catalogue’ of genetic 
susceptibility could be generated and called upon as required to guide management. 
With well over 320 known molecular causes for PID1 to date, there is no established single test 
to enable simultaneous detection of every disease. Currently available strategies focus on the 
identification of PID manifested by T and/or B cell lymphopaenia. However, other important 
forms of PID (including but not limited to granulocyte disorders, complement deficiencies and 
immune dysregulatory conditions) cannot be identified using these tests alone.  
Making a diagnosis of PID is challenging in the current era, due to issues such as lack of 
awareness in the community and by medical practitioners, and variable or atypical 
presentations. There is frequently a delay in diagnosis, sometimes up to several years from 
the onset of symptoms16. We explored the future role of up-front NGS (whole exome or whole 
genome sequencing) as the ideal testing strategy which would enable screening of the largest 
number of additional forms of PID, through identification of mutations in all currently known 
PID-associated genes (Paper V). This approach represents a paradigm shift, as genetic 
studies have, until recently, been used to confirm the findings of screening tests. Up-front NGS 
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has been evaluated in the context of screening for PID and identified one case in 1349 
newborns - a case of complement deficiency28 which would not have been identified by other 
means. This provides further evidence for this approach to be considered to improve diagnostic 
capabilities. However, large, prospective studies are required to evaluate the associated 
technical aspects, feasibility, acceptability, ethical, legal and social issues50. It will also need to 
be determined whether NGS can exist as a stand-alone, up-front technique, or if other current 
strategies (such as TREC/KREC screening) will need to continue to be run in tandem, given 
that not all infants returning an abnormal screening test will have an identifiable molecular 
defect.  
9.4 Conclusions and Future Directions 
Since their inception in the 1960s, newborn screening programs have enabled early 
identification and provision of life-saving treatment for infants with severe diseases which are 
asymptomatic at birth. More recent technological advances have enabled expansion of current 
programs to include screening infants for severe forms of immunodeficiency, facilitating early 
treatment and reducing disease-related morbidity and mortality. 
Although there have been significant, rapid advances in this field over recent years, and 
despite application of best available technology, we are still only able to identify a handful of 
the 320+ different molecular forms of PID. It is anticipated that newborn screening practices 
for PID will continue to evolve and expand in the future, enabling detection of an increased 
number of diseases. It is expected that modalities such as NGS will have a more prominent 
role as costs, turn-around times and technical factors become more acceptable. 
This work also poses several new lines of enquiry to be addressed by future research. For 
example, what is the aetiology of T cell lymphopaenia and combined immunodeficiency in 
infants who return a positive screening test, who do not have a molecular diagnosis? What is 
their prognosis and clinical course? Where do the answers lie regarding pathogenesis of their 
disease? There are also questions raised regarding the most economically feasible 
approaches to screening for PID – is it cost-effective to screen infants in population-based 
screening programs in all countries using current DNA-based technologies? Is it cost-effective 
to screen for other (non-SCID) forms of PID? Will screening for other forms of PID save lives 
and decrease morbidity and mortality? Regarding future testing strategies, if we adopt NGS-
based screening methodologies, will this be acceptable to the public? What are the wider 
implications in terms of ethical and legal issues? Will we still need to run supportive screening 
tests in parallel? Will we miss cases where there is a clear phenotype but no identifiable genetic 
abnormality? It is expected that our work in this field will continue, in an effort to answer some 
of these questions in the future. 
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In conclusion, the findings reported in this thesis contribute to the growing experience and 
literature regarding newborn screening for PID. This work provides further evidence to support 
the case for newborn screening for these significant conditions, and also presents potential 
strategies which could be employed in order to advance our current screening capabilities. The 
ultimate goal of newborn screening programs for immunodeficiency is not only to save lives, 
but also to improve the quality of life of affected patients and their families. 
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Invited speaker, Immunology Stream
Royal College of Pathologists of Australasia (RCPA) Pathology Update
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III. ‘Case studies in paediatric primary immunodeficiency’
Invited speaker
Australasian Society for Clinical Immunology and Allergy (ASCIA) SA
Branch Meeting, February 2018
IV. ‘Newborn screening for primary immunodeficiency diseases’
Invited speaker
SA Pathology Colloquium, Adelaide
November 2017
V. ‘Newborn screening for primary immunodeficiency’
Invited speaker
Australasian Society for Clinical Immunology and Allergy (ASCIA) SA
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FINDING GOLD IN FEINGOLD SYNDROME-2
Cheng Yee Chan1, Jane Watt1, Alex Magee2, Kate Gibson2,
Richard King1
1Genetics Laboratory, Canterbury Health Laboratories,
Christchurch, and 2Genetic Health Services NZ, South Island
Hub, Christchurch, New Zealand
Feingold syndrome-2 (MIM 614326) is a rare autosomal domi-
nant disorder, characterised by a variable combination of short
stature, microcephaly, digital anomalies and learning difficulties.
To date, only 12 cases have been reported in literature, with the
smallest region of overlap (SRO) encompassing MIR17HG and
the first exon of GPC5. Although previous work with mouse
models has demonstrated that MIR17HG haploinsufficiency
produces a phenotype consistent with the skeletal features of
Feingold syndrome-2, the contribution of GPC5 haploinsuffi-
ciency to the phenotype could not previously be ruled out. This
presentation highlights the first known case of Feingold syn-
drome-2 with a 13q31.3 deletion that solely involves the
MIR17HG gene and solidifies previous supportive evidence of
MIR17HG pathogenicity in this disorder.
UTILISING GENOMICS AT THE BC CANCER AGENCY
(BCCA) – MY FELLOWSHIP EXPERIENCE IN
LYMPHOID CANCER RESEARCH
Yasmin Harvey1,2
1Sullivan Nicolaides Pathology, Brisbane, Australia; and
2Centre for Lymphoid Cancer, British Columbia Cancer
Agency, Vancouver, Canada
Advances in technology have enabled expansive research into
genomic aberrations with a recent focus on cancer, including
haematological malignancies. My research fellowship utilised
the Nanostring platform to measure gene expression, and apply
assays to formalin-fixed paraffin-embedded tissue (FFPET)
samples from patients with classical Hodgkin lymphoma and
diffuse large B cell lymphoma. Technical validation of varied
custom Nanostring codesets, ranging from 20 to 800+ genes
were performed. Epstein-Barr virus-encoded RNA2 (EBER2)
gene expression was assessed against EBER in situ hybridisation
in FFPET biopsies from patients with classical Hodgkin
lymphoma.
The BCCA provides an impressive model for research efforts
with a focus on delivering clinically useful research findings
back into the clinic to impact patient management. Dedicated
local collaborative efforts between patients, medical and scien-
tific personnel and complimentary institutions have resulted in
significant and continued contributions to lymphoma research.
The RCPA Foundation Mike and Carole Ralston travelling
fellowship provides a valuable opportunity to gain experience
and insight into applications of genomics which is a rapidly
growing, exciting area of medicine, particularly relevant to
clinical diagnostic pathology.
NEWBORN SCREENING FOR PRIMARY
IMMUNODEFICIENCY DISEASES: THE NEXT
GENERATION
Jovanka King1,2
1Department of Immunopathology, SA Pathology, Women’s and
Children’s Hospital Campus; Robinson Research Institute,
Discipline of Paediatrics, School of Medicine, University of
Adelaide, North Adelaide, SA, Australia; and 2Department of
Clinical Immunology, Karolinska University Hospital
Huddinge, Stockholm, Sweden
Population-based newborn screening programs enable identifi-
cation of infants with a range of severe diseases prior to the onset
of symptoms, facilitating early treatment. Primary immunodefi-
ciency diseases (PID) are a heterogeneous group of genetically
determined inborn errors of immunity. Affected children present
with severe, recurrent or unusual infections, and early diagnosis
improves outcomes for affected patients.
To date, over 300 distinct genetic molecular abnormalities
resulting in PID have been identified. Currently available
newborn screening strategies enable identification of infants with
severe forms of PID manifested by T and B cell lymphopenia,
using PCR-based techniques to quantify T cell receptor excision
circles (TREC) and KREC (kappa recombining exclusion cir-
cles).1 However, this approach will not identify other forms of
PID. Several approaches have been proposed to improve current
PID screening capabilities, including application of protein
based assays and gene copy number variation analyses.2 Given
the advances in -omics-based medicine, it is likely that other
methodologies, including transcriptomic and genomic ap-
proaches will have an increasingly prominent role in newborn
screening practices in the future.2
References
1. Borte S, von Döbeln U, Fasth A, et al. Neonatal screening for severe
primary immunodeficiency diseases using high-throughput triplex
real-time PCR. Blood 2012; 119: 2552–5.
2. King JR, Hammarström L. Newborn screening for primary immuno-
deficiency diseases: history, current and future practice. J Clin Immu-
nol 2017; Nov 8: (Epub ahead of print).
DEVELOPING QUALITYASSURANCE PROGRAM FOR
TOTAL DNA EXTRACTION
Sze Yee Chai1, Nalishia Pillay1, Tony Badrick1,
Bruce Bennetts2, Martin Horan1
1Molecular Genetics, Royal College of Pathologists of
Australasia Quality Assurance Programs (RCPAQAP), Sydney,
and 2 Sydney Genome Diagnostics, The Children’s Hospital at
Westmead, Sydney, NSW, Australia
The extraction of high quality genomic DNA is pivotal for all
downstream genetic analyses. To assist laboratories in the
quality assurance of their DNA isolation procedure, the
RCPAQAP Molecular Genetics discipline developed a DNA
extraction proficiency testing program in 2016 and invited six
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USING QUALITY ASSURANCE TO DETERMINE
UNCERTAINTY OF MEASUREMENT
Louise Wienholt1, Kristie Chapman1, Emma Dawson1,
Grace Moyo1, Katrina Fryer1, Tiffany Hughes1,2
1 The Royal College of Pathologists of Australasia Quality
Assurance Programs (RCPAQAP), Sydney, NSW, and 2 Flinders
Medical Centre (FMC), Adelaide, SA, Australia
Within the context of pathology, the term ‘uncertainty’ is defined
as the doubt of accuracy of a measurement. The commonly used
term used to describe this concept is measurement uncertainty
(MU), which characterises the dispersion of results about a single
measurement. As such, MU provides a quantitative estimate of
the variability in results a laboratory would normally expect if
the measurement were to be repeated at another time. Medical
pathology laboratories are required as part of ISO 15189
accreditation to determine or estimate the MU for all quantitative
results.
Using data obtained from The Royal College of Pathologists of
Australasia Quality Assurance Programs (RCPAQAP) the
following aspects of MU will be discussed:
! The clinical importance of MU data.
! The immunological tests appropriate for UM calculations.
! Understanding how MU is derived referencing The National
Pathology Accreditation Advisory Council (NPAAC) Re-
quirements for the Estimation of Measurement Uncertainty
(2007 edition).
! The optimal way in which this data should be presented to be
clinically useful.
A REVIEW AND WHAT’S NEW IN RCPAQAP
IMMUNOPATHOLOGY
Kristie Chapman1, Louise Wienholt1, Emma Dawson1,
Grace Moyo1, Katrina Fryer1, Tiffany Hughes1,2
1 The Royal College of Pathologists of Australasia Quality
Assurance Programs (RCPAQAP), Sydney, NSW, and 2 Flinders
Medical Centre (FMC), Adelaide, SA, Australia
This session will summarise the current Immunology Programs
available through the RCPAQAP; review the program changes
that were implemented over 2017; and summarise the program
changes planned for 2018.
DIAGNOSTICS IN PRIMARY IMMUNODEFICIENCY
Klaus Warnatz
Center for Chronic Immunodeficiency (CCI), University
Medical center Freiburg, Freiburg, Germany
Primary immunodeficiencies (PID) belong to the rare diseases.
Currently over three hundred different PID entities have been
described. Due to the low prevalence and often variable pre-
sentation a high degree of suspicion has to be raised in order to
avoid unnecessary and potentially harmful delay in diagnosis of
the primary immunodeficiency. Simple, cost effective and
readily available screening tests need to set the path for further
diagnostic steps.
This presentation will enable you to learn the warning signs of
different PIDs and to initiate the first diagnostic steps. In the
second part, you will learn about the potential further steps taken
at experienced diagnostic centres including specialised immu-
nological tests as well as genetic work up by next generation
sequencing. Using case reports, you will learn about the di-
agnostics of combined immunodeficiencies, antibody de-
ficiencies, deficiencies of the innate immune system as well as
haemophagocytic lymphohistiocytosis (HLH). Potential future
developments in the diagnosis of different PID will be pointed
out where appropriate.
NEWBORN SCREENING FOR PRIMARY
IMMUNODEFICIENCY DISEASES: TREC, KREC AND
BEYOND
Jovanka King1,2
1 Department of Immunopathology, SA Pathology, Women’s and
Children’s Hospital Campus; Robinson Research Institute and
Discipline of Paediatrics, School of Medicine, University of
Adelaide, North Adelaide, SA, Australia; and 2 Department of
Clinical Immunology, Karolinska University Hospital
Huddinge, Stockholm, Sweden
Primary immunodeficiency diseases (PID) are a heterogeneous
group of genetically determined inborn errors of immunity,
with affected children presenting with severe, recurrent or
unusual infections. Severe combined immunodeficiency
(SCID) is one form of PID which is fatal without definitive
treatment with haematopoeitic stem cell transplantation. Evi-
dence suggests that outcomes are markedly improved if this is
instituted by 3.5 months of age1 – a goal only achievable
through early identification of affected infants through
newborn screening.
Currently available screening strategies aim to identify new-
borns with severe forms of PID manifested by T and B cell
lymphopenia use PCR-based techniques to quantify T cell
receptor excision circles (TREC) and KREC (kappa recom-
bining exclusion circles), which are surrogate markers for T
and B cell production, respectively. TREC-alone and multi-
plexed TREC-KREC screening approaches have been
described.2 Newborn screening for PID is an evolving field,
and technologies are being developed which may enable future
identification of complement deficiencies, granulocyte disor-
ders and immunoglobulin deficiencies, which cannot be iden-
tified using currently available strategies. Given the rapid
advances in genomic medicine, next generation sequencing
may have an increasingly prominent role in screening for PID
and other diseases.3
References
1. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for
severe combined immunodeficiency, 2000-2009. N Engl J Med
2014; 371: 434–46.
2. Borte S, von Döbeln U, Fasth A, et al. Neonatal screening for severe
primary immunodeficiency diseases using high-throughput triplex
real-time PCR. Blood 2012; 119: 2552–5.
3. King J, Ludvigsson J, Hammarström L. Newborn screening for pri-
mary immunodeficiency diseases: the past, the present and the
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Appendix II: Research Impact 
I. The Royal College of Pathologists of Australasia Media Release
II. Media coverage summary
III. Online newspaper article: ‘Doctors want newborns to be screened for
‘bubble boy’ SCID disease’, Sydney Morning Herald online
IV. Printed newspaper article: ‘Newborn screening call: They could have cured
it, says mum’, Sydney Morning Herald
MEDIA RELEASE  EMBARGOED UNTIL 2 MARCH 2018 
Newborn screening for primary 
immunodeficiency diseases is a health priority
Dr Jovanka King, a speaker at the Royal College of Pathologists of Australasia’s (RCPA) annual 
conference, ‘Pathology Update 2018’, will recommend that newborn screening is expanded to 
include testing for severe immunodeficiency diseases.  Dr King will discuss her research on strategies 
for screening newborn babies for primary immunodeficiency diseases (PID), including Severe 
Combined Immunodeficiency (SCID), a life-threatening condition where babies are born without a 
functional immune system.   
Dr King, a specialist paediatric immunologist and immunopathologist at SA Pathology at the 
Women’s and Children’s Hospital, and the University of Adelaide, explains that this additional 
screening would significantly improve the outcome for children affected by these disorders, in terms 
of survival and wellbeing, and anticipates that it would be cost effective.   
“Screening babies for primary immune deficiency disorders, including SCID, and evaluating how 
these tests can be implemented in each state’s newborn screening service should be a health 
priority in Australia.  Conditions such as SCID are life-threatening, therefore making a diagnosis and 
starting treatment as early as possible is essential.  Achieving a diagnosis is typically delayed, 
therefore babies become critically unwell as a result of severe, recurrent infections and other 
complications. In these cases, they frequently require prolonged hospital and intensive care unit 
admissions.  
“SCID can be cured by a bone marrow or stem cell transplant.  There is evidence that if infants with 
SCID undergo transplantation prior to the age of 3.5 months, their outcomes in terms of survival and 
long-term health are much improved.  Beyond this age, affected babies have a higher burden of 
infection and other complications due to their untreated disease.  The only realistic way to achieve 
the goal of early transplantation for babies with SCID is to diagnose them early in the newborn 
period, before they develop symptoms of the disease.  This is only achievable through newborn 
screening. 
“The current process for screening newborns in Australia involves each baby having a heel prick 
blood test when they are between two and three days old.  That blood sample is blotted onto a 
piece of filter paper, and is sent to specialised neonatal screening laboratories for testing.  Babies 
are currently screened for over 40 different conditions, including inborn errors of metabolism and 
cystic fibrosis, but with recent technological advances we have the potential to expand this further 
to screen for other important conditions.” 
Dr King’s research has included analysing data from a newborn screening program for PID conducted 
in Sweden, where almost 60,000 newborn babies were screened for SCID and other forms of PID 
over a two-year period.   
“Our research from Sweden, where I worked previously, has demonstrated that population based 
newborn screening is an effective way in which to identify babies affected by PID.  Affected infants 
were detected by an abnormal screening test, which enabled rapid medical assessment, 
confirmatory testing and commencement of treatment within the first weeks of life.  This has also 
been demonstrated in similar studies performed in other countries throughout the world. 
“New Zealand recently initiated their screening program for SCID, and almost every state in the 
United States, and many countries throughout Europe, the Middle East and Asia have initiated 
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successful screening programs for PID, which have become routine.  There is a clear need to 
establish a newborn screening program for PID in Australia,” says Dr King.   
In collaboration with other children’s hospitals throughout Australia, Dr King will be conducting a 
cost benefit analysis which is expected to be completed later in the year.  Doctor King believes that, 
not only would this new screening test be beneficial for affected infants and their families around 
the country, it would also be cost effective. 
“The biggest barrier to implementing any new testing strategy is cost, however, economic analyses 
performed in other countries have demonstrated that it is more cost effective to screen newborns 
for SCID than it is to manage a critically unwell child in whom diagnosis and treatment was delayed, 
which is costly to health systems.” 
For a disease to be included as part of a population-based screening program, it needs to meet 
certain criteria.  Diseases need to be severe, and an effective treatment needs to be available.  The 
testing strategy must also be robust, and have been evaluated on a large scale.   
“A retrospective study is underway in our laboratory in South Australia, where we are testing 
samples from our patients who were diagnosed with PID over the past 17 years.  This will determine 
whether their disease could have been diagnosed in the first weeks of life, and hence if this testing 
strategy will be effective in our population.  Following this, our aim is to secure funding to conduct a 
prospective screening study, where every baby born in South Australia will undergo screening for 
these immune deficiency diseases.  There are over 300 different kinds of PID and, through our 
ongoing research efforts, we are also working on new strategies to improve our current capacity to 
diagnose these severe, life-threatening diseases and improve outcomes for affected patients,” 
explains Dr King.  
Dr Jovanka King is a speaker at the RCPA’s Pathology Update 2018 conference, ‘A Bridge to the 
Future’, which takes place at the ICC Sydney from 2nd until 4th March 2018.  
ENDS 
About the Royal College of Pathologists of Australasia: 
The RCPA is the leading organisation representing pathologists in Australasia. Its mission is to train 
and support pathologists and to improve the use of pathology testing to achieve better healthcare.  
Media enquiries: 
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Babies that undergo transplantation before 3.5
months have a greater chance of survival and
recovery.
58,000
SCID affects one in 58,000 births
internationally.
40
Babies are currently screened for more than 40
different conditions, including inborn errors of
metabolism and cystic fibrosis.
Our network Subscribe Log In
NATIONAL HEALTHCARE
Doctors want newborns to be screened for 'bubble
boy' SCID disease
In the first five weeks of his life, Harrison Draper
went from being a healthy, pink-skinned newborn
to a sick child who left doctors stumped.
He stopped gaining weight and developed a
painful abscess on his bottom that wouldn’t heal.
“The doctors kept saying, ‘It’s OK, it happens,' ”
his mother Tracey Brown, from Orange, said. “But
I kept telling them, ‘Stop saying that, my gut is
screaming at me that something’s wrong’, but he
didn’t have other symptoms.”
0
By Esther Han
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At 11 weeks, Harrison was struck down by a double blow of meningitis and pneumonia.
His doctors, confused, conducted “invasive” tests and ordered the pivotal blood test that
provided the answer: Harrison had severe combined immunodeficiency (SCID) which
meant he had virtually no immune protection from bacteria and viruses.
“What saddens me is that if they had found out sooner, his prognosis would've been
incredibly different, they could’ve cured it,” she said of Harrison, who will turn 11 in four
days.
“He has damage because he got so sick before he was diagnosed; he has neurological
damage, hearing loss, an intellectual delay, things that will affect the rest of his life.”
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Doctors are calling for newborn screening to be expanded to include testing for severe
forms of primary immunodeficiency diseases, in particular SCID, which, if detected early
enough, can be cured by a bone marrow or stem cell transplant.
SCID, commonly known as the “bubble boy” disease, is a severe and life-threatening
disease that affects one in 58,000 births internationally.
At the Royal College of Pathologists of Australasia’s annual conference Pathology Update
on Friday, paediatric immunologist Dr Jovanka King said testing for SCID would
significantly improve or even save the lives of affected children.
“The problem is affected babies first appear
to be healthy and it’s not until they develop
lots of infections that they’re diagnosed
and by then there have been lots of
complications,” she said.
“If we can do the transplant before they’re
3½ months, they fare a lot better in terms
of survival and have fewer long-term
complications.”
At present, newborn babies are screened
for SCID in New Zealand, most states in the
US and many countries throughout Europe,
the Middle East and Asia.
Harrison Draper recovering in hospital after a bone marrow transplant.
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Dr King, in collaboration with several
children’s hospitals, is conducting a cost-
benefit analysis, which she expects to
complete by the end of the year.
“Economic analyses performed in other
countries have demonstrated it is more
cost effective to screen newborns for SCID
than it is to manage a critically unwell
child in whom diagnosis and treatment was
delayed,” she said.
Dr Melanie Wong, a paediatric
immunologist at Westmead Children's
Hospital, said her hospital saw about one
case a year, but it was one too many.
She said some newborns were screened for
SCID based on family history. Babies
diagnosed early have a 90 per cent survival
rate, compared to those diagnosed late,
who have a 40 per cent survival rate.
“Some come at two to three months with
devastating infections and need intensive
care and ventilation and there are ones
who present at six to eight months because of their failure to thrive,” she said.
“Then there are a few who have more insidious presentations and, when you go to
transplant, they’ve picked up a whole lot of viruses and that makes it more difficult to do
a transplant.”
Christine Jeffery, from the Immune
Deficiencies Foundation, which counts 14
surviving SCID patients as members,
strongly supported the call, saying most
forms of primary immunodeficiency had no
cure, but SCID did.
“SCID fulfils all the internationally
recognised criteria for a clinical condition
to be screened for at birth through
newborn screening using the standard
Guthrie [dried blood spot] sample,” its
position statement reads.
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On their way to a surgery at Westmead
Children’s Hospital, Ms Brown said all
newborns should be screened for SCID.
Harrison has had several bone marrow
transplants – at four months, 18 months
and eight years – as well as chemotherapy.
“For us, my daughter Ella is the perfect
match, so we were extremely lucky to find a
match so quickly,” she said.
“There are kids overseas who are diagnosed
at birth but have the transplant three
months later because they couldn’t find a
donor match.”
The federal Health Department said it was
up to each of the states and territories to
determine which conditions would be
screened for by their program.
Esther Han
Esther Han is a health reporter at The Sydney Morning Herald. She has previously been
Dr Jovanka King, a specialist paediatric
immunologist and immunopathologist at SA
Pathology at the Women’s and Children’s Hospital
and the University of Adelaide.
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I. Chan, D., King, J., Dzeladini, L., Marchand, B., Gold, M., Quinn, P. (2017)
Ruxolitinib use in a child with chronic mucocutaenous candidiasis and autosomal
dominant signal transducer and activator of transcription 1 gain of function (STAT1
GOF) mutation. Intern Med J, 47: 28. doi:10.1111/imj.78_13578
II. Gold, M., Chan, D., Marchand, B., Dzeladini, L., King, J., Cheung, A., Quinn, P.
(2017) Intussusception: A Novel presentation of activated phosphoinositide 3-
kinase-Δ (PI3KΔ) syndrome (APDS). Intern Med J, 47: 28–29.
doi:10.1111/imj.80_13578
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STRENGTHENING ACCESS CRITERIA FOR IMMUNOGLOBULIN
IN AUSTRALIA
J Roberts,1 J Cameron,1 L Wall,1 N Wicks,1 P Hetzel2 and M Stone1
1National Blood Authority, Canberra, Australia
2Consultant to the National Blood Authority, Canberra, Australia
The National Blood Authority is standardising and strengthening access
criteria for immunoglobulin (Ig) funded by all Australian governments
under the national blood arrangements.
The ‘Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia’
(the Criteria) was first published in 2007 and updated in 2012. After an
independent review of the governance and access arrangements, the
National Blood Authority (NBA) established a network of governance
committees including specialist working groups (SWGs) and developed an
online authorisation system (BloodSTAR). The Criteria currently
included in BloodSTAR reflects the 2012 second edition of the Criteria.
All states and territories, with the exception of NSW, now use
BloodSTAR.
The SWGs reviewed the evidence and made revisions for V3 of the Cri-
teria. In 2015, public consultation was held on proposed V3 changes for
conditions where Ig has an Established or Emerging Therapeutic Role. In
2017, public consultation was held on proposed V3 changes for conditions
listed for Use in Exceptional Circumstances Only and for indications
where Ig use is Not Supported.
The V3 changes were endorsed by the National Immunoglobulin Govern-
ance Advisory Committee prior to presentation to the Jurisdictional Blood
Committee for approval.
The proposed changes, which aim to more clearly articulate and standar-
dise the diagnostic, qualifying and review criteria, are required to assist
with managing the growth in demand for this precious, human-derived
product by ensuring it is only used for clinically appropriate purposes. The
revised Criteria will ensure strengthened qualifying and review criteria, ini-
tial and continuing authorisation periods’, dosing controls and ensure the
submission of supporting evidence.
The V3 Criteria will undergo an extensive process to upload into Blood-
STAR and transition existing patients to the new criteria.
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RUXOLITINIB USE IN A CHILD WITH CHRONIC MUCOCUTANEOUS
CANDIDIASIS AND AUTOSOMAL DOMINANT SIGNAL
TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 GAIN
OF FUNCTION (STAT1 GOF) MUTATION
D Chan,1 J King,1 L Dzeladini,1 B Marchand,1 M Gold1,2 and P Quinn1,2
1Women’s and Children’s Hospital, Adelaide, Australia
2University of Adelaide, Adelaide, Australia
Background: Ruxolitinib is an oral tablet and is an inhibitor for Janus
Associated Kinases (JAKs) JAK1 and JAK2. It is approved in Australia for
the treatment of myelofibrosis. STAT1 GOF mutation was reported as a
cause of autosomal dominant chronic mucocutaneous candidiasis (CMC)
in 2011. Recent case reports with ruxolitinib have reported clinical benefit
in alopecia areata and STAT1 GOF chronic mucocutaneous candidiasis.
Case report: We report our clinical experience in a 4-year-old child who
is part of a large kindred affected by autosomal dominant CMC. She pre-
sented with onychomycosis, mild oral candida, and a large chronic ulcer of
scalp. Scalp fungal scrapings grew aspergillus ornatus a soil fungus, and
Lictheimia corymbifera. Fungal hyphae were seen on direct microscopy.
Staphlococcus aureas and mixed growth including pseudomonas was also
found.
Although we suspected autosomal dominant STAT1 GOF in distant fam-
ily members they did not have a genetic diagnosis established. We per-
formed Sanger sequencing on the index patient and detected a pathologic
variant in STAT1 gene consistent with the diagnosis of STAT1 GOF.
Scalp debridement, standard antimicrobial therapy and antifungal therapy
was implemented to treat the scalp ulcer. Given the severity of the disease,
and lack of response, Ruxolitinib 5 mg nocte was added in as an adjuvant.
Dosage was increased to 10 mg after one month. After 6 weeks of therapy
significant improvement has been noted with hair regrowth, loss of
hyperkeratotic crusting, and early skin regeneration. No significant side
effects were noted.
Use of ruxolitinib or future JAK inhibitors may have a role in management
of STAT1 GOF.
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INFECTED DERMATITIS ASSOCIATED WITH HTLV-1: A COPYCAT
FOR CHILDHOOD CUTANEOUS CONDITIONS
B Marchand, D Rudaks, M Gold, D Chan and P Quinn
Womens and Childrens Hospital, Adelaide, Australia
Background: Infective dermatitis associated with HTLV-1 can easily be
misdiagnosed as atopic dermatitis, putting patients at risk. Human T-
Lymphotropic Virus type 1 (HTLV-1) is a single-stranded RNA retrovirus
that preferentially infects CD4+ T cells. It is highly prevalent in the
Australian Indigenous population. Transmission follows exposure to
infected lymphocytes, which can occur via vertical and horizontal trans-
mission, and importantly long-term breastfeeding. Infective dermatitis
may not simply signal HTLV-1 infection, but is an indicator of increased
risk of more devastating HTLV-1 disease complications. Known complica-
tions are rapidly progressive haematological malignancy (eg adult T-cell
leukaemia/lymphoma), inflammatory disorders (e.g. myelopathy/tropical
spastic paraparesis), pulmonary disease (eg bronchiectasis), as well as life
threatening invasive Staphylococcal infections.
Case report: Our index case is a 2-year-old Indigenous female patient,
referred with recurrent ‘severe infected eczema,’ requiring multiple admis-
sions. Consideration had been given to STAT3 mutation, however, exten-
sive workup, including immunological workup, lead to the diagnosis of
HTLV-1 on blood PCR. Furthermore, she fulfilled the major criteria for
the diagnosis of infective dermatitis associated with HTLV-1. Since diag-
nosis, when compliant with appropriate treatment, response has been
dramatic.
Diagnosis: HTLV-1 infection is diagnosed on blood PCR. Prognostically,
an HTLV-1c proviral load is essential.
In addition to a blood PCR, clinical criteria for diagnosis of infective der-
matitis associated with HTLV-1 requires presence of skin lesions and
chronic relapsing dermatitis recurring post cessation of systemic treatment,
with or without crusting of nostrils.
Treatment: Treatment is aimed at controlling the complicating infections
of staphylococcus aureus and beta haemolytic streptococcus. Long-term tri-
methoprim/sulfamethoxazole is recommended until at least adolescence.
Conclusion: Infective dermatitis associated with HTLV-1 is a clinically
important mimic of other childhood dermatoses which requires high index
of suspicion to ensure aggressive long term treatment to reduce morbidity
and mortality.
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INTUSSCEPTION: A NOVEL PRESENTATION OF ACTIVATED
PHOSPHOINOSITIDE 3-KINASE-Δ (PI3KΔ) SYNDROME (APDS)
M Gold,1,2 D Chan,1 B Marchand,1 L Dzeladini,1 J King,1 A Cheung1
and P Quinn1
1Women’s and Children’s Hospital, Adelaide, Australia
2University of Adelaide, Adelaide, Australia
Activated phosphoinositide 3-kinase-δ (PI3Kδ) syndrome (APDS) is
recently described primary immunodeficiency disorder. The presentation
is diverse and includes recurrent airway infections including bronchiecta-
sis, ear and sinus infections, severe herpes infections, lymphadenopathy
and a predisposition to B cell lymphoma.
The index patient (HC) is now 13 years of age. She presented at 4 years
with an unexpected and life-threatening Adenoviral pneumonia requiring
PICU and high frequency ventilation. Her elder sister (now 17 years) had
a diagnosis of Common Variable Immunodeficiency Disorder with bron-
chiectasis and was receiving IVIG replacement (commenced at 5 years).
Her mother (now aged 46 years) has a chronic history of recurrent upper
respiratory tract infections.
Following this episode HC was demonstrated to have a Specific Antibody
Deficiency and she was commenced on IVIG replacement. She remained
reasonably well until 8 years of age when she presented with 6 weeks of
weight loss and acute abdominal pain. Ultrasound demonstrated an
Abstracts
Editorial material and organization © 2017 Royal Australasian College of Physicians.
Copyright of individual abstracts remains with the authors.
Internal Medicine Journal (2017) 47 (Suppl. 5): 5–33
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intussception with the ileum extending into the descending colon. Multi-
ple well defined hypo-echoic lesions were demonstrated within the bowel
wall suggesting a lymphoma. A laparotomy was performed and a very
thickened distal terminal ileum and caecum was noted. No bowel biopsies
were obtained because of concern about perforation. Biopsies from multi-
ple lymph nodes showed reactive changes without clonality. The intussus-
ception was reduced and she made an uneventful recovery. Subsequent
morbidity has included marked sub-mental infective adenitis requiring
surgical drainage on two occasions. She remains on monthly IVIG replace-
ment without abdominal symptoms or signs. Annual ultrasound abdomi-
nal screening continues to demonstrate multiple mesenteric and bowel
wall nodes.
Next generation sequencing in the index patient (HC), her sibling and
mother show a heterozygous pathogenic variant (based on ACMG guide-
lines) in the PIK3CD gene (c.3061G>A : p.Glu1021Lys) which has been
confirmed by Sanger sequencing. APDS is caused by heterozygous gain-
of-function mutations in PIK3CD that induce hyper-activation of the pro-
tein products p110δ or p85α (respectively). APDS displays features of both
immune deficiency and of immune dysregulation as demonstrated in this
kindred.
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AN AUDIT OF SUBCUTANEOUS IMMUNOGLOBULIN
REPLACEMENT THERAPY IN SYDNEY: 3 YEARS EXPERIENCE IN A
SINGLE CENTRE
C Wijaya,1 M Moussa,2 M Rafferty1 and S Limaye1
1Concord Hospital, Sydney, Australia
2Royal Prince Alfred Hospital, Sydney, Australia
Background: Immunoglobulin replacement therapy (IRT) is the standard
of care for patients with humoral immunodeficiency and can be adminis-
tered via the intravenous or subcutaneous route. Subcutaneous immuno-
globulin (SCIg) is efficacious, well tolerated and results in more stable
serum IgG levels compared with the peaks and troughs associated with
intravenous immunoglobulin (IVIg). Home-based SCIg offers the advan-
tage of improved autonomy and increased convenience for patients com-
pared with intravenous institution-based therapy.
Methods: An audit of patient outcomes was conducted 3 years following
the introduction of SCIg at Concord Hospital, Sydney.
Results: 11 patients were commenced on SCIg over 3 years, and 1 patient
transferred from a paediatric centre. Of the 11 patients who initiated treat-
ment at Concord, 1 withdrew prior to completion of training due to exter-
nal factors. Patients were assessed as competent to self-administer SCIg
after 3–6 weekly training sessions. SCIg products prescribed included Evo-
gam (4 patients) and Hizentra (7 patients), using an approximate 1:1 dose
conversion from IVIg product. Patients were provided with pumps and
consumables. 3 patients required withdrawal of SCIg and recommence-
ment of IVIg due to cutaneous reactions, life-threatening sepsis or patient
preference. Trough levels of patients on SCIg will be presented.
At 3 years, 8 patients remain on SCIg, with half infusing once per week
and half infusing on 2 days/week. Patients predominantly prefer adminis-
tration via an infusion pump, with a minority of patients adopting the
‘push’ technique.
Conclusion: Although SCIg is a safe and established therapy, our audit
reveals a relatively high rate of treatment withdrawal in a small group of
patients with primary immunodeficiency. SCIg represents an effective
method of IRT in carefully selected patients, although close monitoring of
trough levels and adverse events is mandated.
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A NATIONAL AUDIT OF HEREDITARY AND AQUIRED ANGIOEDEMA
IN NEW ZEALAND
K Lindsay,1 P Flanagan,2 P Fitzharris1 and A Jordan1
1Auckland City Hospital, Auckland, New Zealand
2New Zealand Blood Service, Auckland, New Zealand
Hereditary Angioedema (HAE) is a rare potentially life threatening genetic
condition, but access to effective therapies can reduce mortality and
improve quality of life. Patients with this condition in New Zealand remain
uncharacterised by number, geographical distribution, severity or treat-
ment experience.
New Zealand Immunologists were invited to recruit patients with HAE
and AAE to the audit or those identified as having Berinert® for hereditary
or acquired angioedema. Participants were consented, their angioedema
related health information was collected and they were invited to take part
in telephone or face to face interviews about their experience of healthcare.
Twenty-one patients with hereditary angioedema were recruited, three of
whom had acquired angioedema C1 inhibitor deficiency. Three patients
were diagnosed prior to the onset of symptoms due to the diagnosis of a
family member with the disease by screening family members. The average
diagnostic delay was 12.9 years. Variation in delay between different types
of HAE, with the greatest mean delay being in Type 1 HAE at 18.5 years,
13 years in type 2 HAE, and 3.6 years in AAE.
Within the cohort of 21 patients there were reports of 4 deaths of family
members due to HAE. The majority of patients 19/21 (90%) had a written
plan to present to the emergency department. Few (24%) had a Medic
Alert® bracelet. In 2015 there were a total of 217 HAE attacks in
16 patients. Five patients (24%) were asymptomatic. Only one patient had
angioedema of the upper airway in 2015 but did not require intubation.
Six patients had 136 abdominal attacks; some with high frequency (range
1–52). Four patients said HAE had no impact on their life, 10 had minor
impact, and 4 moderate and 3 described it as severe. This study charac-
terises a cohort of AAE and HAE patients in New Zealand.
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QUALITY OF LIFE (QOL) ASSESSMENTS FOLLOWING THE USE OF
PROPHYLACTIC C1 ESTERASE INHIBITOR CONCENTRATE IN
PATIENTS WITH SEVERE HEREDITARY ANGIOEDEMA
A Merry, D Heyworth-Smith, C Kennedy, S Robertson and L James
Greenslopes Private Hospital, Brisbane, Australia
Introduction: Hereditary Angioedema (HAE) is a rare genetic condition
resulting in a deficiency in C1 inhibitor protein and is characterised by
both provoked and unprovoked episodes of angioedema. In a severe phe-
notype patients may experience repeated and frequent facial or limb
angioedema, severe and recurrent abdominal pain and a risk of death by
asphyxiation as a result of upper airway angioedema. The relentless nature
of this condition with frequent and debilitating attacks along with previous
‘on-demand’ treatment requiring a hospital presentation for each attack
has a profound impact on the quality of life for this patient group.
In 2016 the National Blood Authority (NBA) allowed for the routine sup-
ply of C1 inhibitor concentrate to HAE patients experiencing eight or
more acute attacks per month. With appropriate training patients are able
to self administer treatment at home thus avoiding hospital presentations.
This change in treatment is predicted to provide a dramatic change to the
QOL for this patient group.
Methods: HAE patients completed a HAE-QoL score pre and post the
commencement of prophylactic use of C1 inhibitor concentrate, along
with school/work attendance and documentation of disease activity.
Summary of results: Following prophylactic use of C1 inhibitor concen-
trate, we have seen a marked reduction in disease activity and resultant
improvement in quality of the life as measured by HAE-QoL score and
school/work attendance.
Conclusions: The availability of prophylactic use of C1 inhibitor concen-
trate in HAE patients with a severe phenotype has had a significant benefi-
cial effect on the quality of life of this patient group.
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COMBINED IMMUNODEFICIENCY DUE TO DEFICIENCY OF ACTIN-
RELATED PROTEIN COMPLEX 1B (ARPC1B)
P Quinn,1,2 C Pearson,1 A Cheung,1 J King,1,3 D Chan,1 B Marchand,1
D Rudaks,1 A Quach,3 A Ferrante3 and M Gold1,2
1Women’s and Children’s Hospital, Adelaide, Australia
2University of Adelaide, Adelaide, Australia
3SA Pathology, Adelaide, Australia
A number of cytoskeletal defects arising from perturbations in actin poly-
merisation and resulting in combined primary immunodeficiency (PID)
have been described. Defects include Wiskott Aldrich Syndrome (WAS),
WAS Interacting Protein (WIP) and Dedicator of Cytokinesis 8 (DOCK-
8) deficiencies. A newly reported cytoskeletal defect is Actin-related Pro-
tein Complex 1B (ARPC1B) deficiency. Here we report the first
Abstracts
Editorial material and organization © 2017 Royal Australasian College of Physicians.
Copyright of individual abstracts remains with the authors.
Internal Medicine Journal (2017) 47 (Suppl. 5): 5–33
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Australian, youngest yet diagnosed, and 5th only reported case of
ARPC1B deficiency.
A female infant born to Nepalese parents presented with bloody diarrhoea
and metabolic acidosis at 2 months of age. A diagnosis of cow’s milk enter-
itis was made and she was commenced on an elemental formula with reso-
lution of the hematochezia and improvement in the diarrhoea.
Subsequently she developed an eczematous rash which progressed to an
erosive purpuric dermatitis with ulceration, and later took on a psoriasi-
form appearance. Skin biopsy showed a leucocytoclastic vasculitis. Her
progress was complicated by cytomegalovirus infection, recurrent suppu-
rative otitis media, twice by periorbital cellulitis, persistent oral candidiasis,
urinary tract infection and failure to thrive.
Investigations showed defective neutrophil chemotaxis and random migra-
tion, reduced Natural Killer cell cytotoxicity, decreased naïve T-cells, vari-
able thrombocytopenia, eosinophilia, and raised IgA and IgE. Whole
exome sequencing showed her to be homozygote for an exon 2 splice site
mutation in ARPC1B (c.64+2T>A) which is predicted to cause loss of
gene function. Western blot analysis showed low expression of the
ARPC1B protein.
ARPC1B is a regulatory subunit of the actin-related protein 2/3 complex
critical for F-actin polymerisation in haemopoetic cells. Deficiency of
ARPC1B results in defective actin polymerisation and a combined immu-
nodeficiency similar but distinct to WAS.
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SELF-INFUSION OF BERINERT® (HUMAN C1-ESTERASE INHIBITOR)
IN THE HOME. EARLY LEANINGS FROM BERINERT NURSECARE, A
HOME BASED EDUCATION PROGRAM TO TEACH PATIENTS HOW
TO SELF-INFUSE
D Tognarini, E Vagg and S Youssef
Aesir Health, Cheltenham, Victoria, Australia
Hereditary Angioedema (HAE) is a rare condition, affecting approx. 1 in
50 000, and knowledge within the general medical community
(i.e. outside Immunology clinics) is low. To support patients & clinics, the
ASCIA HAE Positioning Paper (2017) recommends that each HAE suf-
ferer has a HAE Action Plan highlighting when to initiate home based self-
administrated medication and when to escalate to ED.
In October 2016, the HAE treatment paradigm changed significantly in
Australia with the NBA funding of C1- INH concentrate. However, the
question remained regarding feasibility regarding home based preparation
and infusion.
Aesir Health (independent provider with 13+ years’ experience educating
patients on self-administered sub-cutaneous injectables) commissioned by
CSL Behring, designed, built and is managing the Berinert NurseCare
Educational Program (initiated in Feb 2017). This national program has
objectives to ensure concordance with BERINERT® (Human C1-Esterase
Inhibitor) prescribing on several levels including:
• competence in reconstitution
• accurate vein identification, site rotation & aseptic venepuncture
• correct administration, post procedure care and documentation
• clarity of patient’s HAE Action Plan including customisation with home
circumstances and support networks
Currently, 16 patients are enrolled, requiring an average of 2.5 visits per
patient and 4.8 total hrs per education per patient. Some attributes facili-
tating uptake and acceptance to home-infusion include having direct fam-
ily/carer support networks, experiencing recent HAE attacks, poor
experience at ED. Learning is complimented by using novel training appa-
ratus plus the opportunity to prepare & administer BERINERT.
These initial findings suggest that home based infusion is feasible and fur-
ther investigation into the elements which patients find challenging or sup-
portive is warranted.
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DEVELOPING A HOME-BASED MODEL OF CARE FOR
ADMINISTRATION OF SUBCUTANEOUS IMMUNOGLOBULINS
J Waymouth, A-M Redden and J Pollard
University Hospital Geelong, Geelong, Australia
Aims: To develop a model of care within the Barwon Health
(BH) Hospital in the Home (HITH) program to transition patients from a
day stay infusion model of intravenous immunoglobulin (IVIg) to a self-
administered home based model of care - subcutaneous immunoglobulin
(SCIg). The program is available to all eligible patients currently receiving
IVIg in BH day infusion centres and who reside within the local catchment
of BH and the surrounding regional communities.
Methods: A model of care has been developed based on previous individ-
ual patient approaches to teaching self-management of IVIg infusions with
ongoing HITH support and facilitation. This program has required further
development and scaling up of existing processes to support a model of
care that can support multiple patients in a systematic, efficient and sus-
tainable manner.
This model has adopted a collaborative approach with the support of CSL
product advisors and educators, treating clinicians, the BH transfusion ser-
vices clinical nurse specialists, existing BH day infusion and pharmacy
services.
Patient education modules, education brochures, SCIg specific care plans
and processes have been developed to support the model of care.
The transition from IVIg to SCIg is occurring with initial treatment and
education in the HITH clinic, followed by treatment and education in the
home setting, Dependent on patient competency and confidence it is envi-
saged that most patients will transition to self-management within 4–6
weeks. HITH will provide ongoing support and education with planned
reviews and facilitation of product ordering and supply and provision of
consumables.
Results: The program is currently in the early stages of implementation.
A questionnaire is being used to measure patient experience and satisfac-
tion. An evaluation of the program based on number of patient enrol-
ments, reduction in health service costs and treating clinician engagement
and satisfaction of treatment efficacy will be utilised to support this
approach to care.
Conclusion: The HITH approach to the implementation of a SCIg pro-
gram is an important initiative providing patients with an alternative and
self-management care option.
COI Disclosure: JW-Financial support to attend the event was provided
by CSL Behring
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USE OF RITUXIMAB TO TREAT MOOREN’S ULCER
N Benwell and A McLean-Tooke
Sir Charles Gairdner Hospital, Perth, Australia
Introduction: Peripheral ulcerative keratitis (PUK) can be a secondary
manifestation of systemic autoimmune diseases, most commonly Rheuma-
toid arthritis (RA) and Granulomatosis Polyangiitis GPA). PUK can pre-
cede systemic symptoms and its presence may herald sight threatening if
not life threatening disease. Mooren’s ulcer is a rare form of idiopathic
PUK, whose aetiology includes autoimmunity and loss of tolerance to
components within the corneal stroma. Whilst biologic agents have been
successful in treating systemic disease and PUK in RA and GPA, their role
in treating PUK in the absence of systemic autoimmune diseases remains
less clear.
Case report: We present the case of a 16-year-old female who developed
sudden onset bilateral painful ulcerative keratitis. She was diagnosed with
Mooren’s ulcer in absence of evidence of systemic autoimmune disease on
clinical examination or autoimmune serology.
Despite topical and systemic steroid therapy, she developed ‘corneal melt’
requiring an urgent tectonic corneal graft and with IV methylprednisolone,
oral prednisolone and mycophenolate mofetil to stabilise disease. Her dis-
ease course was characterised by fluctuating visual acuity and progressive
corneal thinning with recurrent disease within the corneal graft and pro-
gression toward re-perforation despite ongoing immunosuppression. She
was given a trial of rituximab given the aggressive and refractory nature of
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Abstract 
Clearance of fungal pathogens such as Candida albicans from the human body involves their phagocytosis by 
fixed tissue macrophages as well as infiltrating monocytes and neutrophils. Through an efficient phagocytotic 
process the fungi are confined and killed by the oxidative and non-oxidative anti-microbial components of the 
cells. These include oxygen derived reactive species, generated from the activation of the NADPH oxidase 
complex, together with the release of myeloperoxidase to generate hypochlorous acid. Assisting phagocytosis is 
the complement system which opsonises fungi to promote their interaction with a series of complement receptors 
including the recently described complement receptor immunoglobulin. Phagocytosis and killing of Candida can 
be enhanced by the cytokine network of the immune system. Cytokines such as tumour necrosis factor and 
interferon gamma prime phagocytes and increase their anti-microbial power. Patients with primary 
immunodeficiency diseases who have phagocytic defects, such as those with defects in the NADPH oxidase 
complex are predisposed to fungal infections, providing evidence for the critical role of phagocytes in anti-fungal 
immunity. Secondary immunodeficiencies can arise as a result of treatment with anti-cancer or other 
immunosuppressive drugs. These may also predispose patients to fungal infections due to their ability to 
compromise the anti-microbial activity of phagocytes. 
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